Document:

Second Amended and Restated Joint Venture Agreement

 Exhibit 4.6 
 EXECUTION VERSION 
 DATED THIS 9th DAY OF FEBRUARY 2007 
 AMONG 
 THE SEVERAL PERSONS NAMED AS
SHAREHOLDERS 
 (the “Existing Shareholders”) 
 AND 
 WUXI PHARMATECH (BVI) INC. 
 (the “Company”) 
  

 SECOND AMENDED AND RESTATED 
 JOINT VENTURE AGREEMENT 
 relating to 
 WUXI PHARMATECH (BVI) INC. 
  

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	1.	  	DEFINITIONS	  	2
			
	2	  	BUSINESS OF THE GROUP	  	7
			
	3	  	MANAGEMENT OF THE GROUP	  	9
			
	4	  	RESERVED MATTERS	  	12
			
	5	  	UNDERTAKINGS	  	14
			
	6	  	PRE-LISTING ESOS	  	19
			
	7	  	TRANSFERS AND ISSUANCE OF SHARES	  	19
			
	8	  	PUBLIC LISTING	  	25
			
	9	  	CERTAIN SHAREHOLDERS’ LOCK-UP	  	26
			
	10	  	DEFAULT AND TERMINATION	  	27
			
	11	  	PUT OPTION	  	29
			
	12	  	SHARE CERTIFICATE LEGEND	  	30
			
	13	  	ENTIRE AGREEMENT	  	31
			
	14	  	CONFIDENTIALITY	  	31
			
	15	  	NATURE OF RIGHTS AND OBLIGATIONS	  	32
			
	16	  	REPRESENTATIONS AND WARRANTIES	  	32
			
	17	  	NOTICES	  	34
			
	18	  	GENERAL MATTERS	  	35
			
	19	  	GOVERNING LAW AND DISPUTE RESOLUTION	  	36
			
	20	  	TERMINATION	  	38
		
	SCHEDULE 1A	  	39
		
	SCHEDULE 2A	  	45
		
	SCHEDULE 3	  	46
		
	SCHEDULE 4	  	49
		
	SCHEDULE 5	  	56
		
	SCHEDULE 6	  	59

  

 2 

 THIS AGREEMENT is made on the 9th day of February, 2007 
 AMONG: 
  

	(1)	THE SEVERAL PERSONS NAMED AS SHAREHOLDERS IN SCHEDULE 1A, (collectively the “Existing Shareholders” and individually a “Existing Shareholder”);

  

	(2)	THE SEVERAL PERSONS NAMED AS SHAREHOLDERS IN SCHEDULE 1B (collectively “GA”) AND SCHEDULE 1C (collectively, the “Series C Fidelity Investors”);

  

	(3)	WUXI PHARMATECH (BVI) INC., a company incorporated in the British Virgin Islands and having its registered address at P.O. Box 957, Offshore Incorporation Centre, Road Town,
Tortola, British Virgin Islands (the “Company”). 

 WHEREAS:- 
  

	(A)	The Company is a limited liability company incorporated in the British Virgin Islands and has at the date of this Agreement an authorised share capital of US$10,050,000, consisting
of 5,000,000 preference shares of par value US$0.01 each and 10,000,000 ordinary shares of par value US$1.00 each. 

  

	(B)	The Fidelity Greater China Venture Fund L.P. (“Fidelity Greater China”, and collectively with the Series C Fidelity Investors, “Fidelity”), UOB
Hermes Asia Technology Fund (“UOB Hermes”), UOB JAIC Venture Bio Investments Limited (“UOB JAIC”), New America, L.P. (“NAP”), ChinaTechs, Inc. and Dr. J.J. Baldwin entered into a Joint Venture
Agreement dated 9 August 2005 (the “2005 JV Agreement”) to regulate their relationship inter se as shareholders of the Company. 

  

	(C)	Pursuant to the dissolution of ChinaTechs, Inc., the shareholders of ChinaTechs, Inc. were transferred all the ordinary shares held by ChinaTechs, Inc. in the capital of the Company
and each of them has executed a Deed of Ratification dated 28 October 2005, to accede to and ratify the terms of the 2005 JV Agreement as shareholders of the Company. 

  

	(D)	The Existing Shareholders and the Company entered into (a) a Subscription Agreement dated 26 May 2006 (the “Series B Subscription Agreement”), pursuant to
which Fidelity Greater China, UOB Hermes, UOB JAIC, NAP and UOB Venture Technology Investments Ltd subscribed for an aggregate of 2,688,000 Series B Preference Shares of the Company, par value US$0.01 per share (the “Series B
Preference Shares”),; and (b) an Amended and Restated Joint Venture Agreement dated June 1, 2006 (the “Amended and Restated JV Agreement”). 

  

	(E)	The Company, GA, the Series C Fidelity Investors and certain selling shareholders of the Company entered into a Share Subscription Agreement dated January 26, 2007 (the
“Series C Subscription Agreement”) pursuant to which GA and the Series C Fidelity Investors agreed to subscribe for an aggregate of 1,255,619 Series C Preference Shares of the Company, par value US$0.01 per share (the
“Series C Preference Shares”). 

  

	(F)	The Company, GA and J.P. Morgan Securities Ltd. (“JPM”) entered into a Note Purchase Agreement dated January 26, 2007 (the “Note Purchase
Agreement”) pursuant to which GA and JPM agreed to purchase convertible notes (each, a “Note” and collectively, the “Notes” having an aggregate principal amount of US$40 million. 

	(F)	To give effect to their intentions and to regulate their relationship inter se as shareholders in the conduct of the business and affairs of the Company, the Existing
Shareholders, GA, the Series C Fidelity Investors and the Company hereby agree to enter into this Agreement, which shall amend and supersede the Amended and Restated JV Agreement. 

 NOW IT IS HEREBY AGREED that the Amended and Restated JV Agreement shall be amended and restated in its entirety as set forth herein, and the Parties
hereto further agree as follows:- 
  

	1.	DEFINITIONS 

  

	1.1	In this Agreement, unless the subject or context otherwise requires the following words and expressions shall have the following meanings: 

 “Affiliate” means (a) in relation to any individual, the Immediate Family of such individual or any entity controlled by the
individual (and in the case of the Founder, whether by himself or together with other Founders), where “control” shall mean the power to direct the management and policies or appoint or remove members of the board of directors or
other governing body of the entity, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, and “controlled” and “controlling” shall be construed accordingly;
(b) in relation to any legal person, (i) a company which is for the time being a holding company of such legal person, or a Subsidiary of such legal person or of such holding company or (ii) any other person controlled by, controlling
or under common control with such legal person; 
 “Articles” means the articles of association of the Company (as from time
to time amended, modified or supplemented); 
 “Auditors” means the auditors for the time being of the Company; 

“Big Four Accounting Firm” means Deloitte Touche Tohmatsu, Ernst & Young, KPMG or PricewaterhouseCoopers, and any of their
respective successors; 
 “Board” means the Board of Directors of the Company; 
 “Business” has the meaning ascribed to it in Clause 2; 
 “Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks in the State of New York or Shanghai, the PRC are authorized or required by law or executive order to
close; 
 “China” or “PRC” means the People’s Republic of China; 
 “Directors” means the directors for the time being of the Company and shall, where applicable, include their duly appointed alternate
directors; 
 “Encumbrance” means and includes any interest or equity of any person (including, without limitation to any
right to acquire, option or right of pre-emption) or any mortgage, pledge, lien (including without limitation any unpaid vendor’s lien or similar lien), option, charge (whether fixed or floating), assignment, hypothecation, title retention or
conditional sale agreement, lease, hire or hire purchase agreement, restriction as to transfer, use or possession, easement, subordination to any right of any other person, or other agreement or arrangement which has the same or a similar effect to
the granting of security, encumbrance or a security interest over or in the relevant property; 
  

 2 

 “Fidelity Persons” means (1) Fidelity International Limited
(“FIL”), a company incorporated in Bermuda, and any subsidiary undertaking of FIL from time to time (FIL and its subsidiary undertakings being the “FIL Group”); (2) FMR Corp. (“FMR”), a
Delaware corporation, and any subsidiary undertaking of FMR from time to time (FMR and its subsidiary undertakings being the “FMR Group”); (3) any director, officer, employee or shareholder of the FIL Group and/or the FMR Group
or members of his family and any company, trust, partnership or other entity (“Entities”) formed for his or any of their benefit from time to time (any or all of such individuals and Entities being the “Closely Related
Shareholders”); (4) any Entity controlled by Closely Related Shareholders where “control” shall mean the power to direct the management and policies or appoint or remove members of the board of directors or other
governing body of the Entity, directly or indirectly, whether through the ownership of voting securities, contract or otherwise, and “controlled” shall be construed accordingly; and (5) any affiliate of any member of the FIL
Group and/or the FMR Group (where “affiliate” means any Entity controlled by any combination of any Closely Related Shareholders and any member of the Group and/or the FMR Group, and includes the officers, partners and directors of
any affiliate); 
 “Founders” means Li Ge, Liu Xiaozhong, Lin Tao and Zhang Zhaohui, and “Founder” means any
one of them; 
 “Governmental Authorities” means the government of any nation, state or political subdivision thereof or any
entity or agency exercising executive, legislative, judicial, regulatory or administrative functions of any of the foregoing; 
 “Group” or “Group Companies” means the Company and its Subsidiaries, including but not limited to the WXPT Group Companies, and “Group Company” means each of them as the context may
require; 
 “Group Budget” means the annual and supplementary budgets of the Group, including without limitation the capital
expenditure budget, operating budget, investment budget, revenue forecast, cash flow forecast, profit and loss forecast and balance sheet; 
 “IFRS” means, in respect of any entity, the International Financial Reporting Standards issued by the International Accounting Standards Committee from time to time; 
 “Immediate Family” means, in relation to an individual, the spouse, child, adopted child, step-child, sibling and parent of such
individual; 
 “Interest” means, in relation to any Shareholder, any direct or indirect financial or commercial interest of
that Shareholder or its Affiliates arising from any existing or proposed arrangement, contract, litigation or other proceedings between the any of the Group Company on the one hand and that Shareholder and any of its Affiliates on the other;

 “Joinder” means a joinder substantially in the form set out in Schedule 5; 
 “Majority Preference Directors” means such Preference Directors nominated by Preference Shareholders holding in aggregate not less than
85% of the total Preference Shares outstanding; 
 “Memorandum” means the memorandum of association of the Company (as from
time to time amended, modified or supplemented); 
 “NAP Persons” means TianHeDi Growth Capital Fund (or such other name as
may be approved by the relevant authorities), a new investment fund to be set up and managed by Oliver Curme, and/or such other investment fund managed by Oliver Curme; 
  

 3 

 “Option Shares” means (where the Preference Shares have been converted into Ordinary
Shares) the Ordinary Shares held by each of the Preference Shareholders and (where the Preference Shares have not been converted into Ordinary Shares) the Preference Shares held by each of the Preference Shareholders, in respect of which a Put
Option has been exercised; 
 “Ordinary Shares” means the ordinary shares of par value US$1.00 each in the capital of the
Company; 
 “Parties” means the Existing Shareholders, GA, the Series C Fidelity Investors and the Company, and
“Party” shall mean each or any of them; 
 “Pre-Listing ESOS” means the employee share option scheme
implemented and/or to be implemented by the Company prior to a Qualifying IPO, pursuant to which stock options to purchase up to 1,480,889 Ordinary Shares have or may be granted by the Company to employees of the Group, which Shares when issued
pursuant to the Pre-Listing ESOS shall rank pari passu in all respects with the then Ordinary Shares and be treated as the same class of Ordinary Shares; 
 “Preference Directors” means such Directors of the Company for the time being and from time to time appointed by the Preference Shareholders and “Preference Director” shall mean each
or any of them; 
 “Preference Shares” means the Series A Preference Shares, the Series B Preference Shares and the Series C
Preference Shares; 
 “Preference Shareholders” means the holders of the Preference Shares named in Schedule 2A, and shall
include each of their successors and permitted assigns in accordance with the terms of this Agreement (including, without limitation, assignees described in Clauses 7.10.1, 7.10.2, 7.10.3 and 7.10.4); 
 “Put Option” has the meaning ascribed to it in Clause 12.1; 
 “Put Option Price” means, in respect of each Option Share, an amount equal to the sum of the relevant Subscription Price paid on that Option Share by a Preference Shareholder pursuant to the terms of
the relevant Subscription Agreement and an additional sum calculated at a rate of six per cent (6%) per annum for the duration between the date of payment of such Subscription Price by such Preference Shareholder to the Company and the date of
Put Option Completion relating to that Option Share, less any ordinary or preference dividends declared and paid by the Company in respect of that Option Share; 
 “Qualifying IPO” means an underwritten public offering of Ordinary Shares on a Recognised Stock Exchange, in which the net price per share (after underwriters discounts and commissions) issued by the
Company equals at least US$54.295 (subject to anti-dilution adjustment for share splits, share dividends, bonus issues, reorganizations, recapitalizations and similar events); 
 “Qualifying Existing Shareholder IPO” means an underwritten public offering of Ordinary Shares on a Recognised Stock Exchange, in respect
of which the pre-offering valuation of the Company amounts to US$100,000,000. 
 “Recognised Stock Exchange” means NASDAQ,
the New York Stock Exchange or any other internationally recognised stock exchange or other securities organisation as may be agreed to by the Preference Shareholders and the Founders; 
 “Reserved Matters” means each of the matters in Clause 4.1; 
  

 4 

 “RMB” or “Renminbi” means the lawful currency of the PRC; 

“Rexbury” means Rexbury Limited, a company incorporated in Hong Kong and having its registered address at 35F Cheung Kong Center, 2
Queen’s Rd, Central Hong Kong; 
 “Senior Management Personnel” means the persons named as senior management personnel
in Schedule 3 and shall include any other persons appointed to such positions; 
 “Series A Preference Shares” means
the 618,800 Preference Shares subscribed by UOB Hermes, UOB JAIC, NAP and Fidelity Greater China pursuant to the terms of the Series A Subscription Agreement; 
 “Series A Subscription Agreement” means the Subscription Agreement dated 18 June 2005 entered between ChinaTechs, Inc., Dr. J.J., Baldwin, UOB, UOB JAIC, NAP and Fidelity Greater China in
respect of the subscription of the Series A Preference Shares and Ordinary Shares in the Company. 
 “Series B Preference
Shares” has the meaning set forth in Recital D. 
 “Series B Subscription Agreement” has the meaning set forth in
Recital D. 
 “Series C Preference Shares” has the meaning set forth in Recital E. 
 “Series C Subscription Agreement” has the meaning set forth in Recital E. 
 “Shareholders” means each of the Existing Shareholders, the Series C Fidelity Investors and GA, provided that any such person shall, upon
execution by the transferee of all or any portion of the Shares held by such shareholder of the Joinder, cease to be a Shareholder and the transferee of such Shares shall, on execution of such Joinder, be treated as a Shareholder, and this Agreement
shall be construed accordingly and “Shareholder” shall mean each or any of them; 
 “Shareholding
Requirement” means the Preference Shareholders holding Preference Shares amounting to not less than 50% of the number of Preference Shares as at the date hereof (subject to the Adjustment in accordance with the Articles of Association of
the Company); 
 “Shares” means the shares (whether ordinary, preference or otherwise) in the capital of the Company and
“shareholding” shall be construed accordingly; 
 “Subscription Agreements” means the Series A Subscription
Agreement, the Series B Subscription Agreement and the Series C Subscription Agreement and “Subscription Agreement” shall mean each or any of them (as the case may be); 
 “Subscription Price” means the respective price per share paid by the Preference Shareholders for the subscription of the (i) Series
A Preference Shares (such price per share being US$1.00 (subject to anti-dilution adjustment for share splits, share dividends, bonus issues, reorganizations, recapitalizations and similar events)), (ii) Series B Preference Shares (such price
per share being US$7.14 (subject to anti-dilution adjustment for share splits, share dividends, bonus issues, reorganizations, recapitalizations and similar events)) and (iii) Series C Preference Shares (such price per share being US$43.436
(subject to anti-dilution adjustment for share splits, share dividends, bonus issues, reorganizations, recapitalizations and similar events)), pursuant to the terms of the applicable Subscription Agreement; 
 “Subsidiary” means (i) in respect of any person, any entity controlled directly or indirectly by such person, such control being
evidenced by (a) the ownership of more than 50 per cent of the shares of such entity; or (b) the ability to control the 

  

 5 

 
composition of the majority of the board of directors of such entity, or (c) the ability to exercise or control the exercise of more than 50 per
cent. of the voting rights of such entity, and (ii) in respect of the Company, shall also include all the companies mentioned in Schedule 4; 
 “UOB Entities” means UOB Hermes Asia Technology Fund, UOB JAIC Venture Bio Investments Ltd and UOB Venture Technology Investments Ltd; 
 “UOB Persons” means any investment fund set up and managed by UOB Limited and/or its Subsidiary; 
 “U.S.” means the United States of America; 
 “US GAAP” means United States generally accepted accounting principles in the United States of America; 
 “US$” means the lawful currency of the United States of America; 
 “WXPT”
means WuXi PharmaTech Co., Ltd, a company established in the Municipality of Wuxi, Jiangsu Province, the People’s Republic of China; and 
 “WXPT Group Companies” means WXPT and its Subsidiaries, as more particularly set out in Schedule 4. 
  

	1.2	Any references to a document being “in the agreed terms” means in the terms agreed between the parties and for the purpose of identification signed by the parties
named in the document. 

  

	1.3	Any reference to a statutory provision shall include such provision and any regulations made in pursuance thereof as from time to time modified or re-enacted whether before or after
the date of this Agreement so far as such modification or re-enactment applies or is capable of applying to any transactions entered into prior to the date of this Agreement and (so far as liability thereunder may exist or can arise) shall include
also any past statutory provisions or regulations (as from time to time modified or re-enacted) which such provisions or regulations have directly or indirectly replaced. 

  

	1.4	References to “Recitals”, “Clauses” and “Schedules” are to recitals and clauses of and the schedules to this Agreement and
references to this “Agreement” shall mean this Agreement and the Schedules hereto. 

  

	1.5	The headings in this Agreement are for convenience only and shall not affect the interpretation hereof. 

  

	1.6	Unless the context otherwise requires, references to the singular number shall include references to the plural number and vice versa, references to natural persons shall include
bodies corporate, and the use of any gender shall include all genders. 

  

	1.7	References to any agreement or document including this Agreement shall include such agreement or document as amended, modified, varied or supplemented from time to time.

  

	1.8	References to a “company” shall be construed so as to include any company, corporation or other body corporate or other legal entity, wherever and however
incorporated or established. 

  

	1.9	References to a “person” shall be construed so as to include any individual, firm, company, government, state or agency of a state or any joint venture,
association, partnership, works council or employee representative body (whether or not having separate legal personality). 

  

 6 

	1.10	References to times of the day are to local time in the relevant jurisdiction unless otherwise stated. 

  

	1.11	References to any U.S. legal term for any action, remedy, method or judicial proceeding, legal document, legal status, court, official, or any legal concept or thing shall in
respect of any jurisdiction other than U.S. be deemed to include what most nearly approximates in that jurisdiction to the U.S. legal term. 

  

	1.12	The words “written” and “in writing” include any means of visible reproduction. 

  

	1.13	References to “accounts” shall include the directors’ and auditors’ reports, relevant balance sheets and profit and loss accounts and related notes
together with all documents which are or would be required by law to be annexed to the accounts of the company concerned to be laid before the company in general meeting for the accounting reference period in question. 

  

	1.14	Where two or more persons constitute the expression “Senior Management Personnel” or “Founders”, all covenants, agreements, representations,
warranties, undertakings, stipulations, terms, conditions and other provisions hereof shall bind their successors and permitted assigns. 

  

	1.15	References to “liability” or “liabilities” means any responsibility or obligation whether known or unknown, whether absolute or contingent, whether
as primary obligations or guarantee obligations, whether liquidated or unliquidated, whether due or to become due, whether disputed or undisputed, and whether legal or equitable. 

  

	1.16	All figures, percentages and calculations under this Agreement shall where necessary be rounded up to two decimal places, other than those expressed to be
“approximate”. 

  

	1.17	A person who is not a party to this Agreement has no right under the Contracts (Rights of Third Parties) Act to enforce any term of this Agreement but this does not affect any right
or remedy of a third party which exists or is available apart from that Act. 

  

	1.18	Any conversion of an amount from one currency to another currency shall be effected at such rate of exchange as may be agreed by the Parties from time to time. Without prejudice to
the foregoing, unless otherwise agreed by the Parties in writing, any conversion from Renminbi to United States Dollars and vice versa shall be effected at the median rate published by the People’s Bank of China on the relevant accounting date
or date of transaction (as the case may be). 

  

	2	BUSINESS OF THE GROUP 

  

	2.1	Business Scope: Save as provided in this Agreement and except as otherwise approved by the Board of the Company as a Reserved Matter, the Company shall carry on the business
of an investment holding company investing in other companies, including the WXPT Group Companies, which are engaged in the businesses of:- 

  

	 	2.1.1	Providing drug discovery and development outsourcing services including but not limited to combinatorial, medicinal and synthetic chemistry, computer assisted lead compound
identification and optimization, biochemistry experiments and analyses in Good Laboratory Practice (GLP) laboratory, and other relevant technology consulting services, and synthesizing and selling small molecule compounds, compound libraries and
benchmark compounds and standards; 

  

	 	2.1.2	Developing and providing drug design hardware, software and services; 

  

 7 

	 	2.1.3	Developing, optimizing and marketing pharmaceutical products alone or through collaboration with domestic and overseas medicine producing manufacturers or research institutes or
innovation companies or individuals; 

  

	 	2.1.4	Manufacturing and selling of medical instrument, fine chemical and active pharmaceutical ingredients (API), research and clinical materials, building blocks, and various
intermediates and finished dosages of medicinal products; 

  

	 	2.1.5	Providing process chemistry and scale-up manufacturing services including but not limited to synthesis design, production planning, technology transfer, technical services,
technical training, technical contracting, technology brokerage, technical consultancy, and technology investment within chemicals and chemical equipment sectors; 

  

	 	2.1.6	Commercial production and sale of animal research models, principally purpose-bred, high quality, SPF or disease free rats, mice, other rodents, dogs, and non-human primates
required in research and development for new drugs, devices and therapies; providing surgical services to our customers; providing services in validating, maintaining, improving, breeding and testing research models; providing related consulting and
staffing services, vaccine support and in vitro technology products; 

  

	 	2.1.7	Providing preclinical services including but not limited to both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and
program management to support product development from inception to market registration. Service items include but not limited to toxicology studies, pathology services, bioanalysis, pharmacokinetics, and drug metabolism studies;

  

	 	2.1.8	Providing pre-formulation development and formulation development services including but not limited to API physical & chemical properties evaluation, salt form selection,
polymorphism study, powder characterizations, safety study, toxicity study and etc. 

  

	 	2.1.9	Production and processing of fine chemical products and Lafutiding API; research and development of new drugs, computer software and database, provision of consultancy service in
connection with combinatorial chemistry and new drugs; import and export of self-produced products and import of mechanical equipment, spare parts, raw materials and auxiliary materials necessary for the business of the Company; real estate
development on the land granted by the State to the Company, 

 and shall procure that members of the Group engage in only the
aforesaid businesses and such other businesses as may be incidental to or in connection with the aforesaid businesses. 
  

	2.2	Business Entity: Notwithstanding the foregoing, the WXPT Group Companies shall be the primary entities carrying out the businesses set out in Clauses 2.1.1 to 2.1.9 above.
Where the Company and/or WXPT Group Companies have rejected new projects or transactions offered to it, the Founders shall not accept or engage in such new projects or transactions. 

  

	2.3	Conflict of Interest: All dealings between the Group Companies on the one hand and the Shareholders, Founders or their Affiliates or any of them on the other hand shall be in
the ordinary course of the Group’s business and on arm’s length commercial terms, and each of the Shareholders and Founders shall ensure that any existing or potential conflicts of interest are brought to the attention of the Company at
the earliest opportunity so that they can be dealt with in accordance with this Agreement. 

  

 8 

	3	MANAGEMENT OF THE GROUP 

  

	3.1	Constitution of the Board of the Company: Subject to Clause 3.3, each of the Parties agrees that the Board shall consist of ten (10) Directors, of which the Preference
Shareholders shall have the right to appoint four (4) non-executive Directors, the Founders shall appoint four (4) executive Directors, Dr. J.J. Baldwin shall have the right to appoint one (1) non-executive Director, and Rexbury
shall have the right to appoint one (1) non-executive Director. Of the four (4) Directors to be appointed by the Preference Shareholders, one (1) Preference Director shall be nominated by UOB Hermes, one (1) Preference Director
shall be nominated by Fidelity, one (1) Preference Director shall be nominated by NAP and one (1) Preference Director shall be nominated by GA. 

  

	3.2	Removal of Directors: The right of appointment under Clause 3.1 shall include the right to remove such Director appointed by the respective Parties from office at any time,
and the right to determine from time to time the period during which such persons shall hold office as Directors, save that no Director may be removed by the Board unless the prior written consent of the Party who nominated such Director has been
obtained or if there has been, in the unanimous opinion of the other Directors on the Board appointed by the other Parties, serious misconduct by such Director or that such Director has been incapacitated or is otherwise rendered incapable of
fulfilling his duties as a director of the Company; provided, that the Party who nominated such removed Director shall have the right to appoint another person in the place of such removed Director. 

  

	3.3	Manner of Appointment and Removal: Any appointment or removal of a Director as aforesaid shall be made in writing and be signed by or on behalf of the Preference
Shareholders, the Founders or Rexbury as the case may be and shall be delivered to the registered office for the time being of the Company. Subject to Clauses 3.1 and 3.2, in order to give effect to the provisions of this Clause 3.3, each of the
Shareholders shall exercise all his or its voting rights for the time being in the Company to, in the case of an appointment, enable such Director to be appointed and to prevent the passing of any resolutions giving effect to the removal from office
as Director any person so appointed and, in the case of a removal, to effect such removal. 

  

	3.4	Alternate Director: A Director shall be entitled at any time and from time to time to appoint any person to act as his alternate and to terminate the appointment of such
person. Such alternate Director shall be entitled, while holding office as such, to receive notices of meetings of the Board and to attend and vote as a Director at any such meetings at which the Director appointing him is not present and generally
to exercise all the powers, rights, duties and authorities and to perform all functions of his appointor. Further, such alternate Director shall be entitled to exercise the vote of the Director appointing him at any meetings of the Board. An
alternate Director shall represent only one Director. 

  

	3.5	Chairman: Unless otherwise decided by the Board, Dr. Li Ge shall be the Chairman of the Board. The Chairman shall not have a second or casting vote.

  

	3.6	 Quorum: All meetings of the Board shall be convened and conducted in accordance with the provisions of the Articles. For so long as the Shareholding
Requirement is satisfied, the quorum for any meeting of the Board shall be a majority of the Board and shall include at least the Majority Preference Directors and one (1) Director nominated by the Founders. If a quorum is not present half an
hour from the time appointed for the holding of a meeting of the Board when it is first convened, the meeting shall be adjourned to the same day in the week next following at the same time and place and the quorum for such adjourned meeting shall
remain the same. If at such adjourned meeting a quorum is not present within half an hour from the time appointed to hold the meeting, the meeting shall be adjourned for a second time to the same day in the week next following at the same time and
place and the quorum for such second adjourned meeting shall be any two (2) Directors present at such 

  

 9 

	 	 
second adjourned meeting and all business including the Reserved Matters may be transacted at such meeting. Prior written notice of each meeting and/or
adjourned meeting shall be given to all Directors by the Chairman of the Board. 

  

	3.7	Meetings: A meeting of the Board shall be held at such times as the Chairman of the Board shall determine and the business to be transacted at such meeting shall also be
determined by the Chairman of the Board after prior consultation with all Directors, Provided That unless otherwise agreed by all the Directors, a meeting of the Board shall be held at least once every financial quarter and more frequently, if
required, and upon the requisition by any two Directors, the Chairman of the Board shall also convene a Board meeting. Not less than fourteen (14) Business Days’ notice (or such shorter period of notice in respect of any particular meeting
as may be agreed by all the Directors) of each meeting of the Board specifying the date, place and time of the meeting and the business to be transacted thereat shall be given to all Directors. A copy of the minutes of the meeting shall be sent to
all Directors within seven (7) Business Days after the meeting. 

  

	3.8	Resolutions in Writing: Resolutions of the Board may be passed by circular resolution signed by a majority of the Directors of the Board and for so long as the Shareholding
Requirement is satisfied, any such resolutions that contain any Reserved Matter shall also be signed by the Majority Preference Directors and one (1) Director nominated by the Founders as well. Such resolutions may consist of several documents
in original or facsimile in the like form each signed by one or more Directors. 

  

	3.9	Exercise of Voting Rights: Each Shareholder shall procure the Directors appointed by it to exercise or refrain from exercising any voting rights or other powers of control so
as to ensure the passing of any resolution necessary to ensure that the affairs of the Company are conducted in accordance with the provisions of this Agreement and otherwise to give full effect to the provisions of this Agreement and likewise to
ensure that no resolution is passed which does not accord with such provisions. 

  

	3.10	Board Meetings by Telephone or Video Conference: Subject to the provisions of this Clause 3, a Director may participate at a meeting of the Board by telephone conference or
video conference or by means of similar communication equipment whereby all Directors participating in the meeting are able to hear each other without a Director being in the physical presence of another Director or Directors, in which event such
Director shall be deemed to be present at the meeting. A Director participating in a meeting in the manner aforesaid shall be taken into account in ascertaining the presence of a quorum at the meeting. 

  

	3.11	Observer Rights: GA shall have the right to appoint one (1) individual to attend all meetings of the Board as an observer and such individual shall have the right to
receive all documents and participate in all discussions as if he were a member of the Board, but such individual shall not have any voting rights on the Board. 

  

	3.12	Quorum at any General Meeting: The quorum at any general meeting shall be two (2) Shareholders present in person or by proxy, provided that such Shareholders present in
person or by proxy include representatives of the Preference Shareholders holding in aggregate not less than 85% of the total Preference Shares. If a quorum is not present half an hour from the time appointed for the holding of a general meeting
when it is first convened, the meeting shall be adjourned to the same day in the week next following at the same time and place. At such further adjourned meeting, any two (2) Shareholders present in person or by proxy shall form a quorum and
all business may be transacted at such meeting. Notice of each adjourned meeting shall be given to all Shareholders. 

  

 10 

	3.13	Nominees: The Parties irrevocably agree that as the Preference Directors appointed by the Preference Shareholders are the nominees of the Preference Shareholders, such
Directors shall be entitled to report all matters concerning the Company, including but not limited to, matters discussed at any meeting of the Board to the Preference Shareholders and its shareholders. 

  

	3.14	Remuneration: The Parties agree that the remuneration packages of the Senior Management Personnel (i) whose annual remuneration (excluding any stock options) is more
than US$200,000 or (ii) whose remuneration package includes any stock option shall be recommended by the ACF Committee and approved by the Board as a Reserved Matter. 

  

	3.15	Audit, Compensation and Finance Committee: Each of the Parties agrees that an Audit, Compensation and Finance Committee (“ACF Committee”) shall be
established to oversee inter alia the financial reporting process of the Group. The Parties agree that the ACF Committee shall consist of up to six (6) Director-members, comprising three (3) Directors nominated by the Founders, one
(1) Director nominated by UOB Hermes Asia Technology Fund, one (1) Director nominated by Fidelity and one (1) Director nominated by GA. The ACF Committee shall inter alia: 

  

	 	3.15.1	review the annual accounts of the Group Companies to determine whether such accounts give a true and fair view of the financial position of the Group and are in compliance with
IFRS; 

  

	 	3.15.2	examine the annual statements and reports to be made by the directors in relation to the Company’s compliance with applicable laws and regulations; 

  

	 	3.15.3	advise on the appointment and supervise the performance of the Auditors; 

  

	 	3.15.4	oversee, review and recommend the remuneration and compensation (including benefits and severance compensation) paid to Senior Management Personnel of the Group Companies and
approve the service agreements to be entered with such Senior Management Personnel; and 

  

	 	3.15.5	devise, administer, review and implement the guidelines for the Group’s Pre-Listing ESOS and determine the amount of stock options to be issued to each applicable employee,
provided, that the issue of any Shares upon exercise of a stock option granted pursuant to the Pre-Listing ESOS shall always be conditional upon the recipient of such Shares undertaking to observe the terms and conditions of this Agreement (where
applicable), including without limitation, restrictions set out in Clause 9.1 in respect of such Shares, 

 provided, that all
recommendations and decisions taken by the ACF Committee shall require the unanimous agreement of all ACF Committee members. 
  

	3.16	Day-to-Day Management: The Board shall be responsible for the overall direction and control of the management of the Group and the formulation of the policies to be applied
in the conduct of the Business. 

  

	3.17	Management of Group Company: The Company shall exercise its rights as shareholder of such Group Company or, in the case of the Company being an indirect shareholder of such
Group Company, procure its immediate Subsidiary to exercise its rights as shareholder of such Group Company, and the Parties shall procure their representatives who are appointed by the Company and sitting at the board of directors of such Group
Company to exercise their voting rights in such manner so as to ensure that in respect of any Reserved Matters that are applicable to any Group Company:- 

  

	 	3.17.1	unless the said Reserved Matter has been approved in advance by the Board in accordance with Clause 4.1 below, they will vote against the resolution concerning such Reserved Matter;
and 

  

 11 

	 	3.17.2	if the said Reserved Matter has been approved by the Board in accordance with Clause 4.1 below, they will vote in favour of the resolution or otherwise act in accordance with such
decision or instruction of the Board concerning such Reserved Matter and sign and fax the board resolutions and the relevant documents within seven (7) Business Days after being requested by the relevant Group Company. 

 

	3.18	Observer Rights: The Parties hereby agree that NAP and Rexbury shall each have the right to nominate one (1) person to attend all meetings of the ACF Committee as an
observer and such persons shall have the right to receive all documents and participate in all discussions as if he were a member of the ACF Committee, but such person shall not have any voting rights on the ACF Committee. 

 

	3.19	Other Committees. Prior to a Qualifying IPO, the GA Director shall have the right to serve on each committee of the Board (in addition to the ACF Committee as set forth in
Section 3.15). 

  

	4	RESERVED MATTERS 

  

	4.1	Special Resolution of the Board: Save as otherwise provided in this Agreement and for so long as the Shareholding Requirement is satisfied, the Parties hereby agree and the
Company shall ensure that none of the Group Companies (including the Company) carries out any of the following without the affirmative vote of at least the Majority Preference Directors:- 

  

	 	4.1.1	participate in or carry out any acquisitions, mergers, restructuring, amalgamation or reconstruction, or dispose of any substantial assets, amounting to a sum in excess of
US$3,000,000; 

  

	 	4.1.2	effect any material amendment to any part of its constitutive documents (including but not limited to its memorandum of association and articles of association) which may adversely
affect any part of or all of the rights, interests and special privileges enjoyed by the Preference Shareholders, whether directly or indirectly, in relation to the relevant Group Company, save for the amendments made to the aforesaid documents in
order to comply with law or the Series C Subscription Agreement give effect to any provision in this Agreement; 

  

	 	4.1.3	any material change of the nature or scope of its business or its business activities; 

  

	 	4.1.4	create, issue, purchase, redeem, increase, reduce, sub-divide, change or cancel its authorised, issued or registered share capital (as the case may be) or issue or grant any option
(including any employee share option scheme) over its unissued share capital or enters into any transaction which may lead to a change in the capital structure including but not limited to the issue of new equity, debt or quasi-equity issue;

  

	 	4.1.5	take any action which would result in the variation or abrogation of the rights, privileges, obligations or liabilities of any Preference Shareholder or which would result in a
dilution of any Preference Shareholders’ shareholdings in the Company; 

  

	 	4.1.6	accumulate borrowings (whether from bank or through issuance of debt instruments) amounting to an aggregate principal sum in excess of US$20,000,000, or any single borrowing
(whether from bank or through issuance of debt instruments) exceeding the principal sum of US$3,000,000; 

  

 12 

	 	4.1.7	grant any loan to a third party for a sum in excess of US$500,000 for any single transaction (excluding inter-company funding amongst the Group Companies to ensure that each of the
Group Companies can meet its going concerns in the ordinary course of its business, provided that such inter-company funding does not result in any material adverse effect on the Group); 

  

	 	4.1.8	grant any guarantee, indemnity, charge or any security whatsoever over any of its assets for the benefit of any Group Company or third parties, except for the purpose of securing
borrowings of any Group Company from banks in the ordinary course of business not exceeding US$3,000,000 for any single transaction; 

  

	 	4.1.9	enter into any debts, contracts, agreements, transactions or arrangements with any Party or any of the Affiliates of such Party in excess of US$300,000 in aggregate in any financial
year; 

  

	 	4.1.10	any dealings between the Group Companies on the one hand and their shareholders, directors or their Affiliates on the other hand of an amount in excess of US$300,000 in aggregate in
any financial year (but excluding any inter-company funding amongst the Group Companies); 

  

	 	4.1.11	any advance or loan by any Group Company to any of its shareholders, directors or their Affiliates for an accumulated amount in excess of US$300,000 in aggregate in any financial
year (but excluding any inter-company funding amongst the Group Companies); 

  

	 	4.1.12	enter into any swap, forward, futures or option arrangement in respect of any securities, that is speculative in nature; 

  

	 	4.1.13	approval of annual business forecast and annual Group Budget, including any variation, modification and supplements thereto; 

  

	 	4.1.14	commence, institute, defend or settle any legal or arbitration proceedings (other than routine debt collection from its debtors in its ordinary course of business) involving a claim
amount in excess of US$1,000,000; 

  

	 	4.1.15	declare any dividend or change its dividend policy; 

  

	 	4.1.16	change in the composition of the Board or the service contracts of any Director; 

  

	 	4.1.17	any proposal relating to the listing of the shares of any Group Company, including the alteration or change in the plan or timetable in respect of such listing on a Recognised Stock
Exchange; 

  

	 	4.1.18	enter into any underwriting arrangement or commitment with any third parties in respect of any Qualifying IPO, provided that the Preference Shareholders and the Founders shall have
a common recommendation in respect of such third party; 

  

	 	4.1.19	employ or terminate (save for the summary dismissal of any employee in accordance with the terms of employment of such employee) the employment of its chief executive officer, chief
financial officer and chief operating officer or other equivalent positions, or vary the terms and conditions of their employment or any increase of their compensation or salary package; 

  

	 	4.1.20	issue any employment contract to any of the Senior Management Personnel or other equivalent employees whose annual remuneration (excluding stock option) exceeds the sum of
US$200,000, including determining their remuneration, or vary the terms and conditions of their employment or revise their compensation or salary package; 

  

 13 

	 	4.1.21	sell, transfer or dispose of, or otherwise encumber or create any security over the whole or part of its interest in any of its Subsidiaries or its undertaking, goodwill, assets or
property which in aggregate will have a book value or market value in excess of US$2,000,000 in any financial year, save for those set out in the annual Group Budget approved by the Board as a Reserved Matter; 

  

	 	4.1.22	enter into any joint venture or partnership arrangement or incorporate any subsidiary with an investment commitment in excess of US$2,000,000 for any single transaction;

  

	 	4.1.23	incur any commitment to invest a sum in excess of US$2,000,000 in respect of any expansion into new businesses, whether carried out singly, over a series or otherwise within a
financial year; 

  

	 	4.1.24	incur any capital commitment in excess of US$2,000,000 in value in respect of any transaction whether carried out singly, over a series or otherwise within a financial year, save
for those set out in the annual Group Budget approved by the Board as a Reserved Matter; 

  

	 	4.1.25	pass any resolution for its liquidation or winding up or apply for the appointment of a receiver, judicial manager, administrator or like officer over its business, undertakings or
assets; or 

  

	 	4.1.26	amend, ratify, restate or restructure the Pre-Listing ESOS or approve, adopt, implement or amend any other employee share option schemes. 

  

	4.2	Ordinary Resolution of the Board: Other than the Reserved Matters, all matters (to the extent permitted by law or otherwise) shall be approved by a majority of the Directors.

  

	4.3	Shareholder Resolution: The Shareholders shall procure that no act or event shall occur which is analogous to or has a substantially similar effect to any of the Reserved
Matters without the prior approval of the Board in accordance with Clause 4.1. In the event that any of the Reserved Matters is considered at any general meeting of the Company, the other Shareholders hereby undertake that for so long as the
Shareholding Requirement is satisfied, they will not approve any resolution for such Reserved Matters without the prior written approval of the Preference Shareholders holding in aggregate not less than 85% of the total Preference Shares.

  

	4.4	Group Decision: Insofar as any of the Reserved Matters is applicable to any of the Subsidiaries of the Company, the Company hereby undertakes to exercise its voting rights
and to procure its Affiliates and the directors appointed by it to such Subsidiary to exercise their voting rights in accordance with the instructions of the Board, and to procure that such Subsidiary shall not without the prior written consent of
the Board do any of the Reserved Matters. 

  

	5	UNDERTAKINGS 

  

	5.1	Information: The Company hereby undertakes to the Preference Shareholders that all statutory records and books of account of each Group Company will be duly entered up and
maintained in accordance with all legal requirements applicable thereto and will contain true, full and accurate records of all matters required to be dealt with therein and all such records and books which are its property, will be in its
possession or under its control and all accounts, documents and returns required to be delivered or made to the Governmental Authorities of its jurisdiction and/or in any relevant country will be duly and correctly delivered or made.

  

 14 

	5.2	Further Undertakings: The Company further undertakes to each of the Preference Shareholders that, for so long as such Preference Shareholder holds any Shares:

  

	 	5.2.1	unaudited monthly consolidated financial reports detailing the income statement, balance sheet and cash flow statements of the Group (on a consolidated basis) from time to time for
each month shall be produced and delivered to the Preference Shareholders as soon as practicable but in any event within twenty (20) days after the end of the relevant month; 

  

	 	5.2.2	unaudited quarterly consolidated financial reports detailing the income statement, balance sheet and cash flow statements of the Group and the nature and the amount of all dealings
between the Group Companies on the one hand and the Founders and/or their Affiliates or any of them on the other hand from time to time for each financial quarter prepared in accordance with PRC GAAP shall be produced and delivered to the Preference
Shareholders as soon as practicable but in any event within forty-five (45) days after the end of the relevant fiscal quarter; 

  

	 	5.2.3	unaudited annual consolidated financial statements detailing the income statement, balance sheet and cash flow statements of the Group Companies (on a per company basis as well as
consolidated basis) prepared in accordance with PRC GAAP (and in respect of the individual company accounts, in accordance with the PRC GAAP applicable to such company) shall be produced and delivered to the Preference Shareholders within sixty
(60) days of the end of the fiscal year of the relevant Group Company from time to time; 

  

	 	5.2.4	audited annual consolidated financial statements detailing the income statement, balance sheet and cash flow statements of the Group Companies (on a per company basis as well as
consolidated basis) prepared by a Big Four Accounting Firm in accordance with US GAAP (and in respect of the individual company accounts, in accordance with the US GAAP applicable to such company) shall be produced and delivered to the
Preference Shareholders within one hundred and twenty (120) days of the end of the fiscal year of the relevant Group Company from time to time; 

  

	 	5.2.5	produce and deliver to the Preference Shareholders the annual business plan, annual Group Budget, and projected financial statements of each Group Company from time to time for the
following financial year at least thirty (30) Business Days prior to end of the current financial year; 

  

	 	5.2.6	produce and deliver to the Preference Shareholders, if so requested by the Preference Shareholders, such other operations statistics and other trading and financial information, in
such commercially reasonable form and manner as the Preference Shareholders may require in order for them to be kept properly informed about the Group and to generally protect the interest of the Preference Shareholders; 

  

	 	5.2.7	grant the Preference Shareholders, if so requested by the Preference Shareholders and at their own costs, free and unfettered access to the properties, books and other records of
each Group Company from time to time and permit the carrying out of audits and interviews with officers, employees, and professional advisors of the Company by representatives of the Preference Shareholders, all in a commercially reasonable manner;

  

 15 

	 	5.2.8	grant the Preference Shareholders the opportunity to discuss and review with the Company the accounts set out in Clauses 5.2.1, 5.2.2, 5.2.3 and 5.2.4 above, within thirty
(30) days from the Preference Shareholder’s receipt of the same; 

  

	 	5.2.9	the Company’s obligations under the foregoing provisions shall include the obligations to produce the relevant accounts on a consolidated basis. In the event that the Company
acquires or establishes any further Subsidiaries, the Company’s obligations set out in this Clause 5.2 shall be deemed to include the obligation to produce the relevant records, accounts and documents of such Subsidiaries;

  

	 	5.2.10	the Company will take up and pay for an appropriate and sufficient insurance policy to indemnify each Director from and against all actions, losses, claims, proceedings, costs,
demands and liabilities suffered by the Director in the execution or attempted execution of any of the rights, powers, remedies, authorities or discretions vested in the Director under or pursuant to his rights, privileges and duties as a director
of the Company, unless such actions, losses, claims, proceedings, costs, demands and liabilities shall have arisen out of the willful default and gross negligence of the Director. The Group shall also maintain insurance in such amounts and covering
such risks as are usually and customarily carried with respect to similar businesses according to its locations; 

  

	 	5.2.11	the Company will provide GA, Fidelity and their respective Affiliates and any other person they designate all information and cooperation necessary to enable the making and
maintenance of an election to treat the Company, the WXPT Group Companies and/or any other direct or indirect subsidiary of the Company as a “Qualified Electing Fund” under Section 1295 of the U.S. Internal Revenue Code of 1986, as
amended. Without limitation to the foregoing, the Company shall and shall procure that the WXPT Group Companies and any future direct or indirect subsidiary of the Company shall (i) provide to GA and Fidelity and their respective Affiliates and
their designees, on a timely basis as required, a “PFIC Annual Information Statement” (within the meaning of United States Treas. Reg § 1.1295-1(g)) for each taxable year, setting forth shares of GA’s or Fidelity’s (as
applicable) “ordinary earnings” and “net capital gain” for such taxable year; (ii) make available and permit, on a timely basis as required, GA and Fidelity and their respective Affiliates and their designees to inspect and
copy, permanent books of account, records, and such other documents of the Company, the WXPT Group Companies and such other future direct or indirect subsidiary of the Company as they maintain to establish the “ordinary earnings”,
“net capital gain” and “earnings and profits” of the Company, the WXPT Group Companies and any other direct or indirect subsidiary of the Company, and any other information that the United States Internal Revenue Service
(“IRS”) may require, determined in accordance with U.S. income tax principles, and to verify these amounts and pro rata shares thereof; and (iii) make available, on a timely basis as required, all information needed to complete
Form 5471 and other IRS forms; 

  

 16 

	 	5.2.12	The Company shall at all times reserve and keep available out of its authorized Ordinary Shares, solely for the purpose of issue or delivery upon conversion of the Preference
Shares, as provided in the Memorandum and Articles, the maximum number of Ordinary Shares that may be, in the Company’s reasonable judgment, issuable or deliverable upon such conversion. The Company shall issue such Ordinary Shares, in
accordance with the terms of the Memorandum and Articles, and otherwise comply with the terms; and 

  

	 	5.2.13	The Company shall permit each Preference Shareholders, for as long as the Shareholding Requirement is satisfied, and representatives or the Preference Shareholders reasonably
acceptable to the Company, to visit and inspect any of its properties, to examine its corporate, financial and operating records and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with their respective
directors, officers and independent public accountants, all at such reasonable times during normal business hours and as often as may be reasonably requested upon reasonable advance notice to the Company. The Company shall not be required to
disclose details of contracts with or work performed specific customers or by specific suppliers where to do so would violate confidentiality obligations to those parties. The Preference Shareholders may exercise their rights under this Clause
5.2.13 only for purposes reasonably related to its interests under this Agreement. The Preference Shareholders’ rights under this Clause 5.2.13 may not be transferred. Any Preference Shareholders afforded inspection rights under this Clause
5.2.13 shall bear its own costs associated with the inspection. 

 Each of the Preference Shareholders hereby agrees that the
Company shall not be obliged to disclose any information under Clause 5.2.5 and Clause 5.2.6 above if such disclosure is prohibited by law or by any contractual obligation binding on the Company. 
  

	5.3	Non-Competition: 

 The Company agrees with and
undertakes to the Preference Shareholders that it will procure that each of the Senior Management Personnel will irrevocably and unconditionally, agree with and undertake to the Preference Shareholders and the Company, and each of the Founders
hereby irrevocably and unconditionally agrees with and undertakes to the Preference Shareholders for himself, that they will not (i) during their term of employment with the Group Company take up any executive position in any company other than
the Group Companies and will commit most of his efforts towards the development of the business and operations of the Group, except for Naruhito Masai who is currently also engaged in other businesses in Japan but not in competition with the
Business and (ii) during their term of employment with the Group Company and for a period of at least six (6) months (provided that it shall be at least twelve (12) months for the Founders who are Senior Management Personnel) after
they cease to be employed by any Group Company:- 
  

	 	5.3.1	either on his own account or in conjunction with or on behalf of any person, firm or company carry on or be employed, engaged, concerned, provide technical expertise or be
interested directly or indirectly in, any business, whether as shareholder, director, employee, partner, agent or otherwise, that is, in the opinion of the Company in competition (whether directly or indirectly) with any business carried on or
proposed to be carried on by the Group Companies from time to time; 

  

	 	5.3.2	either on his own account or in conjunction with or on behalf of any other person, firm or company, solicit or entice away or attempt to solicit or entice away from the Group
Companies from time to time, the customer of any person, firm, company or organisation who shall at any time have been a customer, client, agent or correspondent of the Group Companies or in the habit of dealing with the Group Companies; or

  

 17 

	 	5.3.3	either on his own account or in conjunction with or on behalf of any other person, firm or company, solicit or entice away or attempt to solicit or entice away from the Group from
time to time, any person who is an officer, manager or employee of the Group whether or not such person would commit a breach of his contract of or employment by reason of leaving such employment. 

  

	5.4	Provisions Reasonable for Protection of Legitimate Interest: Notwithstanding that the Parties Agree that the restrictions in Clause 5.3 are considered to be reasonable in all
the circumstances, it is agreed between the Parties that if any one or more of such restrictions shall either taken by itself or themselves together be adjudged to go beyond what is reasonable in all the circumstances for the protection of the
legitimate interest of any Group Company from time to time, but would be adjudged reasonable if any particular restriction or restrictions were deleted or if any part or parts of the wording thereof were deleted, restricted or limited in any
particular manner, the restrictions shall apply with such deletions, restrictions or limitations, as the case may be. 

  

	5.5	Intellectual Property Rights: The Company further undertakes to the Preference Shareholders that:- 

  

	 	5.5.1	it will seek to protect the Group’s intellectual property rights as well as all future intellectual property rights of the Group through all requisite, appropriate and
desirable means including but not limited to registration of trade marks, patents, inventions and copyright with the appropriate authorities in the relevant jurisdictions and proper and enforceable legal documentation for all licenses;

  

	 	5.5.2	it will procure all employees and consultants of the Group Companies to enter into standard agreement or undertaking with the Company, undertaking not to divulge, use (other than
for the purpose and benefit of the Group) or infringe the trade marks, logo, inventions, know-how, technology, proprietary information and other intellectual property rights of the Group Companies; and 

  

	 	5.5.3	all trade marks, logo, inventions, know-how, technology, proprietary information and other intellectual property rights developed, acquired or filed by the employees of any Group
Company in the course of their work or employment shall belong solely to such Group Company or transferred by such Group Company to its customers in the ordinary course of its business. 

  

	5.6	Compliance with Law: The Company will at all times comply with all applicable legislation or regulation and all conditions of any authority or consent relating to this
Agreement and/or its business and operations in all material respects, and will notify the Preference Shareholders in writing immediately in the event of any material breach or non-compliance furnishing details of the same. Notwithstanding the
foregoing, neither the Company nor any Subsidiary nor any of their respective directors, officers or senior management staff shall effect any act or transaction involving the making or authorizing of any payment, or the giving of anything of value,
to any government official, political party, party official or candidate for political office for the purpose of influencing the recipient in his or its official capacity in order to obtain business, retain business or direct business to the Company
or such Subsidiary or any other Person. 

  

	5.7	 Dividends: Subject to the approval of the Board in accordance with Section 4.1.15 hereof and any requirement of the Articles, the Company shall, on an
annual basis, declare and pay in cash dividends in respect of the Ordinary Shares and the Preference Shares amounting to an aggregate of not less than 10% of the annual net earnings of the Company for the preceding financial 

  

 18 

	 	 
year; provided however that, for the avoidance of doubt, GA and the Series C Fidelity Investors shall not be entitled to any dividends for any financial year
ending prior to the date of this Agreement. 

  

	5.8	Employee Profits Sharing: Subject to the approval of the Board, the Company may, on an annual basis, set aside not more than 10% of the annual net earnings of the Company for
the preceding financial year for distribution to the employees of the Group and the details of such distribution (including, without limitation, the designation of the employees who are entitled to such distribution) shall be decided and approved by
the ACF Committee. 

  

	5.9	Directors’ Conflict: Each of the Existing Shareholders hereby represents and warrants to each other that in the event that it and/or its Affiliates invest in other
companies that are in similar business as and are in competition with the Group (“Competing Companies”), it shall (a) not appoint the Director of the Company as the director or other officer of the Competing Companies;
(b) not appoint the director or other officer of the Competing Companies as the Director of the Company; and (c) put in place suitable safeguards and Chinese wall to ensure that the Directors appointed by it (if any) to the Board do not
disclose and/or share the information concerning the Group with the Competing Companies and that it will procure the resignation of such Directors from the Board as soon as practicable, if there is any actual conflict of interest arising from its
aforesaid investment. 

  

	6	PRE-LISTING ESOS 

 Upon the recommendation of the ACF
Committee and subject to the approval of the Board (including approval from the Majority Preference Directors as provided in Clause 4.1.26), the Company shall formally adopt and implement the Pre-Listing ESOS prior to a Qualifying IPO. The ACF
Committee shall administer the Pre-Listing ESOS and be responsible for recommending the grant of all options thereunder. The terms of the Pre-Listing ESOS shall provide that upon exercise of any option, the holder of such option shall execute a
Joinder and become a party to this Agreement as if an original signatory hereto. 
  

	7	TRANSFERS AND ISSUANCE OF SHARES 

  

	7.1	Restriction on Transfer: 

  

	 	7.1.1	No Shareholder shall sell, transfer or otherwise dispose of any Shares held by it otherwise than in accordance with the provisions of this Agreement. The Parties shall procure the
Company and the Board to, and the Company and the Board shall, decline to accept any instrument of transfer and register any sale, transfer or disposal of Shares that is in breach of the provisions of this Agreement. 

  

	 	7.1.2	Without prejudice to the foregoing provision, from the date of this Agreement up to the date of termination of this Agreement or the date falling one hundred-eighty (180) days
after the closing of the Qualifying IPO (whichever is the earlier), none of the Founders shall, sell, transfer or otherwise dispose of any Shares held by it in the Company, or otherwise create any Encumbrance over all or any part of its interest in
such Shares, without the prior written consent of all the Preference Shareholders, save for any transfer of Shares not exceeding in aggregate ten per cent (10%) of the shareholding of such Founder. Each Shareholder hereby waives its pre-emption
rights in respect of any transfer of Shares in accordance with the foregoing. 

  

	 	7.1.3	The Shareholders shall not circumvent the restrictions set forth in this Clause 7.1 by disposing of, directly or indirectly, their beneficial interests in the Company, including
without limitation, by way of a disposition of shares they hold in the relevant holding entities that hold their Shares. 

  

 19 

	7.2	Pre-emption Right: Subject to the provisions of Clause 7.1, any Share proposed to be transferred by any Shareholder (in this Clause referred to as the
“Transferor”), other than a transfer pursuant to Clause 7.10 or Clause 7.14, shall first be offered to the Preference Shareholders and the Founders, and subject to Clause 7.15 below the Company as well in accordance with the
priority set out below:- 

  

	 	7.2.1	If any holder of outstanding Preference Shares wishes to transfer its Preference Shares, then:- 

  

	 	(i)	the other holders of outstanding Preference Shares shall have the pre-emption right to acquire such Preference Shares on the same terms; 

  

	 	(ii)	If any of the holders of outstanding Preference Shares decide not to exercise its aforesaid pre-emption rights, then the Founders shall have the pre-emption right to acquire such
untaken Preference Shares on the same terms. 

  

	 	(iii)	If the holders of the outstanding Preference Shares and the Founders decide not to exercise their aforesaid pre-emption rights, the Company shall have the pre-emption right to
acquire such untaken Preference Shares on the same terms, subject to Clause 7.15 below. 

  

	 	7.2.2	If any Shareholder wishes to transfer its Ordinary Shares, then:- 

  

	 	(i)	the Preference Shareholders and the Founders shall have the pre-emption right to acquire such Ordinary Shares on the same terms; 

  

	 	(ii)	If the Preference Shareholders and the Founders decide not to exercise their aforesaid pre-emption rights, the Company shall have the pre-emption right to acquire such untaken
Ordinary Shares on the same terms. 

 The offer by the Transferor above shall be made by giving a notice in writing to the
Company that it desires to transfer the same (the “Transfer Notice”) at a price to be set by the Transferor (the “Transfer Price”), and the Transfer Notice shall also set out the identity and background of the third
party (if known to the Transferor) that the Transferor proposes to transfer its Shares to (“Third Party Purchaser”) and the terms of such transfer. The Transfer Notice shall constitute the Company as the Transferor’s agent for
the sale of all the shares specified in the Transfer Notice (the “Transfer Shares”) during the period of thirty (30) days from the date of the Transfer Notice (the “Period”) and shall not be revocable except
with the Board’s unanimous consent. 
  

	7.3	Notification to the Shareholders: Upon receipt of the Transfer Notice, the Company shall forthwith by notice in writing inform each Preference Shareholder and Founder, of the
number of the Transfer Shares and the Transfer Price and invite such Preference Shareholders and Founders to apply in writing to the Company within fourteen (14) days of the date of despatch of the notice (which date shall be specified
therein), for such maximum number of the Transfer Shares (being all or any thereof) as it shall specify in such application. 

  

	7.4	 Allocation of Transfer Shares: If any of the Preference Shareholders and/or Founders shall within the period of fourteen (14) days as set out in Clause
7.3 apply for all or any of the Transfer Shares, the Directors shall allocate the said Shares (or so many of them as shall be applied for as aforesaid) to each of the participating Preference Shareholders and/or Founders and in case of competition,
pro rata (as nearly as possible) according to the number of Shares (“First Allotment”) equivalent to 

  

 20 

	 	 
the product obtained by multiplying the aggregate number of the Transfer Shares by a fraction, the numerator of which is the number of Ordinary Shares
(calculated on an as-if-converted basis in the case of Preference Shares) held by such Preference Shareholder and/or Founder at the time of the transaction and the denominator of which is the total number of Ordinary Shares owned by all the
participating Preference Shareholders and/or Founders at the time of the transaction (calculated on an as-if-converted basis in the case of Preference Shares) provided that no Preference Shareholder or Founder shall be obliged to take more than the
maximum number of Transfer Shares specified by it or him as aforesaid. To the extent that any participating Preference Shareholder or Founder does not exercise its right to purchase to the full extent of its First Allotment, the Company shall,
within five (5) days after the end of the period of fourteen (14) days as set forth in Clause 7.3, make such adjustments to the First Allotment of each participating Preference Shareholder and/or Founder so that any remaining Transfer
Shares may be allocated to those Preference Shareholders and/or Founders exercising their pre-emption rights on a pro rata basis (provided that such Preference Shareholders and/or Founders have indicated their agreement to subscribe for such
additional Transfer Shares) and give notice of such allocations (the “Allocation Notice”) to the Transferor and to the Preference Shareholders and/or Founders to whom the Transfer Shares have been allocated and shall specify in such
Allocation Notice the place and time (being not later than ten (10) days after the date of the Allocation Notice) at which the sale of the Transfer Shares so allocated shall be completed. Each of the Preference Shareholders may assign its
rights and obligations under Clauses 7.2, 7.3 and 7.4 to any of its Affiliates. 

  

	7.5	Transfer of Shares: The Transferor shall be bound to transfer the Transfer Shares included in an Allocation Notice to the purchaser(s) named therein at the time and place
therein specified and, if he shall fail to do so, the Chairman of the Company or some other person appointed by the Directors shall be deemed to have been appointed attorney of the Transferor with full power to execute, complete and deliver, in the
name and on behalf of the Transferor, transfers of the Transfer Shares to the purchaser(s) thereof against payment of the price to the Auditors or such other person which the Company may appoint for the purpose of holding such price monies in escrow
for the Transferor (such auditors or person, the “Escrow Agent”). The Company shall procure that, on payment of the price to the Escrow Agent, the Escrow Agent shall forthwith pay the price into a separate bank account in the Escrow
Agent’s name and shall hold such price in trust for the Transferor and the fees of the Escrow Agent shall be borne by the Transferor and can be deducted from the amount due to the Transferor. 

  

	7.6	Co-sale/Tag-along Rights: 

  

	 	7.6.1	 Subject to and without prejudice to Clauses 7.1 and 7.2, each of the Founders hereby agrees and undertakes that in the event that it, through a transaction or
series of transactions, transfers or intends to transfer or to procure a sale or transfer of any number of its Shares to any Third Party Purchaser, the Preference Shareholders shall have the right (the “Co-Sale Right”), and not the
obligation, exercisable upon written notice to Transferor, the Company and each other Preference Shareholder (“Co-sale Notice”) within twenty (20) days after receipt of the Transfer Notice (the “Co-sale Right
Period”), to participate in such sale of Shares at the same price as set forth in the Transfer Notice. The Co-Sale Notice shall set forth the number of Transfer Shares (on both an absolute and as-converted to Ordinary Shares basis) that
such participating Preference Shareholder wishes to include in such sale or transfer, and which amount shall not exceed the Co-Sale Pro Rata Portion (as defined below) of such Preference Shareholder. To the extent one or more of the Preference
Shareholders exercise such Co-Sale Right in accordance with the terms and conditions set forth below, the number of Transfer Shares that the Transferor may sell in the transaction shall be correspondingly reduced. Each Preference Shareholder may
sell all or any part of that number of Ordinary Shares held by it that is equal to the product obtained by multiplying (x) the aggregate number of the Transfer Shares 

  

 21 

	 	 
subject to the co-sale right hereunder by (y) a fraction, the numerator of which is the number of Ordinary Shares (on an as-converted basis) owned by
the Preference Shareholder at the time of the sale or transfer and the denominator of which is the combined number of Ordinary Shares (on an as-converted basis) at the time owned by all Preference Shareholders (“Co-Sale Pro Rata
Portion”). To the extent that any Preference Shareholder does not participate in the sale to the full extent of its Co-Sale Pro Rata Portion, the Transferor and the participating Preference Shareholders shall, within five (5) days
after the end of such Co-Sale Right Period, make such adjustments to the Co-Sale Pro Rata Portion of each participating Preference Shareholder so that any remaining Transfer Shares may be allocated to other participating Preference Shareholders on a
pro rata basis. 

  

	 	7.6.2	In the event that any of the Preference Shareholders chooses to exercise its Co-Sale Rights set out in Clause 7.6.1, the aforesaid Founder shall not transfer or dispose of its
Shares to such Third Party Purchaser unless such Third Party Purchaser has agreed to purchase and does purchase the relevant number of Shares held by the Preference Shareholders on terms no less favourable than those offered to such Founder.

  

	7.7	Transfer to Third Party Purchaser: Subject to the provisions of Clause 7.1 to 7.6, if none of the Preference Shareholders accept the offer referred to above in respect of all
the Transfer Shares set out in the Transfer Notice or if not all of the Transfer Shares are agreed to be taken up within thirty (30) days after the Transfer Notice is served, the Transferor may after the Period be at liberty to sell all (and
not part only) of the Transfer Shares to the Third Party Purchaser set out in the Transfer Notice; provided, that:- 

  

	 	7.7.1	if any of the Preference Shareholders chooses to exercise its rights under Clause 7.6 above, there shall be no transfer of the Transfer Shares by the Transferor unless such Third
Party Purchaser has agreed to purchase the Preference Shareholder’s Shares in accordance with the said Clause 7.6 and the Transfer Shares and the aforesaid Preference Shareholder’s Shares are transferred to the Third Party Purchaser at the
same time; 

  

	 	7.7.2	the Transferor has received the prior written consent of the Board in relation to the Transfer, such consent not to be unreasonably withheld if (i) the provisions in this
Clause 7 are complied with and (ii) the Third Party Purchaser is not a competitor or any past or existing customer or supplier of any of the Group Companies, is financially sound and is capable of performing and complying with the provisions of
this Agreement applicable to the Transferor; 

  

	 	7.7.3	the price at which such Third Party Purchaser acquires the Transfer Shares shall not be below the Transfer Price and shall be on terms no more favourable than those specified in the
Transfer Notice; 

  

	 	7.7.4	such Third Party Purchaser is not a competitor of the WXPT Group and will not cause any conflict of interest as a result of its shareholding in the Company; and

  

	 	7.7.5	the Transferor shall remain and continue to be liable and be responsible for the discharge, observance and performance of all his liabilities and obligations, whether actual or
contingent, arising out of or in connection with this Agreement at any time up to and including the date of the transfer of the Transfer Shares and shall remain entitled to all accrued rights and benefits arising out of or in connection with the
Transfer Shares. 

  

 22 

	7.8	Subsequent Sale: In the event the Transfer Shares are not sold by the Transferor to the Third Party Purchaser within three (3) months of the date of the Transfer Notice,
any subsequent sale, transfer or disposal of the Transfer Shares shall be subject to fresh compliance with the provisions hereinbefore set out. 

  

	7.9	Condition of Transfer: Unless otherwise agreed by the Shareholders, it shall be a condition precedent to the right of any Transferor to transfer Shares that the Transferee
(if not already bound by the provisions of this Agreement) executes a Joinder under which the Transferee shall agree to be bound by the obligations and shall be entitled to the benefit of this Agreement as if it is an original party hereto in place
of the Transferor. If the Transferor transfers only part of the Shares it holds in the Company, the Transferee holding shares in the Company after such transfer, together with the Transferor, shall collectively be deemed as the
“Shareholder” in this Agreement upon such transfer and, the rights of the Transferor under this Agreement shall be exercised collectively. 

  

	7.10	Transfer to Preference Shareholder’s Affiliates: Notwithstanding any other provision of this Agreement, the Parties agree that: 

  

	 	7.10.1	each Preference Shareholder shall be entitled at any time to transfer any of its Shares to its Affiliates; 

  

	 	7.10.2	each of the UOB Entities shall be entitled to transfer its Shares to such other UOB Entities or any other UOB Persons; 

  

	 	7.10.3	Fidelity shall be entitled to transfer its Shares to any Fidelity Persons or charitable organization; 

  

	 	7.10.4	NAP shall be entitled to transfer its Shares to any NAP Persons; 

  

	 	7.10.5	GapStar, LLC may pledge and grant a security interest in its Shares to a lender to secure its obligations under a bona fide loan made to acquire such Shares;

 provided that such transferee is not a competitor of the WXPT Group and will not cause any conflict of interest as a result
of its shareholding in the Company. Pursuant to such transfer, the transferee shall execute a Joinder, provided, that in the event that such transferee ceases to be an Affiliate or a UOB Entity or other UOB Person, a Fidelity Person, a NAP Person or
GA (as the case may be) or becomes a competitor of the WXPT Group or cause any conflict of interest as aforesaid, the Preference Shareholders or the UOB Entities, Fidelity, NAP or GA (as the case may be) shall procure such transferee to transfer
such Shares back to the Preference Shareholders or UOB Entities or Fidelity or NAP or GA (as the case may be). Each Shareholder hereby waives its pre-emption rights in respect of such transfer of shares by the Preference Shareholders to any such
persons. In the event that any Preference Shareholder transfers any of its Shares pursuant to any of Clauses 7.10.1, 7.10.2, 7.10.3 or 7.10.4, the transferee thereof shall have the same rights and obligations under this Agreement as those enjoyed by
the transferring Preference Shareholder. 
  

	7.11	 Further Issue of Shares: Subject to Clause 7.13, the Shareholders shall take such steps for the time being as lie within their power to procure that the
Company shall not issue any further Shares whether forming part of its unissued Shares or new Shares without first offering to each of the Shareholders such number of Shares in proportion to their then existing shareholdings in the Company (and in
the case of the Preference Shareholders, their shareholding shall be computed on “as converted” basis) as shall enable each such Shareholder to maintain their respective proportionate shareholdings in the issued share capital of the
Company. Such offer shall be made by notice specifying the number of new Shares offered, the proportionate entitlement of each Shareholder, the price per Share and limiting a period (not being less than thirty (30) days) 

  

 23 

	 	 
within which the offer, if not accepted, will be deemed to be declined. Upon the expiration of such period the Directors shall offer the Shares so declined,
to the other Shareholders who have notified their willingness to take all or any of such Shares in accordance with the terms of the offer and in case of competition, pro rata (as nearly as possible) according to the number of Ordinary Shares
in the Company of which such other Shareholders are registered or unconditionally entitled to be registered as holders (and in the case of the Preference Shareholders, their shareholding shall be computed on “as converted” basis). For the
avoidance of doubt, the number of Ordinary Shares and Preference Shares issued by the Company from time to time shall be aggregated for the purpose of computing the proportionate shareholding of each Shareholder hereunder. Each of the Preference
Shareholders may assign its rights and obligations under this Clause 7.11 to any of its Affiliates. 

  

	7.12	Quasi-Equity: Without prejudice to Clause 7.11 above, the Shareholders hereby agree that the Preference Shareholders shall have the first right to subscribe for any
preference shares, quasi-equity issue or any other instruments that can be converted into equity that may be issued by any Group Company. 

  

	7.13	Exceptions: The rights of the Shareholders to participate in an issue by the Company of further Shares pursuant to Clause 7.11 shall not apply in the following instances:

  

	 	7.13.1	where the issue of further Shares by the Company is made pursuant to the terms and conditions of the Series C Subscription Agreement or the conversion of the Preference Shares
contemplated thereunder; 

  

	 	7.13.2	where the further issue of Shares by the Company amounts to the consideration paid by the Company pursuant to an acquisition or merger by the Company of or with another business
entity, provided, that such acquisition or merger shall have received the prior approval of the Board as a Reserved Matter; 

  

	 	7.13.3	where the issue of further Shares by the Company is made pursuant to a Qualifying IPO; 

  

	 	7.13.4	where the issue of further Shares by the Company is made to persons or entities with which the Company has business relationships and provided, that such issue is not for the main
purpose of obtaining equity financing and has been approved by the Preference Shareholders; 

  

	 	7.13.5	where the issue of further Shares by the Company is made pursuant to the Company’s Pre-Listing ESOS to be implemented by the Company from time to time; or

  

	 	7.13.6	where the issue of further Shares by the Company is made in connection with any share split, share dividend or other similar event in which all Preference Shareholders are entitled
to participate on a pro rata basis. 

  

	7.14	Permitted Transfer by Founder or Other Shareholders: Notwithstanding any other provision of this Agreement, the Parties agree that: 

  

	 	7.14.1	 Any Founder or other Shareholder who is an individual shall be entitled at any time to transfer any of his Shares to any estate arising from his death or any trust
set up by him for the benefit of his Immediate Family (all of the beneficial interests in such trust being owned by such Founder or other Shareholder or his Immediate Family) (a “Permitted Trust”) or any company wholly-owned and
controlled by him; provided that such transferee (“Permitted Transferee”) is not a competitor of the WXPT Group and will not cause any conflict of interest as a result of his shareholding in the Company. Pursuant to such transfer,
the Permitted Transferee shall execute a Joinder Provided, 

  

 24 

	 	 
that in the event that such Permitted Transferee ceases to qualify as a Permitted Transferee as aforesaid or becomes a competitor of the WXPT Group or cause
any conflict of interest as aforesaid, the relevant transferor shall procure such transferee to transfer such Shares back to the said transferor. Each Shareholder hereby waives its pre-emption rights in respect of such transfer of shares by the
Shareholders to any such Permitted Transferee. 

  

	 	7.14.2	In the event of a transfer to a Permitted Trust pursuant to Clause 7.14.1, such Permitted Trust (after having become a Shareholder by executing a Joinder) shall be entitled at any
time to transfer any Shares held by the Permitted Trust to (i) the Shareholder who transferred those Shares to the Permitted Trust pursuant to Clause 7.14.1, (ii) any member of the Immediate Family of such transferring Shareholder referred
to in the foregoing clause (i), (iii) another trust having as its sole primary beneficiary or sole primary beneficiaries any one or more of the members of the Immediate Family of the Shareholder who initially transferred the Shares to the
Permitted Trust, (iv) by any trust described in the preceding clause (iii) to any one or more of the Persons described in any of the preceding clauses of this sentence (determined as if the Shareholder who initially transferred the Shares
to the Permitted Trust was the transferring Shareholder) or (v) any company wholly-owned and controlled by one or more of the Persons described in any of the preceding clauses of this sentence. Each of the Persons described in the foregoing
clauses (i)-(v) shall also be Permitted Transferees hereunder; provided, however, that notwithstanding anything to the contrary set forth in this Clause 7.14.2, none of such Permitted Transferees shall be a competitor of the WXPT
Group and will not cause any conflict of interest as a result of its shareholding in the Company. Pursuant to any such transfer, the Permitted Transferee shall execute a Joinder, provided, that in the event that such Permitted Transferee ceases to
qualify as a Permitted Transferee as aforesaid or becomes a competitor of the WXPT Group or cause any conflict of interest as aforesaid, the relevant transferor shall procure such transferee to transfer such Shares back to the original transferor.
As used in this Clause 7.14.2, the terms “primary beneficiary” and “primary beneficiaries”, when used with respect to a trust, mean the Person or Persons who are eligible at the time of the transfer to receive distributions of
income or principal from that trust on a current basis. 

  

	7.15	Buy-back of Untaken Shares by Company: Notwithstanding the foregoing provisions, in the event that the Company is entitled to, exercise its pre-emption rights under Clause
7.2 above to acquire the Shares not taken up by the relevant Shareholders (“Untaken Shares”), the Company may, subject to approval by the Board as an ordinary resolution and compliance with applicable laws, effect a buy-back of the
Untaken Shares by the Company at the Transfer Price and the Shareholder who is the Transferor shall abstain from voting in respect of such decision. 

  

	7.16	The Company and each Shareholder hereby waives any and all rights it may have under this Clause 7, Clause 7 of the Amended and Restated JV Agreement, the Memorandum and Articles of
Association and otherwise in respect of (i) the issuance of the Series C Preference Shares and the Convertible Notes pursuant to, and all other transactions contemplated by the Series C Subscription Agreement and the Note Purchase Agreement and
(ii) the transactions and transfers contemplated by the Sellers Agreement (as defined in the Series C Subscription Agreement). 

  

	8	PUBLIC LISTING 

  

	8.1	 Qualifying IPO: The Company and the Founders agree that each of them will use their best endeavours to procure a Qualifying IPO by 31 December 2007 (or
such other date as the Company and the Preference Shareholders may agree). In connection 

  

 25 

	 	 
with the foregoing, the Founders will procure that the Company will support the application for such a Qualifying IPO and they will exercise their votes at
any general meeting of the Company called for such purpose. The terms of such a Qualifying IPO, the appointment of any manager, arranger, underwriter or other financial advisor for such a Qualifying IPO shall be subject to the prior written consent
of the Preference Shareholders and the Founders (such consent not to be unreasonably withheld), provided that if the Preference Shareholders and/or the Founders shall fail to respond or to unanimously agree within thirty (30) days after being
notified of such terms and appointment, such matters shall then be decided by the Board. 

  

	8.2	Preference Shareholders’ Offer of its Shares upon Listing: In respect of the listing of any of the Ordinary Shares on a Recognised Stock Exchange, subject to the
requirements of the issue manager or underwriter of the Qualifying IPO and the terms of the relevant Subscription Agreement, the Preference Shareholders shall have the right (but not the obligation) to convert their Preference Shares into Ordinary
Shares and to offer, at its option, such number of the Ordinary Shares in the Company held by it in the proportion such shareholding in the Company bears to the Company’s total issued share capital, computed immediately before the issue of new
shares pursuant to the said listing, to the public by way of an offer for sale at the initial public offer. For the avoidance of doubt, the Parties agree that the Preference Shareholders shall not be regarded as promoters of the Company for the
purposes of any relevant legislation or regulation of any Recognised Stock Exchange, and shall not be named as “promoter” in any prospectus or offer document of the Company for the Qualifying IPO or for any other purpose. The Company shall
ensure that the Preference Shareholders is not locked into its investment for any period of time as if it is such a promoter or otherwise. 

  

	8.3	Founders’ Offer of its Shares upon Listing: In respect of the listing of any of the Ordinary Shares on a Recognised Stock Exchange, subject to the requirements of the
issue manager or underwriter of the Qualifying IPO and the terms of the relevant Subscription Agreement, if the Preference Shareholders exercised their rights under Clause 8.2 above to sell their Ordinary Shares at the Qualifying IPO, the Founders
shall have the right (but not the obligation) to offer, at its option, such number of the Ordinary Shares in the Company held by it for sale to the public at the aforesaid Qualifying IPO, provided that the number of Ordinary Shares that all such
Founders may offer for sale shall be limited to one-third of the total number of Ordinary Shares offered for sale by the Preference Shareholders at the aforesaid Qualifying IPO under Clause 8.2 above. 

  

	8.4	IPO Participation Right: Subject to applicable legal and regulatory requirements and any determination by the lead underwriter in such offering that the exercise of such
right would be seriously detrimental to such offering or the aftermarket performance of the Company’s securities, including without limitation U.S. securities laws, GA shall have the right, but not the obligation, to purchase an aggregate of up
to 15% of the Ordinary Shares offered in the Company’s initial public offering of Ordinary Shares at a price per share equal to the final price per share (after deduction of underwriting discounts and commissions) stated in the final prospectus
used in connection with such offering. 

  

	9	CERTAIN SHAREHOLDERS’ LOCK-UP 

  

	9.1	Lock-up Period: Subject to Clause 7.1, each of the Founders and Rexbury irrevocably and unconditionally undertakes to the Preference Shareholders not to sell, transfer, grant
an option to purchase or otherwise dispose of or encumber any of its Shares for a period from the date of this Agreement up to one hundred and eighty (180) days after the closing of the Qualifying IPO, without the prior written approval of the
Preference Shareholders. 

  

	9.2	[Intentionally left blank.] 

  

 26 

	9.3	Exceptions to Lock-Up : Notwithstanding Clauses 9.1 above, in the event that the Preference Shareholders have collectively disposed of more than 50% of the total number of
Preference Shares (including, for purposes of calculation, the Ordinary Shares issuable upon conversion of such Preference Shares) held by them as at the date hereof (“Preference Shareholders’ Sale Shares”), the Founders shall
have the right (and not the obligation) to dispose of their Shares in the Company subject to the following terms: 

  

	 	9.3.1	If the average sale price of the Preference Shareholders’ Sale Shares (“Preference Shareholders’ Average Price”) is at a valuation above or equal to that
for a Qualifying IPO, then the Founders may dispose of such number of Shares as may be equal to the total number of Preference Shareholders’ Sale Shares (on an as-converted basis) (“Founders’ Sale Portion”).

  

	 	9.3.2	If the Preference Shareholders’ Average Price is at a valuation below that for a Qualifying IPO, then the Founders’ Sale Portion shall be reduced to one-third of the total
number of Preference Shareholders’ Sale Shares (on an as-converted basis). 

  

	 	9.3.3	Subject to the pre-emption, co-sale and other rights accorded to the Parties under Clause 7, the Founders shall be entitled to transfer their Founders’ Sale Portion (as
determined in accordance with this Clause 9.3) to a third party (“Founders’ Third Party Purchaser”). 

  

	 	9.3.4	In addition, the Founders shall satisfy and ensure that the Founders’ Third Party Purchaser satisfy the requirements under Clause 7.7 and Clause 7.9 in respect of the aforesaid
transfer of Shares. 

  

	10	DEFAULT AND TERMINATION 

  

	10.1	Event of Default: Without prejudice to Clause 7, a Shareholder shall be deemed to have appointed the Company as its agent for the sale of all the Shares held by such
Shareholder (the “Affected Shareholder”) in any of the following events: 

  

	 	10.1.1	the Affected Shareholder or any other person takes any action or any legal proceedings are started or other steps taken for: 

  

	 	(a)	the Affected Shareholder to be adjudicated bankrupt or insolvent; or 

  

	 	(b)	the winding-up, liquidation or dissolution of the Affected Shareholder, and such actions, proceedings or steps are not withdrawn, discontinued or dismissed within twenty Business
Days after they are started; or 

  

	 	10.1.2	the Affected Shareholder has a winding-up, bankruptcy or administration order made in relation to it; or 

  

	 	10.1.3	the Affected Shareholder is affected in any way in any jurisdiction other than the U.S. by anything equivalent to any of the things referred to in Clauses 10.1.1 to 10.1.2 above.

  

	10.2	Sale by Company: 

  

	 	10.2.1	 Within twenty (20) Business Days of the Company becoming aware of the occurrence of an event listed in Clause 10.1, the Company shall notify the Affected
Shareholders (“Company Notice”) of its intention to offer, on behalf of the Affected Shareholder, all the Shares held by the Affected Shareholder (the “Affected Shares”) to the other Shareholders in the proportion,
as nearly as is practicable, to their respective shareholding in the Company (and in the 

  

 27 

	 	 
case of the Preference Shareholders, their shareholding shall be computed on “as converted” basis). If the Affected Shareholder fails to sell the
Affected Shares on its own accord (subject always to compliance with Clause 7 above and the pre-emption right and co-sale right of the other Shareholders thereunder) within three (3) months after its receipt of the Company Notice, the Company
shall proceed with the aforesaid offer and send a written notice to each of the other Shareholders (a “Compulsory Offer”) stating the number of the Affected Shares being offered to that Shareholder and the Fair Price (as defined
below) as being the price per Share. 

  

	 	10.2.2	For the purposes of this Clause 10, the “Fair Price” means the price mutually agreed by the Parties within twenty (20) Business days after their receipt of the
Compulsory Offer and failing agreement within such period, it shall be the price which the Auditors state in writing to be in their opinion the fair value of the Shares, having regard to the value, as a going concern, of the Group’s business
and net assets and on the basis of an arm’s length transaction on a sale as between a willing seller and a willing purchaser (taking no account of whether the Shares do or do not carry control of the Company) and, if the Company is then
carrying on business as a going concern, on the assumption that it will continue to do so. 

  

	 	10.2.3	At any time within fourteen days after the date of despatch of the Compulsory Offer (which date shall be specified therein), each Shareholder shall, subject to Clause 10.2.6 below,
have the right, but not the obligation, to purchase some or all of the Affected Shares offered to it at the price stated in the Compulsory Offer, which right shall be exercisable by written notice to the Company, stating a closing date not more than
thirty days after the date of the despatch of the Compulsory Offer. If a Shareholder agrees to purchase all of the Affected Shares offered to it pursuant to the Compulsory Offer, that Shareholder may indicate in the written notice to the Company
that it is prepared to purchase additional Affected Shares. An offer for such Affected Shares made pursuant to this Clause 10.2.3 shall, unless earlier declined or accepted, remain open for thirty (30) days and shall then be taken to be
declined if not accepted. 

  

	 	10.2.4	If the Company has not received offers to purchase all the Affected Shares offered pursuant to the Compulsory Offers within thirty days after the date of despatch of the Compulsory
Offer, the Company shall make a written offer of all Affected Shares which have been declined or taken to have been declined, to the Shareholders which indicated a preparedness to purchase additional Affected Shares, at the price stated in the
Compulsory Offer (a “Further Compulsory Offer”). Each Shareholder receiving a Further Compulsory Offer shall subject to Clause 10.2.6, have the right, but not the obligation, to purchase all or some only of the Affected Shares
offered to it at the price stated in the Compulsory Offer. Such right shall be exercisable by written notice to the Company, stating a closing date not later than the closing date agreed by the Shareholder pursuant to Clause 10.2.3 or where that
date has passed, a date not more than fourteen (14) days after the date of the Further Compulsory Offer. Each offer pursuant to this Clause 10.2.4 shall, unless earlier declined or accepted, remain open for fourteen (14) days and shall
then be taken to be declined if not accepted. 

  

	 	10.2.5	If there are insufficient Shares offered pursuant to Clause 10.2.4 above to satisfy in full all offers to purchase additional Affected Shares, the Affected Shares offered pursuant
to Clause 10.2.4 shall be distributed among the Shareholders which offered to accept such Affected Shares in the proportions, as nearly as practicable, in which such Shareholders hold Shares respective to each other. 

  

 28 

	 	10.2.6	In the event that after the operation of Clauses 10.2.1 to 10.2.5 above, some or all of the Affected Shares remain unsold, the Company may offer those Affected Shares to a third
party approved in writing by all the Shareholders (excluding the Affected Shareholder). If the Company does not enter into a contract for the sale of all of the Affected Shares or the remaining Affected Shares (as the case may be) with such a third
party within three months of the date when the Further Compulsory Offer is deemed to be declined pursuant to Clause 10.2.4, the Company shall at the Company’s option exercisable within fourteen days after expiration of such three-month period,
either: 

  

	 	(a)	confirm in writing all acceptances of offers made by the Company whereupon the Shareholders who have accepted those offers shall be entitled and bound to purchase and the Affected
Shareholder shall be bound to transfer in accordance with the terms of the offers; or 

  

	 	(b)	disclaim in writing all acceptances of offers made by the Company whereupon: 

  

	 	(i)	the Affected Shareholder shall be released absolutely from all liability incurred by reason of acceptance of those offers; and 

  

	 	(ii)	the Shareholders who have accepted such offers shall be released absolutely from all liability so incurred. 

  

	10.3	Subject to the provisions of this Agreement, this Agreement shall take effect without limit in point of time. If any Party transfers all of its Shares in accordance with the
provisions of this Agreement and with the Articles, it shall be released from all of its obligations hereunder without prejudice to obligations as to antecedent defaults or breaches. If following any such transfer there shall be at least two parties
bound by the provisions of this Agreement, this Agreement shall continue in full force and effect as between the continuing parties Shareholders Provided That this Agreement shall terminate upon the listing of the Shares of the Company on a
Recognised Stock Exchange. 

  

	11	PUT OPTION 

  

	11.1	Grant of Put Option: The Company hereby irrevocably grants to each Preference Shareholder an option (“Put Option”) to require the Company to purchase from
such Preference Shareholder, free from Encumbrances and with all rights attaching thereto on the Put Option Completion, any or all of the Option Shares held by such Preference Shareholder, upon the terms and subject to the conditions in this Clause
11 and this Agreement. 

  

	11.2	Exercise: If (i) with respect to the holders of Series C Preference Shares only, a Qualifying IPO, and (ii) with respect to the holders of Series A Preference
Shares and Series B Preference Shares only, Qualifying Existing Shareholder IPO, does not occur before 31 December 2007, the Put Option may be exercised by each Preference Shareholder in respect of all (and not some only) of its Option Shares,
by serving the notice of exercise of the Put Option set out in Schedule 6 (the “Put Option Notice”) on the Company at any time from 1 January 2008 and up till and including 30 March 2009. 

 

	11.3	Exercise Price: The Company agrees that it will, upon service of the Put Option Notice by a Preference Shareholder, purchase from such Preference Shareholder, free from
Encumbrances and with all rights attaching thereto on the Put Option Completion, the Option Shares at the Put Option Price (the “Put Option Proportion”). 

  

 29 

	11.4	Payment of the Put Option Price: Upon the exercise of the Put Option, the Put Option Price shall be paid by the Company in three (3) installments, in the following
manner: 

  

	 	 11.4.1
	 one-third of the Put Option Price on the fifteenth (15th) day after the receipt of the Put Option Notice; 

  

	 	 11.4.2
	 one-third of the Put Option Price on the one hundred and fifth (105th) day after the receipt of the Put Option Notice; 

  

	 	 11.4.3
	 one-third of the Put Option Price on the two hundred and fifth (205th) day after the receipt of the Put Option Notice; 

 provided always, that if any one of the above deadlines for payment of any portion of the Put Option Price falls after 31 December 2008, such remaining portion of the Put Option Price remaining unpaid as at
31 March 2009 shall be accelerated and paid on that date. 
  

	11.5	Completion: The Put Option Completion shall take place at the principal place of business of the Company (or at such other place as such Preference Shareholder and the
Company may agree in writing) on the date of payment of the final portion of the Put Option Price. 

  

	11.6	Waiver of Pre-emption: The exercise of the Put Option by the Preference Shareholders in accordance with the provision of this Clause 11 shall not be subject to any
restrictions on transfer and all rights of pre-emption conferred on the other shareholders of the Company, whether by virtue of the Articles or otherwise, are hereby waived by such shareholders. 

  

	12	SHARE CERTIFICATE LEGEND 

  

	12.1	Share Certificate Legend. A copy of this Agreement shall be filed with the Secretary of the Company and kept with the records of the Company. Each certificate representing
Shares now held or hereafter acquired by any Shareholder shall for as long as this Agreement is effective bear legends substantially in the following forms: 

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR ANY
FOREIGN JURISDICTION. THE SECURITIES MAY NOT BE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE AND FOREIGN SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF SUCH ACT AND SUCH LAWS. 
 THE SALE, ASSIGNMENT, HYPOTHECATION, PLEDGE, ENCUMBRANCE OR OTHER DISPOSITION (EACH A
“TRANSFER”) AND VOTING OF ANY OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE RESTRICTED BY THE TERMS OF THE SECOND AMENDED AND RESTATED JOINT VENTURE AGREEMENT AMONG THE COMPANY AND THE SHAREHOLDERS NAMED THEREIN, A COPY OF
WHICH MAY BE INSPECTED AT THE COMPANY’S PRINCIPAL OFFICE. THE COMPANY WILL NOT REGISTER THE TRANSFER 

  

 30 

 
OF SUCH SECURITIES ON THE BOOKS OF THE COMPANY UNLESS AND UNTIL THE TRANSFER HAS BEEN MADE IN COMPLIANCE WITH THE TERMS OF THE JOINT VENTURE AGREEMENT.

  

	13	ENTIRE AGREEMENT 

 This Agreement shall be the final
expression of all Parties’ agreement and be a complete and exclusive statement of the agreement and understanding of the parties in respect of the subject matter contained herein, and supersede all prior negotiations, agreements, including the
2005 JV Agreement and the Amended and Restated JV Agreement, and understandings, whether oral or written, between the Company and the Shareholders or among the Shareholders (either in writing or orally) with respect to such subject matter.

  

	14	CONFIDENTIALITY 

  

	14.1	Confidential Undertaking: Each of the Parties agrees that the contents herein and all communications between the Parties and the Group Companies or any of them and all
information and other material supplied to or received by any of them from the others which is either marked “confidential” or is by its nature intended to be exclusively for the knowledge of the recipient alone and any information
concerning the business transactions or the financial arrangements of the Parties or any person with whom any of them is in a confidential relationship with regard to the matter in question coming to the knowledge of the recipient are of a
confidential nature and further undertakes with each other that, during the subsistence of this Agreement and for a period of three (3) years after the termination thereof, it will not, and will procure (not including the need to take legal
action) that none of its Affiliates, officers, employees and agents will divulge or disclose the contents of this Agreement or the arrangements hereunder to any other person or entity. 

  

	14.2	Exceptions: The restriction in Clause 14.1 above shall not apply if the information or knowledge concerned:- 

  

	 	14.2.1	has become public knowledge other than as a result of unauthorised disclosure by the relevant Party; 

  

	 	14.2.2	has been disclosed in the proper performance of the relevant Party’s obligations under or consequent to this Agreement; 

  

	 	14.2.3	is received by the relevant Party from a third party without any duty of confidentiality in relation thereto; 

  

	 	14.2.4	is already in the possession of the relevant Party before negotiations commenced between the Parties; 

  

	 	14.2.5	is developed or prepared by the relevant Party independently of information received after negotiations commenced between the Parties; 

  

	 	14.2.6	is disclosed by the relevant Party to its Subsidiaries or Affiliates for internal reporting purposes provided that such Subsidiaries or Affiliates (as the case may be) shall have
undertaken to comply with the confidentiality obligations hereto; 

  

	 	14.2.7	 is otherwise required to be disclosed by law or any regulatory authority or any rules of the relevant stock exchanges or any court properly exercising jurisdiction
over the relevant Party or in accordance with the best accounting practice in the accounts of the relevant Party, provided that, if any Party is required to make a disclosure by reason of this 

  

 31 

	 	 
Clause 14.2.7, it shall, to the extent reasonably possible, supply a copy of the contents of any such disclosure to the other Party prior to the making of
such disclosure, failing which it shall do so as soon as is reasonably practicable after the making of such disclosure; or 

  

	 	14.2.8	is disclosed by a Preference Shareholder on its worldwide web page, provided however that (i) such information may include only the name of the Company, the name of the Chief
Executive Officer of the Company, a brief description of the business of the Company and the Company’s logo and (ii) to the Company is given prior opportunity to approve any such information (except for such information mentioned in
(i) above that is already public on such Preference Shareholder’s worldwide web page). 

  

	14.3	Limited Disclosure: All Parties shall procure (not including the need to take legal action) the observance of the abovementioned restrictions by the Company and shall take
all reasonable steps to minimise the risk of disclosure of confidential information, by ensuring that only their Affiliates, employees and directors and those of the Company whose duties will require them to possess any of such information shall
have access thereto, and that the Parties shall procure (not including the need to take legal action) that their respective Affiliates, employees and directors shall treat the same as confidential. 

  

	14.4	Announcement: None of the Parties shall be entitled to make or permit or authorise the making of any press release or other public statement or disclosure concerning this
Agreement or any of the transactions contemplated in it without prior written consent of the other Party (except as required by the Recognised Stock Exchange when such Party shall first supply a copy of such statement, release or disclosure to the
others and shall incorporate any amendments or additions reasonably required by that other Parties). 

  

	14.5	Obligations to Survive: The obligations contained in this Clause 14 shall endure, even after the termination of this Agreement, except to the extent that and until any
confidential information enters the public domain or otherwise as set out in Clause 14.1 above. 

  

	15	NATURE OF RIGHTS AND OBLIGATIONS 

  

	15.1	Reliance: The Company and the Founders hereby jointly and severally acknowledge and covenant that the undertakings and obligations binding upon them in this Agreement are
owed to, and shall be for the benefit of the Preference Shareholders, their assigns, transferees and successors-in-title and for the avoidance of doubt also for the benefit of the transferees (of the Shares in the Company held by the Preference
Shareholders) who pursuant to any assignment, transfers or succession, come to hold such Shares in the Company. 

  

	15.2	Company’s obligations: The Founders and the Preference Shareholders shall procure and undertake that the Company will perform all its obligations under this Agreement
and will observe all the terms and conditions set out in this Agreement. 

  

	16	REPRESENTATIONS AND WARRANTIES 

  

	16.1	General Representations: Each of the Parties represents and warrants to and for the benefit of the other Parties as follows: 

  

	 	16.1.1	each of them (which is a corporation) is a company with limited liability duly registered and validly existing under its law of incorporation, and has the power and authority to own
assets and to conduct the business which it conducts; 

  

 32 

	 	16.1.2	each of them has the power to enter into, exercise its rights and perform and comply with its obligations under this Agreement and each of them (which is a corporation) has taken or
obtained all necessary corporate and other action to authorise the execution and delivery of this Agreement; 

  

	 	16.1.3	neither the execution nor delivery of this Agreement by it, nor the consummation of the transactions contemplated hereby or thereby will: 

  

	 	(a)	(where it is a corporation) violate any provision of its memorandum of association, articles of association, bye laws or other constitutive documents; 

  

	 	(b)	conflict with or violate any law, rule, regulation, ordinance, order, writ, injunction, judgment or decree applicable to it or by which its properties or assets is bound or
affected; or 

  

	 	(c)	conflict with or result in any breach of or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights
of termination, acceleration or cancellation of, or result in the creation of, any lien, charge or Encumbrance on any of its properties or assets pursuant to any of the terms, conditions or provisions of any note, bond, mortgage, indenture, permit,
licence, franchise, agreement or other instrument or obligation to which it is a party or by which it or any of its properties or assets is bound or affected; 

  

	 	16.1.4	all actions, conditions and things required to be taken, fulfilled and done including the obtaining of any authorisations, filings, registration, documentation or claim in order:

  

	 	(a)	to enable it to lawfully enter into, exercise its rights and perform and comply with its respective obligations under this Agreement; and 

  

	 	(b)	to ensure that those obligations are legally binding and enforceable have been done, fulfilled and obtained and there has been no default in the observance of the conditions or
restrictions (if any imposed) in or in connection with any of the same, 

 have been taken, fulfilled and done or will be
taken, fulfilled and done within the statutory period as the case may be; 
  

	 	16.1.5	there are no pending proceedings or outstanding commitments against it which could have an adverse material impact on its ability to perform its obligations herein;

  

	 	16.1.6	it is not insolvent and (where it is a corporate entity) no petition or application in its respective country of incorporation or elsewhere for its winding up or dissolution (or
analogous proceedings) has been presented and served on it and no order has been made or effective resolution passed for its winding up and no administrator or receiver and manager or judicial manager or similar officer has been appointed over any
part of its material assets or undertakings; and 

  

	 	16.1.7	no litigation, arbitration or administrative proceedings are current or pending or, so far as it is aware, threatened (i) to restrain the entry into, exercise of its rights
under or performance or enforcement of or compliance with its obligations under this Agreement or (ii) which has or could have a material adverse effect on it. 

  

 33 

	17	NOTICES 

  

	17.1	Mode of Correspondence: All notices, demands or other communications required or permitted to be given or made hereunder shall be in writing and delivered personally or sent
by prepaid registered post or by telefax, addressed to the intended recipient thereof at his or its address or telefax number set out below (or to such other address or telefax number as any Party may from time to time notify the others in writing).

 Existing Shareholders: As set out in column 2 of Schedule 1A 
 Company 
  

					
	Address	  	:	 	 No. 1 Building, #288 FuTe ZhongLu,
 Waigaoqiao Free
Trade Zone, Shanghai
 200131, P.R.China

	Facsimile No.	  	:	 	(86-21) 5046 3718
	Attention	  	:	 	Dr. Li Ge
	Email Address	  	:	 	geli@pharmatechs.com
	Telephone	  	:	 	(86-21) 5046 3309
			
	with a copy to:	  	:	 	 O’ Melveny & Myers LLP
 Plaza 66, 37th Floor,
1266 Nanjing Road West
 Shanghai, 200040, PRC

	Facsimile No.	  	:	 	(86-21) 2307-7300
	Attention	  	:	 	Kurt Berney
			
	GA	  		 	
			
	Address	  	:	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza Greenwich, CT 06830
 USA

	Facsimile No.	  	:	 	(203) 302-3044
	Attention	  	:	 	David A. Rosenstein
			
	with a copy to:	  	:	 	 Paul, Weiss, Rifkind, Wharton & Garrison LLP
 1285
Avenue of the Americas
 New York, NY 10019-6064
 USA

	Facsimile No.	  	:	 	(212) 757-3990
	Attention	  	:	 	Douglas A. Cifu, Esq.
			
	with a copy to:	  	:	 	 Paul, Weiss, Rifkind, Wharton & Garrison
 12/F,
Hong Kong Club Building
 3A Chater Road, Central
 Hong
Kong

	Facsimile No.	  	:	 	(852) 2536-9622
	Attention	  	:	 	Jeanette K. Chan

  

 34 

					
	Series C Fidelity Investors
			
	Address	  	:	 	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong

	Facsimile No.	  	:	 	(852) 2509 0371
	Attention	  	:	 	Daniel Auerbach/Norman Chen
	Email Address	  	:	 	 daniel.auerbach@fidelity.com
 norman.chen@fidelity.com

	Telephone	  	:	 	(852) 2629 2833

  

	17.2	Effect of Delivery: Any notice or document shall be deemed to have been served: 

  

	 	17.2.1	if by hand delivered letter when delivered personally; or 

  

	 	17.2.2	if posted, at 10.00 a.m. on the fifth Business Day after it was put into the post; or 

  

	 	17.2.3	if sent by facsimile process when confirmed by an activity report confirming the facsimile number to which such Notice was sent, the number of pages transmitted and that such
transmission was successfully completed. 

  

	17.3	Deemed Delivery: In proving service of a notice or document it shall be sufficient to prove that delivery was made or that the envelope containing the notice or document was
properly addressed and posted as a prepaid letter or that the facsimile message was properly addressed and despatched and the successful transmission acknowledgement was received, as the case may be. 

  

	17.4	Service of Processes: The Parties agree that the provisions of this Clause 17 shall not apply to the service of any writ, summons, order, judgment or other document relating
to or in connection with any legal proceedings. 

  

	18	GENERAL MATTERS 

  

	18.1	Remedies: No remedy conferred by any of the provisions of this Agreement is intended to be exclusive of any other remedy which is otherwise available at law, in equity, by
statute or otherwise, and each and every other remedy shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law, in equity, by statute or otherwise. The election of any one or more of such
remedies by any of the Parties shall not constitute a waiver by such Party of the right to pursue any other available remedies. 

  

	18.2	Actions by Shareholders: The Shareholders agree that they shall procure the convening of all meetings, the giving of all waivers and consents and the passing of all
resolutions and shall otherwise exercise all powers and rights available to them in their capacity as Shareholders in order to give effect to the provisions of this Agreement. 

  

	18.3	 Prevalence of Agreement: Without prejudice to the generality of Clause 18.2, the Shareholders agree that, if any provisions of the memorandum of association
or the articles of association or by-laws (as applicable) of any Group Company at any time conflict with any provisions of this Agreement, the provisions of this Agreement shall prevail and the Shareholders shall exercise their powers and rights
available to them in their capacity as Shareholders or procure the Company and/or its Affiliates to exercise their powers and rights available to them in their capacity as shareholders to procure the amendment of 

  

 35 

	 	 
the memorandum of association or the articles of association or by-laws (as applicable) of such Group Company to the extent necessary to permit such Group
Company and its affairs to be regulated as provided in this Agreement. 

  

	18.4	Benefit: This Agreement shall benefit and be binding on the Parties, their respective successors and any permitted assignee or transferee of some or all of a Party’s
rights or obligations under this Agreement. Any reference in this Agreement to any Party shall be construed accordingly. 

  

	18.5	Assignment: This Agreement, and all rights and obligations hereunder, are personal to the Parties and subject to the express provisions of this Agreement, each Party shall
not assign, transfer or novate or attempt to assign, transfer or novate all or any of its rights or obligations hereunder to any third party. For the avoidance of doubt, this Clause 18.5 shall not prejudice the rights of the Parties to sell,
transfer or otherwise dispose of its Shares in accordance with the terms and conditions of this Agreement or to assign, transfer or novate all or any of its rights or obligations to the transferee in accordance with the terms and conditions of this
Agreement. Notwithstanding the foregoing, in the event that the Company conducts a restructuring, capital reorganization, recapitalization or reincorporation, the Company shall procure that any entity that acquires all or substantially all of the
Company’s assets or the listing vehicle of the Group shall assume the obligations of the Company under this Agreement upon the consummation of the restructuring. 

  

	18.6	Further Acts: The Shareholders shall execute and do and take such steps as may be in their power to, procure that all other necessary persons, if any, execute and do all such
further documents, agreements, deeds, acts and things as may be required so that full effect may be given to the provisions of this Agreement. 

  

	18.7	Severance: If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the legality, validity and enforceability of the
remainder of this Agreement shall not be affected. 

  

	18.8	Counterparts: This Agreement may be signed in any number of counterparts and by the Parties on separate counterparts, each of which when so executed shall be an original, but
all counterparts shall together constitute one and the same document. Each counterpart may be signed and executed by a Party and transmitted by facsimile transmission and shall be valid and effectual as if an original. 

  

	18.9	Amendment and Variation: No amendment or variation of this Agreement shall be effective unless made in writing and signed by and on behalf of each of the Parties.

  

	18.10	Costs and Expenses: The costs and expenses relating to the drafting, negotiation and execution of this Agreement shall be borne by the Parties in accordance with Clause 10.14
of the Series C Subscription Agreement. The persons appointed to sit on the Board and/or the ACF Committee shall be reimbursed by the Company for their traveling and accommodation expenses when attending the Board and/or ACF Committee meetings and
subject to the approval of the Board, such persons may be paid a fee by the Company for such duty and services to be undertaken by them. 

  

	19	GOVERNING LAW AND DISPUTE RESOLUTION 

  

	19.1	GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. 

  

 36 

	19.2	Dispute Resolution.  

  

	 	(a)	Dispute Resolution. Any disputes, claims or controversies among the parties arising out of or in connection with this Agreement, whether in contract, tort, equity or
otherwise and including those relating to the existence, meaning, interpretation, effect, validity, performance, termination or enforcement of this Agreement (all of which are referred to as “Disputes”) shall be referred to and
finally resolved through binding and final arbitration in accordance with the Rules of the London Court of International Arbitration (the “Arbitration Rules”) in effect, at the time of commencement of the arbitration. The
Arbitration Rules are hereby incorporated by reference into this clause except as modified herein. In such event, each party agrees to submit itself and its property to the jurisdiction of the arbitration tribunal convened to resolve such Dispute.

  

	 	(b)	Appointment of Arbitrators. The arbitration tribunal shall consist of three arbitrators. One arbitrator shall be nominated by each of the two respective parties in the
dispute and the third, who shall be the Chairman of the arbitration tribunal, shall be nominated by the two party nominated arbitrators within 14 calendar days of the last of their appointments (failing which the Chairman shall be selected by the
London Court of International Arbitration). It is hereby expressly agreed that if there is more than one claimant party and/or more than one respondent party, the claimant parties shall together nominate one arbitrator and the respondent parties
shall together nominate one arbitrator. 

  

	 	(c)	Authority of the Arbitrators. The arbitrators shall have the authority to assess the costs and expenses of the arbitration proceedings (including, but not limited to, the
parties’ reasonable legal costs and expenses) and allocate them between the parties in whatever manner or allocation the arbitrators deem appropriate. 

  

	 	(d)	Conduct of the Arbitration. The arbitration proceedings shall be conducted, and the award or decision (the “Award”) of the arbitrators shall be rendered, in
the English language. 

  

	 	(e)	Place of Arbitration. The seat, or legal place, of the arbitration shall be London, England. 

  

	 	(f)	Joinder of Disputes. In order to facilitate the comprehensive resolution of related Disputes, all claims among the parties that arise under or in connection with this
Agreement may be dealt with in a single set of arbitration proceedings. Upon the request of any party to any arbitration proceedings commenced pursuant to this Clause 19.2, the arbitral tribunal shall consolidate those arbitration proceedings with
any other proceedings involving any of the parties hereto, and relating to this Agreement, if the arbitral tribunal determines that: 

  

	 	(i)	there are issues of fact or law common to the proceedings so that a consolidated proceeding would be more efficient than separate proceedings; and 

  

	 	(ii)	no party would be materially prejudiced as a result of such consolidation through undue delay or otherwise. 

 In the event of different determinations of (i) and (ii) by different arbitral tribunals constituted under this Agreement, the ruling of the
arbitral tribunal constituted first in time shall be determinative, and unless the parties otherwise agree, such arbitral tribunal shall serve as the arbitral tribunal for any consolidated arbitration proceedings. 
  

 37 

	 	(g)	Provisional Remedies. By agreeing to arbitration, the parties to this Agreement do not intend to deprive any court of its jurisdiction to issue a pre-arbitral injunction,
pre-arbitral attachment or other order in aid of arbitration proceedings and the enforcement of any Award. Without prejudice to such national court, the arbitral tribunal established under this Clause 19.2 shall have full authority to grant
provisional remedies. 

  

	 	(h)	Decision Final. 

  

	 	(i)	The Award shall be final and binding upon the parties as from the date rendered. Judgment upon any Award may be entered in any court having jurisdiction thereof.

  

	 	(ii)	The parties waive any rights of application or appeal to any court or tribunal of competent jurisdiction to the fullest extent permitted by law in connection with any question of
law arising in the course of arbitration or with respect to any Award made except for actions relating to enforcement of this Agreement or arbitral Award and except for actions seeking interim or other provisional relief in aid of arbitration
proceeding in any court of competent jurisdiction. 

  

	 	(i)	Payment of the Award. Any monetary award shall be made and payable in US$ free of any tax, deduction or set off. Each party against which the Award assesses a monetary
obligation shall pay that obligation on or before the 30th day following the date of the Award or such other date as the Award may provide. The arbitral tribunal shall have the authority to award any remedy or relief proposed by the claimant(s) or
respondent(s) in accordance with the terms of this Agreement, including, a declaratory judgment, specific performance of any obligation created under this Agreement or the issuance of any injunction. 

  

	 	(j)	Confidentiality of Arbitration. Once any Dispute has been submitted to arbitration proceedings pursuant to this Clause 19.2, such Dispute shall be resolved in a confidential
manner. Unless required by applicable law, neither party shall disclose or permit the disclosure to any person except its counsel, consultants and controlled Affiliates of any information about the evidence adduced or the documents produced by the
other party in the arbitration proceedings or about the existence, contents or results of the proceeding except as may be required by a Governmental Authority or as required in an action in aid of arbitration or for enforcement of an arbitral award.
Before making any disclosure permitted by the preceding sentence, the party intending to make such disclosure shall give the other party reasonable written notice of the intended disclosure and afford the other party a reasonable opportunity to
protect its interests. 

  

	20	TERMINATION 

 The following Clauses of this Agreement shall automatically
terminate upon the consummation of the Qualifying IPO: 2, 3, 4, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 7, 8, 10, 12 and 16. 
 [The remainder of this page is intentionally left blank] 
  

 38 

 SCHEDULE 1A 
 DETAILS OF THE EXISTING SHAREHOLDERS 
  

			
	 Shareholder
 (1)
	 	 Contact Particulars
 (2)

	Dr. Li Ge	 	 No. 1 Building, #288 FuTe ZhongLu, Waigaoqiao Free
 Trade
Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463309
 Fax:
86-21-50463718
 E-mail: geli@pharmatechs.com

		
	 J.P. Morgan Trust Company of Delaware, as
 Trustee of the
Ge Li 2006 Grantor Retained
 Annuity Trust
	 	 c/o Dr. Li Ge
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463309
 Fax: 86-21-50463718
 E-mail:
geli@pharmatechs.com

		
	EWEP Inc.	 	 c/o Dr. Li Ge
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463309
 Fax: 86-21-50463718
 E-mail:
geli@pharmatechs.com

		
	NJZ Advance Limited	 	 c/o Dr. Li Ge
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463309
 Fax: 86-21-50463718
 E-mail:
geli@pharmatechs.com

		
	 J.P. Morgan Trust Company of Delaware, as
 Trustee of the
Ning Zhao 2006 Grantor Retained
 Annuity Trust
	 	 c/o Dr. Ning Zhao
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463512
 Fax: 86-21-50463718
 E-mail:
Zhao_ning@pharmatechs.com

		
	I-Invest World Ltd	 	 c/o Liu Xiaozhong
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463317
 Fax: 86-21-50463718
 E-mail:
liuxiaozhong@pharmatechs.com

		
	AssetValue Ltd	 	 c/o Lin Tao
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463320
 Fax: 86-21-50463718
 E-mail:lintao@pharmatechs.com

  

 39 

			
	i-growth Ltd	 	 c/o Zhang Zhaohui
 No. 1 Building, #288 FuTe ZhongLu,
Waigaoqiao Free
 Trade Zone, Shanghai 200131, P.R.China
 Telephone: 86-21-50463320
 Fax: 86-21-50463718
 E-mail:
zhangzhaohui@pharmatechs.com

		
	Kaifu Limited	 	 Room 1706,No.6 Building Kingdom Garden,
 No.9,Wen Hui
Yuan North Road, Haidian District,
 Beijing 100088,P.R.China
 Telephone: 010-62268962/0086-13601003166/0049-1724136688
 Fax: -
 E-mail: plde@gmx.net

		
	Walter C. Greenblatt	 	 430 Nassau Street,
 Princeton, NJ08540, USA
 Telephone: 1-609-497-0793
 Fax: 1-609-497 1282
 E-mail: wgreenblatt@mba1982.hbs.edu

		
	Dr. J. J. Baldwin	 	 621 Gypsy Hill CR Gwynedd VLY PA 19437, USA
 Telephone:
(1-215) 628 3675
 Fax: (1-215) 628 3675
 E-mail:
sixmilecross@aol.com

		
	UOB Hermes Asia Technology Fund	 	 c/o UOB Venture Management Pte Ltd
 80 Raffles Place
#30-20
 UOB Plaza 2
 Singapore 048624
 Telephone: (65) 6539 3593/6539 3044
 Fax: (65) 6538 2569
 E-mail: Jean.ThohJH@UOBgroup.com

		
	UOB JAIC Venture Bio Investments Limited	 	 c/o UOB Bioventures Management Pte Ltd
 80 Raffles Place
#30-20
 UOB Plaza 2
 Singapore 048624
 Telephone: (65) 6539 3593/6539 3044
 Fax: (65) 6538 2569
 E-mail: Jean.ThohJH@UOBgroup.com

		
	UOB Venture Technology Investments Ltd	 	 c/o UOB Venture Management Pte Ltd
 80 Raffles Place
#30-20
 UOB Plaza 2
 Singapore 048624
 Telephone: (65) 6539 3593/6539 3044
 Fax: (65) 6538 2569
 E-mail: Jean.ThohJH@UOBgroup.com

  

 40 

			
	The Fidelity Greater China Venture Fund L.P.	 	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong
 Telephone: (852) 2629 2833

Fax: (852) 2509 0371
 E-mail: daniel.auerbach@fidelity.com/
 norman.chen@fidelity.com

		
	New America, L.P.	 	 930 Winter Street, Suite 2500
 Waltham, MA 02451,
USATelephone: (1- 617) 817 3610
 Fax: (1-781) 634 0202
 E-mail:
simin@tiandigrowth.com

		
	Rexbury Limited	 	 No. 5 Bridge, Mashan, Binhu District, Wuxi,
 Municipality, Jiangsu Province, P.R. China
 Telephone: 86-510-8599-4817
 Fax: 86-510-8599-4817
 E-mail: xyehen@pub.wx.jsinfo.net
 Attention: Ms. Chen Xiuyu

  

 41 

 SCHEDULE 1B 
 GA 
  

			
	 Name of Shareholder
	 	 Contact Particulars

	General Atlantic Partners (Bermuda), L.P.	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

		
	GAP-W International, LLC	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

		
	GapStar, LLC	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

		
	GAP Coinvestments III, LLC	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

		
	GAP Coinvestments IV, LLC	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

		
	GAP Coinvestments CDA, L.P.	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

		
	GAPCO GmbH & Co. KG	 	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email:Drosenstein@generalatlantic.com
 Attention: David A. Rosenstein

  

 42 

 SCHEDULE 1C 
 SERIES C FIDELITY INVESTORS 
  

			
	 Name of Shareholder
	 	 Contact Particulars

	Fidelity Asia Ventures Fund L.P.	 	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong
 Telephone: (852) 2629 2833

Fax: (852) 2509 0371
 E-mail: daniel.auerbach@fidelity.com/
 norman.chen@fidelity.com

		
	Fidelity Asia Principals Fund L.P.	 	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong
 Telephone: (852) 2629 2833

Fax: (852) 2509 0371
 E-mail: daniel.auerbach@fidelity.com/
 norman.chen@fidelity.com

  

 43 

 SCHEDULE 2A 
 PREFERRED SHAREHOLDERS 
  

							
	 Subscribers
 (1)
	  	 Nos. of Series A
Preference Shares
held
 (2)
	  	 Nos. of Series B
Preference Shares
held
 (3)
	  	 No. of Series C
Preference Shares
subscribed
 (4)

	 UOB Hermes Asia Technology Fund
	  	140,868	  	582,917	  	0
	 UOB JAIC Venture Bio Investments Limited
	  	45,056	  	313,083	  	0
	 UOB Venture Technology Investments Ltd
	  	0	  	256,978	  	0
	 The Fidelity Greater China Venture Fund L.P.
	  	232,050	  	1,008,000	  	0
	 New America, L.P.
	  	0	  	495,400	  	0
	 General Atlantic Partners (Bermuda), L.P.
	  	0	  	0	  	607,157
	 GAP-W International, LLC
	  	0	  	0	  	230,987
	 GapStar, LLC
	  	0	  	0	  	13,859
	 GAP Coinvestments III, LLC
	  	0	  	0	  	55,296
	 GAP Coinvestments IV, LLC
	  	0	  	0	  	12,944
	 GAP Coinvestments CDA, L.P.
	  	0	  	0	  	1,155
	 GAPCO GmbH & Co. KG
	  	0	  	0	  	2,550
	 Fidelity Asia Ventures Fund L.P.
	  	0	  	0	  	319,747
	 Fidelity Asia Principals Fund L.P.
	  	0	  	0	  	11,924
	 Total
	  	417,974	  	2,656,378	  	1,255,619

  

 44 

 SCHEDULE 3 
 PARTICULARS OF THE COMPANY 
 (Recital A and Clauses 1.1 & 2.1.7) 
  

					
		
	 Registered number:
	  	I.B.C. No. 599267
		
	 Registered office:
	  	P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands.
		
	 Date and place of Incorporation:
	  	June 3rd, 2004
		
	 Directors:
	  	Dr. Li Ge; Mr. Liu Xiao Zhong; Mr. Lin Tao; Mr. Zhang Zhaohui; Mr. Seah Kian Wee; Mr. Daniel Auerbach; Dr. John J. Baldwin; Ms Zhou Simin; Mr Zhu Zhiming
		
	 Secretary:
	  	Kandy Secretaries Limited
		
	 Registered Agent:
	  	Offshore Incorporations Limited
		
	 Accounting reference date:
	  	January 1st to December 31.
		
	 Auditors:
	  	Deloitte Touche Tohmatsu
		
	 Share capital:
	  	

  

							
	 Class
	  	 Authorised
 US$ (1)
	  	 Issued
 US$ (1)
	  	 Par Value
 US$

	 Ordinary Shares
	  	10,000,000	  	4,981,200	  	1.00
	 Preference
	  	50,000	  	33,068	  	0.01

	(1)	Prior to the transactions contemplated by the Transaction Documents (as defined in the Series C Subscription Agreement). 

  

 45 

 Senior Management Personnel: 
  

					
	 Name
	  	 Position
	  	 Address, telephone & fax nos.

			
	 Dr. Li Ge
	  	Chairman & CEO	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463309;
 Fax: 86-21-50463718

			
	 Dr. Tao Lin
	  	Vice President for Internal Operation	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463320;
 Fax: 86-21-50463718

			
	 Dr. Suhan Tang
	  	Vice President for Process R&D	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463723;
 Fax: 86-21-50463718

			
	 Dr. Shuhui Chen
	  	Chief Science Officer	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463721;
 Fax: 86-21-50463718

			
	 Mr. Xiaozhong Liu
	  	Executive Vice President	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463317;
 Fax: 86-21-50463718

			
	 Dr. Zhaohui Zhang
	  	Vice President for Domestic Marketing	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463321;
 Fax: 86-21-50463718

			
	 Dr. Ning Zhao
	  	Vice President for Analytical R&D	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463725;
 Fax: 86-21-50463718

  

 46 

					
			
	 Dr. Naruhito Masai
	  	Vice President	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463724;
 Fax: 86-21-50463718

			
	 Mr. Jagdish Sastry
	  	Vice President of Operations	  	 Jiangzhuang Village, Caojing
 Town, Shanghai
201507,
 P.R.China;
 Telephone: 86-21-67256267;
 Fax: 86-21-67256005

			
	 Dr. Angela Wong
	  	Vice President	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50463241;
 Fax: 86-21-50463718

			
	 Mr. Benson Tsang
	  	Chief Financial Officer	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131, P.R.China;
 Telephone:
86-21-50464100;
 Fax: 86-21-50463718

			
	 Ee Hoon See
	  	Vice President of Human Resources	  	 No. 1 Building, #288 FuTe
 ZhongLu, Waigaoqiao
Free
 Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50461852;
 Fax: 86-21-50463718

			
	 Dr. Hai Mi
	  	Vice President, Investor Relations	  	 No. 1 Building, #288 FuTe
 ZhongLu,
Waigaoqiao
 Free Trade Zone, Shanghai 200131,
 P.R.China;
 Telephone: 86-21-50461852;
 Fax:
86-21-50463718

  

 47 

 SCHEDULE 4 
 PART A 
 PARTICULARS OF THE WXPT GROUP COMPANIES 
 (Clause 1.1) 
  

	A.	WuXi PharmaTech Co., Ltd. 

  

					
	 Name
	  	:	  	WuXi PharmaTech Co., Ltd.
			
	 Nature
	  	:	  	Wholly Foreign-owned Enterprise
			
	 Place of incorporation
	  	:	  	WuXi Municipality, Jiangsu Province, P.R.China
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	December 1st, 2000
			
	 Registered address
	  	:	  	No. 5 Bridge, Binhu District, WuXi Municipality, Jiangsu Province, China
			
	 Total investment
	  	:	  	US$16.8 Million
			
	 Registered capital
	  	:	  	US$9 Million
			
	 Name of Subscribers
	  	:	  	WuXi PharmaTech (BVI) Inc.
			
	 Names of directors
	  	:	  	Li Ge; Liu Xiao Zhong; Lin Tao; Zhang Zhao Hui; Seah Kian Wee; Daniel Auerbach; John J. Baldwin
			
	 Legal representative
	  	:	  	Li Ge

  

 48 

	B.	Shanghai Branch of WuXi PharmaTech Co., Ltd. 

  

					
	 Name
	  	:	  	Shanghai Branch of WuXi PharmaTech Co., Ltd.
			
	 Nature
	  	:	  	Branch of Sino-foreign Equity Joint Venture
			
	 Place of incorporation
	  	:	  	Shanghai Municipality, P.R.China
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	March 29th, 2001
			
	 Registered address
	  	:	  	Section A, 2nd Floor, Building 1, No. 288 FuTe Zhong Road,
Shanghai Wai Gao Qiao Free Trade Zone, Shanghai
			
	 Total investment
	  	:	  	N/A
			
	 Registered capital
	  	:	  	N/A
			
	 Name of Subscribers
	  	:	  	N/A
			
	 Names of directors
	  	:	  	N/A
			
	 Legal representative
	  	:	  	Li Ge

  

 49 

	C.	Shanghai PharmaTech Co., Ltd. 

  

					
	 Name
	  	:	  	Shanghai PharmaTech Co., Ltd.
			
	 Nature
	  	:	  	Sino-foreign Equity Joint Venture
			
	 Place of incorporation
	  	:	  	Shanghai Municipality, P.R.China
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	April 2nd, 2002
			
	 Registered address
	  	:	  	No. 1 Building, #288 FuTe ZhongLu, Wai Gao Qiao Free Trade Zone, Shanghai
			
	 Total investment
	  	:	  	US$18 Million
			
	 Registered capital
	  	:	  	US$8 Million
			
	 Name of Subscribers
	  	:	  	WuXi PharmaTech Co., Ltd.; WuXi PharmaTech (BVI) Inc.
			
	 Names of directors
	  	:	  	Li Ge; Liu Xiao Zhong; Lin Tao; Zhang Zhao Hui; Seah Kian Wee; Daniel Auerbach; John J. Baldwin
			
	 Legal representative
	  	:	  	Li Ge

  

 50 

	D.	Shanghai SynTheAll Pharmaceutical Co., Ltd. 

  

					
	 Name
	  	:	  	Shanghai SynTheAll Pharmaceutical Co., Ltd.
			
	 Nature
	  	:	  	Sino-foreign Equity Joint Venture
			
	 Place of incorporation
	  	:	  	Shanghai Municipality, P.R.China
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	Jan. 23rd, 2003
			
	 Registered address
	  	:	  	No. 9 GuiHua 3 Road, Jinshan District (West), Shanghai Chemical Industry Park, P.R. China.
			
	 Total investment
	  	:	  	US$ 7.4 Million
			
	 Registered capital
	  	:	  	US$ 3.7 Million
			
	 Name of Subscribers
	  	:	  	WuXi PharmaTech (BVI) Inc. and Shanghai PharmaTech Co., Ltd.
			
	 Names of directors
	  	:	  	Li Ge; Liu Xiao Zhong; Lin Tao; Zhang Zhao Hui; SEAH Kian Wee; Daniel Auerbach; John J. Baldwin
			
	 Legal representative
	  	:	  	Li Ge

  

 51 

	E.	Shanghai PharmaTech Chemical Technology Co., Ltd. 

  

					
	 Name
	  	:	  	Shanghai PharmaTech Chemical Technology Co., Ltd.
			
	 Nature
	  	:	  	Sino-foreign Equity Joint Venture
			
	 Place of incorporation
	  	:	  	Shanghai Municipality, P.R.China
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	Jan. 27th , 2006
			
	 Registered address
	  	:	  	5th Floor, No. 2 Building, #288 FuTe ZhongLu, Wai Gao Qiao
Free Trade Zone, Shanghai
			
	 Total investment
	  	:	  	US$ 710,000
			
	 Registered capital
	  	:	  	US$ 500,000
			
	 Name of Subscribers
	  	:	  	WuXi PharmaTech (BVI) Inc. and Shanghai PharmaTech Co., Ltd.
			
	 Names of directors
	  	:	  	Li Ge; Liu Xiao Zhong; Zhang Zhao Hui
			
	 Legal representative
	  	:	  	Li Ge

  

 52 

	F.	Tianjin PharmaTech Co., Ltd. 

  

					
	 Name
	  	:	  	Tianjin PharmaTech Co., Ltd.
			
	 Nature
	  	:	  	Sino-foreign Equity Joint Venture
			
	 Place of incorporation
	  	:	  	Tianjin Municipality, P.R.China
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	June 5, 2006
			
	 Registered address
	  	:	  	No. 111, Huanghai Road, Tianjin Economic-technological Development Area, Tianjin, China
			
	 Total investment
	  	:	  	US$ 15,000,000
			
	 Registered capital
	  	:	  	US$ 6,000,000
			
	 Name of Subscribers
	  	:	  	WuXi PharmaTech (BVI) Inc. and WuXi PharmaTech Co., Ltd.
			
	 Names of directors
	  	:	  	Li Ge; Liu Xiao Zhong; Lin Tao; Zhang Zhao Hui; Jean Thoh Jing Herng; Daniel Auerbach; John J. Baldwin
			
	 Legal representative
	  	:	  	Li Ge

  

 53 

	G.	Suzhou PharmaTech Co., Ltd. 

  

					
	 Name
	  	:	  	Suzhou PharmaTech Co., Ltd.
			
	 Nature
	  	:	  	Sino-foreign Equity Joint Venture
			
	 Place of incorporation
	  	:	  	Suzhou Municipality, PRC
			
	 Registration number
	  	:	  	

			
	 Date of establishment
	  	:	  	October 8, 2006
			
	 Registered address
	  	:	  	40 Feng Jin Road, Wuzhong Economic Development Region
			
	 Total investment
	  	:	  	US$ 60 million
			
	 Registered capital
	  	:	  	US$ 20 million (to be paid)
			
	 Name of Subscribers
	  	:	  	WuXi PharmaTech Co., Ltd.; WuXi PharmaTech (BVI) Inc.
			
	 Names of directors
	  	:	  	Li Ge; Liu Xiao Zhong; Lin Tao; Zhang Zhao Hui; Jean Thoh Jing Herng; Daniel Auerbach; and John J. Baldwin
			
	 Legal representative
	  	:	  	Li Ge

  

 54 

 SCHEDULE 5 
 FORM OF JOINDER 
 THIS JOINDER is made on the          day of
             
 BETWEEN 
  

	(1)	[    ] of [    ] (the “New Shareholder”); 

 AND 
  

	(2)	THE PERSONS WHOSE NAMES ARE SET OUT IN SCHEDULE 1 (collectively the “Current Shareholders” and individually a “Current Shareholder”);

 AND 
  

	(3)	WUXI PHARMATECH (BVI) INC., a company incorporated in the British Virgin Islands and having its registered address at [    ] (the “Company”).

 WHEREAS a second amended and restated joint venture agreement was entered into on February 9, 2007 by and among, inter
alia, the Current Shareholders and the Company (the “Joint Venture Agreement”), a copy of which the New Shareholder hereby confirms that it has been supplied with and acknowledges the terms therein. 
 NOW IT IS AGREED as follows: 
  

	1.	In this Joinder, unless the context otherwise requires, words and expressions respectively defined or construed in the Joint Venture Agreement shall have the same meanings when used
or referred to herein. 

  

	2.	The New Shareholder hereby accedes to and ratifies the Joint Venture Agreement and covenants and agrees with the Current Shareholders and the Company to be bound by the terms of the
Joint Venture Agreement as if it had been a party thereto from the outset and to duly and punctually perform and discharge all liabilities and obligations whatsoever from time to time to be performed or discharged by it under or by virtue of the
Joint Venture Agreement in all respects as if named as a party therein. 

  

	3.	Each of the Current Shareholders and the Company covenants and agrees that the New Shareholder shall be entitled to all the benefits of the terms and conditions of the Joint Venture
Agreement to the intent and effect that the New Shareholder shall be deemed, with effect from the date on which the New Shareholder is registered as a shareholder of the Company, to be a party to the Joint Venture Agreement.

  

	4.	This Joinder shall hereafter be read and construed in conjunction and as one document with the Joint Venture Agreement and references in the Joint Venture Agreement to “the
Agreement” or “this Agreement”, and references in all other instruments and documents executed thereunder or pursuant thereto to the Joint Venture Agreement, shall for all purposes refer to the Joint Venture Agreement incorporating
and as supplemented by this Joinder. 

  

	5.	THIS JOINDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. 

  

	6.	Clause 19.2 of the Joint Venture Agreement shall apply to this Joinder and shall be incorporated herein by reference. 

  

 55 

	7.	The address of the undersigned for purposes of all notices under the Joint Venture Agreement is: [        ]. 

  

			
	 [NEW SHAREHOLDER]

		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	

  

 56 

 Schedule 1 to JOINDER 
 The Current Shareholders 
  

 57 

 SCHEDULE 6 
 FORM OF PUT OPTION NOTICE 
  

			
	Date:	 	[            ]
	To:	 	[            ]

 From: [name of subscriber] 
 We refer to the Second Amended and Restated Joint Venture Agreement dated February 9, 2007 (“Joint Venture Agreement”) made between
inter alia yourself and ourselves. Terms defined in the Joint Venture Agreement shall have the same meanings as used herein. 
 We
hereby give you notice that we require you to purchase from us in accordance with the terms and conditions of the Joint Venture Agreement, all the following Option Shares on the date falling thirty (30) Business Days from the date of service of
this Put Option Notice on you:- 
 [state the number and type of Option Shares] 
  

	
	 Yours faithfully

	
	  

	 Name:

  

 58 

 IN WITNESS WHEREOF this Agreement has been entered into the day and year first above written. 

The Existing Shareholders 
  

			
	UOB HERMES ASIA TECHNOLOGY FUND
		
	By:	 	UOB Venture Management Pte Ltd, its investment manager
	
	 /s/ Kian-Wee Seah

	Name:	 	Kian-Wee Seah
	Title:	 	Managing Director
	
	UOB JAIC VENTURE BIO INVESTMENTS LTD
		
	By:	 	UOB Bioventures Management Pte Ltd, its investment manager
	
	 /s/ Kian-Wee Seah

	Name:	 	Kian-Wee Seah
	Title:	 	Executive Director
	
	UOB VENTURE TECHNOLOGY INVESTMENTS LTD
		
	By:	 	UOB Venture Management Pte Ltd, its investment manager
	
	 /s/ Kian-Wee Seah

	Name:	 	Kian-Wee Seah
	Title:	 	Managing Director

  

					
		 		 	

 The Existing Shareholders 
  

			
	FIDELITY GREATER CHINA VENTURES FUND L.P.
		
	By:	 	FIL Greater China Ltd., its General Partner
	
	 /s/ Ben Gufford

	Name:	 	Ben Gufford
	Title:	 	Director

  

					
		 		 	

 The Existing Shareholders 
  

			
	NEW AMERICA, L.P.
	
	 /s/ Oliver D. Curme

	Name:	 	Oliver D. Curme
	Title:	 	Managing Partner

  

					
		 		 	

 The Existing Shareholders 
  

			
	DR. LI GE
	
	 /s/ Ge Li

	Name:	 	Ge Li
	
	I-INVEST WORLD LTD.
	
	 /s/ Xiaozhong Liu

	Name:	 	Xiaozhong Liu
	Title:	 	Director
	
	ASSETVALUE LTD.
	
	 /s/Tao Lin

	Name:	 	Tao Lin
	Title:	 	Director
	
	I-GROWTH LTD.
	
	 /s/ Zhaohui Zhang

	Name:	 	Zhaohui Zhang
	Title:	 	Director

  

					
		 		 	

 The Existing Shareholders 
  

			
	J.P. MORGAN TRUST COMPANY OF DELAWARE, AS TRUSTEE OF THE GE LI 2006 GRANTOR RETAINED ANNUITY TRUST
	
	 /s/ Michael B. Yulsman

	Name:	 	Michael B. Yulsman
	Title:	 	Vice President
	
	J.P. MORGAN TRUST COMPANY OF DELAWARE, AS TRUSTEE OF THE NING ZHAO 2006 GRANTOR RETAINED ANNUITY TRUST
	
	 /s/ Michael B. Yulsman

	Name:	 	Michael B. Yulsman
	Title:	 	Vice President

  

					
		 		 	

 The Existing Shareholders 
  

			
	KAIFU LIMITED
	
	 /s/ Peng Li

	Name:	 	Peng Li
	Title:	 	Director

  

					
		 		 	

 The Existing Shareholders 
  

			
	WALTER C. GREENBLATT
	
	 /s/ Walter C. Greenblatt

	Name:	 	Walter C. Greenblatt

  

					
		 		 	

 The Existing Shareholders 
  

			
	DR. JOHN J. BALDWIN
	
	 /s/ John J. Baldwin

	Name:	 	John J. Baldwin

  

					
		 		 	

 The Existing Shareholders 
  

			
	REXBURY LIMITED
	
	 /s/ Zhiming Zhu

	Name:	 	Zhiming Zhu
	Title:	 	Director

  

					
		 		 	

 The Company 
  

			
	WUXI PHARMATECH (BVI) INC.
	
	 /s/ Ge Li

	Name:	 	Ge Li
	Title:	 	Chief Executive Officer

  

					
		 		 	

 GA 
  

			
	GENERAL ATLANTIC PARTNERS (BERMUDA), L.P.
		
	By:	 	GAP (BERMUDA) LIMITED, its General Partner
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	Vice President
	
	GAP-W INTERNATIONAL, LLC
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	Vice President
	
	GAP COINVESTMENTS III, LLC
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	A Managing Member
	
	GAP COINVESTMENTS IV, LLC
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	A Managing Member
	
	GAPSTAR, LLC
		
	By:	 	GENERAL ATLANTIC LLC, its Sole Member
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	Managing Director

  

					
		 		 	

 GA 
  

			
	GAP COINVESTMENTS CDA, L.P.
		
	By:	 	GENERAL ATLANTIC LLC, its General Partner
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	Managing Director
	
	GAPCO GMBH & CO. KG
		
	By:	 	GAPCO MANAGEMENT GMBH, its General Partner
	
	 /s/ Matthew Nimetz

	Name:	 	Matthew Nimetz
	Title:	 	Managing Director

  

					
		 		 	

 Series C Fidelity Investors 
  

			
	FIDELITY ASIA VENTURES FUND L.P.
		
	By:	 	Fidelity Asia Partners, L.P., its General Partner
		
	By:	 	FIL Asia Ventures Limited, its General Partner
	
	 /s/ Allan Pelvang

	Name:	 	Allan Pelvang
	Title:	 	Director
	
	FIDELITY ASIA PRINCIPALS FUND L.P.
		
	By:	 	Fidelity Asia Partners, L.P., its General Partner
		
	By:	 	FIL Asia Ventures Limited, its General Partner
	
	 /s/ Allan Pelvang

	Name:	 	Allan Pelvang
	Title:	 	DirectorRegistration Rights Agreement

 Exhibit 4.7 
 EXECUTION COPY 
  

 REGISTRATION RIGHTS AGREEMENT 
 by and among 
 WUXI PHARMATECH (CAYMAN) INC. 
 and 
 THE OTHER PARTIES NAMED HEREIN 
  

 Dated: JUNE 4, 2007 

  

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page
	 1.
	 	Definitions	  	2
			
	 2.
	 	General; Securities Subject to this Agreement	  	8
			
	 3.
	 	Demand Registration	  	8
			
	 4.
	 	Incidental or “Piggy-Back” Registration	  	11
			
	 5.
	 	Form F-3 Registration	  	12
			
	 6.
	 	Holdback Agreements	  	15
			
	 7.
	 	Registration Procedures	  	16
			
	 8.
	 	Indemnification; Contribution	  	21
			
	 9.
	 	Additional Covenants	  	23
			
	 10.
	 	Non-U.S. Listings	  	24
			
	 11.
	 	Miscellaneous	  	24

  

 i 

 REGISTRATION RIGHTS AGREEMENT 
 REGISTRATION RIGHTS AGREEMENT, dated June 4, 2007 (this “Agreement”), among WuXi PharmaTech (Cayman) Inc., a company organized
and existing under the laws of the Cayman Islands with its principal office located at P.O. Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands (the “Company”), WuXi PharmaTech (BVI) Inc. with its
registered office at P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands (the “Sub”), and the Persons listed on Schedule 1 hereto. 
 WHEREAS, pursuant to the Share Subscription Agreement, dated January 26, 2007 (the “Subscription Agreement”), among the Sub,
General Atlantic Partners (Bermuda), L.P., a Bermuda limited partnership (“GAP LP”), GAP-W International, LLC, a Delaware limited liability company (“GAP-W”), GapStar, LLC, a Delaware limited liability company
(“GapStar”), GAP Coinvestments III, LLC, a Delaware limited liability company (“GAP Coinvestments III”), GAP Coinvestments IV, LLC, a Delaware limited liability company (“GAP Coinvestments IV”), GAP
Coinvestments CDA, L.P., a Delaware limited partnership (“GAP Coinvestments CDA”), GAPCO GmbH & Co. KG, a German limited partnership (“GmbH Coinvestment” and, together with GAP LP, GAP-W, GapStar, GAP
Coinvestments III, GAP Coinvestments IV and GAP Coinvestments CDA, “General Atlantic”) and Fidelity Asia Ventures Fund LP, a Bermuda limited partnership (“Fidelity Ventures”), Fidelity Asia Principals Fund LP, a
Bermuda limited partnership (“Fidelity Principals” and, together with Fidelity Ventures, “Fidelity”, and collectively with GAP LP, GapStar, GAP-W, GAP Coinvestments III, GAP Coinvestments IV, GAP Coinvestments CDA
and GmbH Coinvestment, the “Purchasers”), the Sub issued and sold to the Purchasers, an aggregate of 1,255,619 shares of Series C Preferred Shares, par value US$0.01 per share, of the Sub (the “Series C Preferred
Shares”); 
 WHEREAS, pursuant to the Note Purchase Agreement, dated January 26, 2007 (the “Note Purchase
Agreement”), among the Sub, General Atlantic and JP Morgan Securities Ltd. (“JPM”), the Sub issued and sold to General Atlantic and JPM, convertible notes (each, a “Note” and collectively, the
“Notes”) having an aggregate principal amount of US$40 million. 
 WHEREAS, the Sub, the Purchasers and the other
shareholders of the Company named therein entered into the Joint Venture Agreement (as hereinafter defined), pursuant to which the parties thereto agreed to, among other things, certain first offer and tag-along rights, preemptive rights and certain
corporate governance rights and obligations; 
 WHEREAS, the Sub and the other parties named therein entered into a Registration Rights
Agreement on February 9, 2007 (the “Original Reg Rights Agreement”); 
 WHEREAS, in order to effect a corporate
restructuring whereby the Sub will become a wholly-owned subsidiary of the Company, (i) the Company and the shareholders of the Sub entered into a Share Exchange Agreement, dated as of the date hereof 

 
(“Share Exchange Agreement”), pursuant to which all of the shareholders of the Sub will sell to the Company and the Company will purchase
from all of the shareholders of the Sub the entire issued share capital of the Sub in exchange for the same proportional equity interests in the Company as their proportional interests in the Sub, subject to and upon the terms and conditions of the
Share Exchange Agreement and (ii) the Company and the Sub entered into a Assignment and Assumption Agreement, dated as of the date hereof (“Assumption Agreement”), pursuant to which the Sub will transfer, convey, assign and
deliver to the Company all rights, title, benefit, privileges and interest of the Sub under the Subscription Agreement, Note Purchase Agreement, Joint Venture Agreement and the Notes, and the Company will irrevocably accept the assignments and
assume all rights, obligations and liabilities of the Sub under the Subscription Agreement, Note Purchase Agreement, Joint Venture Agreement and the Notes; and 
 WHEREAS, the parties hereto wish to terminate the Original Reg Rights Agreement and replace the rights and obligations set forth therein with this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Definitions. As used in this Agreement, and
unless the context requires a different meaning, the following terms have the meanings indicated: 
 “ADSs” means American
Depositary Shares, each of which will represent a certain number of Ordinary Shares. 
 “Affiliate” means, with respect to
any Person, any other Person that directly, or indirectly through one or more intermediaries, Controls, is Controlled by or is under common Control with, the Person specified. 
 “Agreement” has the meaning set forth in the preamble to this Agreement. 
 “Approved Underwriter” has the meaning set forth in Section 3(e) of this Agreement. 
 “Automatic Shelf Registration Statement” means an “automatic shelf registration statement” as defined in Rule 405 promulgated
under the Securities Act. 
 “Board of Directors” means the Board of Directors of the Company. 
 “Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks in the State of New York or Shanghai,
the PRC are authorized or required by law or executive order to close. 
 “Closing Price” means, with respect to the
Registrable Securities, as of the date of determination: (a) if the Registrable Securities are listed on a national securities exchange in the United States, the closing price per share of a Registrable Security on 

 
such date published in The Wall Street Journal (National Edition) or, if no such closing price on such date is published in The Wall Street Journal
(National Edition), the average of the closing bid and asked prices on such date, as officially reported on the principal national securities exchange in the United States on which the Registrable Securities are then listed or admitted to
trading; (b) if the Registrable Securities are not then listed or admitted to trading on any securities exchange but are designated as national market system securities by the NASD, the last trading price per share of a Registrable Security on
such date; (c) if there shall have been no trading on such date or if the Registrable Securities are not designated as national market system securities by the NASD, the average of the reported closing bid and asked prices of the Registrable
Securities on such date as shown by The Nasdaq Stock Market, Inc. (or its successor) and reported by any member firm of The New York Stock Exchange, Inc. selected by the Company; or (d) if none of (a), (b) or (c) is applicable, a
market price per share determined in good faith by the Board of Directors or, if such determination is not satisfactory to the Designated Holder for whom such determination is being made, by a nationally-recognized investment banking firm selected
by the Company and such Designated Holder, the expenses for which shall be borne equally by the Company and such Designated Holder. If trading is conducted on a continuous basis on any exchange, then the closing price shall be at 4:00 p.m. New York
City time. 
 “Commission” means the United States Securities and Exchange Commission or any similar agency then having
jurisdiction to enforce the Securities Act. 
 “Company” has the meaning set forth in the preamble to this Agreement.

 “Company Underwriter” has the meaning set forth in Section 4(a) of this Agreement. 
 “Control” (including the terms “Controlling,” “Controlled by” and “under common Control
with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 
 “Demand Registration” has the meaning set forth in Section 3(a) of this Agreement. 
 “Designated Holder” means each of the General Atlantic Shareholders, the Fidelity Shareholders, the TianDi Shareholders, the UOB
Shareholders, the Founders, the Founder Entities, Rexbury and JP Morgan. 
 “Determination Date” has the meaning set forth
in Section 5(e) of this Agreement. 
 “Disclosure Package” means, with respect to any offering of securities,
(i) the preliminary prospectus, (ii) each Free Writing Prospectus and (iii) all other information, in each case, that is deemed under Rule 159 promulgated under the Securities Act to have been conveyed to purchasers of securities at
the time of sale of such securities (including a contract of sale). 

 “Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission thereunder. 
 “Exchange Act Registration” means the date the Company becomes a
reporting company under the Exchange Act. 
 “F-3 Initiating Holders” has the meaning set forth in Section 5(a) of this
Agreement. 
 “F-3 Registration” has the meaning set forth in Section 5(a) of this Agreement. 
 “Fidelity Shareholders” means Fidelity, The Fidelity Greater China Venture Fund L.P., any Subsequent Purchaser that is an Affiliate of
Fidelity or The Fidelity Greater China Venture Fund L.P. and any Affiliate thereof to whom Registrable Securities are transferred, subject to Section 11(f) of this Agreement, other than a transferee to whom Registrable Securities have been
transferred pursuant to a Registration Statement under the Securities Act or Rule 144 or Regulation S under the Securities Act (or any successor rule thereto). 
 “Founder Entities” means the Founder Trusts, EWEP Inc., NJZ Advance Limited, I-Invest World Ltd, AssetValue Ltd, and i-growth Ltd, and “Founder Entity” means any one of them.

 “Founder Group” means the Founders and the Founder Entities, any Subsequent Purchaser that is an Affiliate of the
Founders or the Founder Entities and any Affiliate thereof to whom Registrable Securities are transferred, subject to Section 11(f) of this Agreement other than a transferee to whom Registrable Securities have been transferred pursuant to a
Registration Statement under the Securities Act or Rule 144 or Regulation S under the Securities Act (or any successor rule thereto). 
 “Founder Trusts” means J.P. Morgan Trust Company of Delaware, as Trustee of the Ge Li 2006 Grantor Retained Annuity Trust, J.P. Morgan Trust Company of Delaware, as Trustee of the Ning Zhao 2006 Grantor Retained Annuity
Trust, and J.P. Morgan Trust Company of Delaware, as Trustee of the Li Children’s 2006 Irrevocable Trust and J.P. Morgan Trust Company of Delaware, as Trustee of the NGM Family 2006 Irrevocable Trust, and “Founder Trust” means
any one of them. 
 “Founders” means Li Ge, Liu Xiaozhong, Lin Tao, Zhang Zhaohui and Ning Zhao, and
“Founder” means any one of them. 
 “Free Writing Prospectus” means any “free writing prospectus”
as defined in Rule 405 promulgated under the Securities Act. 

 “GAP Coinvestments III” has the meaning set forth in the recitals to this Agreement.

 “GAP Coinvestments IV” has the meaning set forth in the recitals to this Agreement. 
 “GAP Coinvestments CDA” has the meaning set forth in the recitals to this Agreement. 
 “GAP LP” has the meaning set forth in the recitals to this Agreement. 
 “GAP-W” has the meaning set forth in the recitals to this Agreement. 
 “GapStar” has the meaning set forth in the recitals to this Agreement. 
 “General Atlantic” has the meaning set forth in the recitals to this Agreement. 
 “General Atlantic Shareholders” means GAP LP, GAP-W, GapStar, GAP Coinvestments III, GAP Coinvestments IV, GAP Coinvestments CDA and
GmbH Coinvestment, any Subsequent Purchaser that is an Affiliate of General Atlantic, and any Affiliate thereof to whom Registrable Securities are transferred, subject to Section 11(f) of this Agreement other than a transferee to whom
Registrable Securities have been transferred pursuant to a Registration Statement under the Securities Act or Rule 144 or Regulation S under the Securities Act (or any successor rule thereto). 
 “GmbH Coinvestment” has the meaning set forth in the preamble to this Agreement. 
 “Holders’ Counsel” has the meaning set forth in Section 7(a)(i) of this Agreement. 
 “Incidental Registration” has the meaning set forth in Section 4(a) of this Agreement. 
 “Indemnified Party” has the meaning set forth in Section 8(c) of this Agreement. 
 “Indemnifying Party” has the meaning set forth in Section 8(c) of this Agreement. 
 “Initial Public Offering” means an underwritten initial public offering of the Ordinary Shares or ADSs of the Company pursuant to an
effective Registration Statement filed under the Securities Act on a Recognized Share Exchange (as defined in the M&AA). 
 “Initiating Holders” has the meaning set forth in Section 3(a) of this Agreement. 

 “Inspector” has the meaning set forth in Section 7(a)(vii) of this Agreement.

 “IPO Effectiveness Date” means the date upon which the Company closes its Initial Public Offering. 
 “Joint Venture Agreement” means the Amended and Restated Joint Venture Agreement, dated February 9, 2007, among the Sub, the
Purchasers and the other shareholders of the Sub named therein, as assumed by the Company pursuant to the Assumption Agreement. 
 “JP Morgan” means J. P. Morgan Securities Ltd., a company incorporated with limited liability under the laws of England and Wales. 
 “Liability” has the meaning set forth in Section 8(a) of this Agreement. 
 “Market Price” means, on any date of determination, the average of the daily Closing Price of the Registrable Securities for the immediately preceding ten (10) days on which the relevant securities exchanges or trading
systems are open for trading. 
 “M&AA” means the memorandum and articles of association of the Company, as the same may
be amended from time to time. 
 “NASD” means the National Association of Securities Dealers, Inc. 
 “TianDi Shareholders” means TianDi Growth Capital L.P., any Subsequent Purchaser that is an Affiliate of TianDi Growth Capital L.P. and
any Affiliate thereof to whom Registrable Securities are transferred, subject to Section 11(f) of this Agreement, other than a transferee to whom Registrable Securities have been transferred pursuant to a Registration Statement under the
Securities Act or Rule 144 or Regulation S under the Securities Act (or any successor rule thereto). 
 “Notes” has the
meaning set forth in the recitals to this Agreement. 
 “Ordinary Share Equivalent” means any security or obligation that is
by its terms, directly or indirectly, convertible, exchangeable or exercisable into or for Ordinary Shares, including, without limitation, the Preferred Shares, and any option, warrant or other subscription or purchase right with respect to Ordinary
Shares or any Ordinary Share Equivalent. 
 “Ordinary Shares” means the Ordinary Shares, par value US$1.00 per share, of the
Company or any other share capital of the Company into which such stock is reclassified or reconstituted and any other ordinary shares of the Company. 
 “Person” means any individual, firm, corporation, partnership, trust, incorporated or unincorporated association, joint venture, joint stock company, limited liability company, government (or an
agency or political subdivision thereof) or other entity of any kind, and shall include any successor (by merger or otherwise) of such entity. 

 “Preferred Shares” means the Series A Preferred Shares, the Series B Preferred Shares
and the Series C Preferred Shares. 
 “Records” has the meaning set forth in Section 7(a)(vii) of this Agreement.

 “Registrable Securities” means, subject to Section 2(b) hereof, each of the following: (a) any and all Ordinary
Shares issued or issuable upon conversion of the Preferred Shares, (b) any and all Ordinary Shares issued or issuable upon conversion of the Notes, (c) any other Ordinary Shares acquired or owned by any of the Designated Holders prior to
the IPO Effectiveness Date, or acquired or owned by any of the Designated Holders after the IPO Effectiveness Date if such Designated Holder is an Affiliate of the Company and (d) any Ordinary Shares issued or issuable to any of the Designated
Holders with respect to the Registrable Securities by way of share dividend or share split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise and any Ordinary Shares or voting
ordinary shares issuable upon conversion, exercise or exchange thereof. 
 “Registration Expenses” has the meaning set forth
in Section 7(d) of this Agreement. 
 “Registration Statement” means a Registration Statement filed pursuant to the
Securities Act, including an Automatic Shelf Registration Statement. 
 “Rexbury” means Rexbury Limited, a company
incorporated in Hong Kong and having its registered address at 35F Cheung Kong Center, 2 Queen’s Rd, Central Hong Kong, any Subsequent Purchaser that is an Affiliate of Rexbury Limited and any Affiliate thereof to whom Registrable Securities
are transferred, subject to Section 11(f) of this Agreement other than a transferee to whom Registrable Securities have been transferred pursuant to a Registration Statement under the Securities Act or Rule 144 or Regulation S under the
Securities Act (or any successor rule thereto). 
 “Rule 144” means Rule 144 under the Securities Act. 
 “Securities Act” means the United States Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated
thereunder. 
 “Series A Preferred Shares” means the Series A Preferred Shares, par value US$0.01 per share, of the Company.

 “Series B Preferred Shares” means the Series B Preferred Shares, par value US$0.01 per share, of the Company. 

“Series C Preferred Shares” has the meaning set forth in the recitals to this Agreement. 

 “Subscription Agreement” has the meaning set forth in the recitals to this Agreement.

 “Subsequent Purchaser” means any Affiliate of a Designated Holder that, after the date hereof, acquires any Ordinary
Shares, Preferred Shares or Ordinary Share Equivalents. 
 “UOB Shareholders” means UOB Hermes Asia Technology Fund, UOB
JAIC Venture Bio Investments Limited, UOB Venture Technology Investments Ltd., any Subsequent Purchaser that is an Affiliate of UOB Hermes Asia Technology Fund, UOB JAIC Venture Bio Investments Limited or UOB Venture Technology Investments Ltd. and
any Affiliate thereof to whom Registrable Securities are transferred, subject to Section 11(f) of this Agreement, other than a transferee to whom Registrable Securities have been transferred pursuant to a Registration Statement under the
Securities Act or Rule 144 or Regulation S under the Securities Act (or any successor rule thereto). 
 “Valid Business
Reason” has the meaning set forth in Section 3(a) of this Agreement. 
 “Well-Known Seasoned Issuer” means a
“well-known seasoned issuer” as defined in Rule 405 promulgated under the Securities Act. 
 2. General; Securities Subject to
this Agreement. 
 (a) Grant of Rights. The Company hereby grants registration rights to the Designated Holders upon the terms and
conditions set forth in this Agreement. 
 (b) Registrable Securities. For the purposes of this Agreement, Registrable Securities
will cease to be Registrable Securities, when: (i) a Registration Statement covering such Registrable Securities has been declared effective under the Securities Act by the Commission and such Registrable Securities have been disposed of
pursuant to such effective Registration Statement; (ii) the entire amount of the Registrable Securities owned by a Designated Holder may be sold in a single sale, in the opinion of counsel satisfactory to the Company and such Designated
Holder, each in their reasonable judgment, without any limitation as to volume pursuant to Rule 144(k) (or any successor provision then in effect) under the Securities Act; or (iii) the Registrable Securities are proposed to be sold or
distributed by a Person not entitled to the registration rights granted by this Agreement. 
 3. Demand Registration. 
 (a) Request for Demand Registration. At any time commencing one hundred and eighty (180) days after the IPO Effectiveness Date, each of the
Designated Holders (each, an “Initiating Holder”), may make a written request to the Company to register, and the Company shall register, under the Securities Act (other than pursuant to a Registration Statement on Form F-4,
S-4 or S-8 or any successor thereto) (a “Demand Registration”), the number of Registrable Securities stated in such request; provided, however, that the Company shall not be obligated to effect: 
 (i) more than two such Demand Registrations for the General Atlantic Shareholders as a group, more than two such Demand Registrations for the Fidelity
Shareholders as a group, more than one such Demand Registration for the TianDi Shareholders as a group, more than two such Demand Registrations for the UOB Shareholders as a group, more than two such Demand Registrations for the Founder Group and
more than two such Demand Registrations for Rexbury; 

 (ii) a Demand Registration if the Initiating Holder propose to sell its Registrable Securities at an
aggregate price (calculated based upon the Market Price of the Registrable Securities on the date of filing of the Registration Statement with respect to such Registrable Securities) to the public of less than US$20,000,000; 
 (iii) a Demand Registration in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 
 (iv) a Demand Registration if the Initiating Holder(s) may dispose of shares of Registrable Securities pursuant to a Registration Statement on Form F-3
pursuant to a request made under Section 5 hereof; 
 (v) a Demand Registration in any jurisdiction other than the jurisdiction(s) in
which the Company has already effected a registered public offering of its equity securities; 
 (vi) a Demand Registration during the
period ending on the date six (6) months immediately following the effective date of any Registration Statement pertaining to Ordinary Shares or ADSs (other than a Registration Statement pertaining to a transaction under Rule 145
promulgated under the Securities Act (“Rule 145”) (including Form S-4 or F-4 or any successor thereto) or with respect to an employee benefit plan (including Form S-8 or any successor thereto)); or 
 (vii) a Demand Registration if the Company, within ten (10) days of the receipt of the request of the Initiating Holders, gives notice of its bona
fide intention to effect the filing of a Registration Statement with the Commission within sixty (60) days of receipt of such request (other than with respect to a Registration Statement pertaining to a Rule 145 transaction (including Form
S-4 or F-4 or any successor thereto), with respect to an employee benefit plan (including Form S-8 or any successor thereto) or any other registration which is not appropriate for the registration of Registrable Securities). 
 For purposes of the preceding sentence, two or more Registration Statements filed in response to one demand shall be counted as one Demand Registration. If the
Board of Directors, in its good faith judgment, determines that any registration of Registrable Securities 

 
should not be made or continued because it would (i) be seriously detrimental to the Company or (ii) require the disclosure of important
confidential information that the Company has a material business purpose for preserving as confidential or the disclosure of which would materially impede the Company’s ability to consummate a significant transaction (a “Valid Business
Reason”), then the Company may (i) postpone filing a Registration Statement relating to a Demand Registration until such Valid Business Reason no longer exists, but in no event for more than one hundred and twenty (120) days; and
(ii) in case a Registration Statement has been filed relating to a Demand Registration, if the Valid Business Reason has not resulted from actions taken by the Company, the Company may cause such Registration Statement to be withdrawn and its
effectiveness terminated or may postpone amending or supplementing such Registration Statement. The Company shall give written notice to the Initiating Holders of its determination to postpone or withdraw a Registration Statement and of the fact
that the Valid Business Reason for such postponement or withdrawal no longer exists, in each case, promptly after the occurrence thereof. Notwithstanding anything to the contrary contained herein, the Company may not postpone or withdraw a filing
under this Section 3(a) more than once in any twelve (12) month period. Each request for a Demand Registration by the Initiating Holders shall state the amount of the Registrable Securities proposed to be sold and the intended method of
disposition thereof. 
 (b) Effective Demand Registration. Subject to the postponement provisions in Section 3(a), the Company
shall use its reasonable best efforts to cause any such Demand Registration to become and remain effective not later than ninety (90) days after it receives a request under Section 3(a) hereof. A registration shall not constitute a
Demand Registration until it has become effective and remains continuously effective for the lesser of (i) the period during which all Registrable Securities registered in the Demand Registration are sold, (ii) ninety (90) days and
(iii) the date on which all of the Registrable Securities registered under the Registration Statement are eligible for sale pursuant to Rule 144(k) (or any successor provision); provided, however, that a registration shall not
constitute a Demand Registration if (x) after such Demand Registration has become effective, such registration or the related offer, sale or distribution of Registrable Securities thereunder is interfered with by any stop order, injunction or
other order or requirement of the Commission or other governmental agency or court for any reason not attributable to the Initiating Holder(s) and such interference is not thereafter eliminated or (y) the conditions specified in the
underwriting agreement, if any, entered into in connection with such Demand Registration are not satisfied or waived, other than by reason of a failure by the Initiating Holder(s). 
 (c) Expenses. The Company shall pay all Registration Expenses in connection with a Demand Registration. 
 (d) Underwriting Procedures. If the Company or the Initiating Holders holding a majority of the Registrable Securities held by all of the
Initiating Holders so elect, the Company shall use its commercially reasonable efforts to cause such Demand Registration to be in the form of a firm commitment underwritten offering and the managing underwriter or underwriters 

 
selected for such offering shall be the Approved Underwriter selected in accordance with Section 3(e). If the Approved Underwriter advises the Company
that the aggregate amount of Registrable Securities requested to be included in such offering exceeds the number that can be reasonably sold in such offering, then the Company shall include in such registration only the aggregate amount of
Registrable Securities that the Approved Underwriter believes may reasonably be sold and shall reduce the amount of Registrable Securities to be included in such registration, first as to the Company, second as to the Designated
Holders (who are not Initiating Holders and who requested to participate in such registration pursuant to Section 4 hereof) as a group, if any, pro rata based on the number of Registrable Securities then owned by each such Designated Holder and
third as to the Initiating Holders as a group, pro rata based on the number of Registrable Securities then owned by each such Initiating Holder. 
 (e) Selection of Underwriters. If any Demand Registration or F-3 Registration, as the case may be, of Registrable Securities is in the form of an underwritten offering, the Company shall use its reasonable best
efforts to select and obtain an investment banking firm of international reputation to act as the managing underwriter of the offering (the “Approved Underwriter”); provided, however, that the Approved Underwriter
shall, in any case, also be reasonably acceptable to the Initiating Holders or F-3 Initiating Holders, as the case may be. 
 4.
Incidental or “Piggy-Back” Registration. 
 (a) Request for Incidental Registration. If the Company proposes to file
a Registration Statement under the Securities Act with respect to an offering (i) by the Company for its own account (other than a Registration Statement on Form F-4, S-4 or S-8 or any successor thereto) or (ii) for the account
of any shareholder of the Company (including without limitation an Initiating Holder pursuant to Section 3, but excluding for the account of an F-3 Initiating Holder, which shall be governed exclusively by Section 5) (in each case, an
“Incidental Registration”), then the Company shall give written notice of such proposed filing to each of the Designated Holders at least fifteen (15) days before the anticipated filing date, and such notice shall describe the
proposed registration and distribution and offer such Designated Holders the opportunity to register the number of Registrable Securities as each such Designated Holder may request (a “Notice of Incidental Registration”). Upon the
written request of any Designated Holder made within fifteen (15) days after receipt of a Notice of Incidental Registration (which request shall specify the Registrable Securities intended to be disposed of by such Designated Holder), the
Company shall use its commercially reasonable efforts to permit or, in the case of a proposed underwritten offering, cause the managing underwriter or underwriters (the “Company Underwriter”) to permit each of the Designated Holders
who have requested in writing to participate in the Incidental Registration to include its or his Registrable Securities in such offering on the same terms and conditions as the securities of the Company or the account of such other shareholder, as
the case may be, included therein. In connection with any Incidental Registration under this Section 4(a) involving an underwritten offering, the Company shall not be required to include any Registrable Securities in such underwritten offering
unless the Designated Holders thereof accept the terms of the underwritten offering as agreed upon between the 

 
Company, such other shareholders, if any, and the Company Underwriter, and then only in such quantity as the Company Underwriter believes will not jeopardize
the success of the offering by the Company. In the case of an offering by the Company for its own account or for the account of any shareholder of the Company (other than for an Initiating Holder in connection with a Demand Registration pursuant to
Section 3 or an F-3 Initiating Holder in connection with a F-3 Registration pursuant to Section 5), if the Company Underwriter determines that the registration of all or part of the Registrable Securities which the Designated Holders have
requested to be included would exceed the number that can be reasonably sold in such offering, then the Company shall be required to include in such Incidental Registration, to the extent of the amount that the Company Underwriter believes may be
reasonably sold, first, all of the securities to be offered for the account of the Company; second, the Registrable Securities to be offered for the account of the Designated Holders pursuant to this Section 4, pro rata based on
the number of Registrable Securities owned by each such Designated Holder; and third, any other securities requested to be included in such offering; and any securities so excluded shall be withdrawn from and shall not be included in the
Incidental Registration. For the avoidance of doubt and notwithstanding anything to the contrary set forth in this Section 4(a), (i) in the case of a Demand Registration pursuant to Section 3, to the extent that there is any cutback
in the number of shares sold in such offering, such cutback shall be governed by Section 3(d) and (ii) in the case of a F-3 Registration pursuant to Section 5, to the extent that there is any cutback in the number of shares sold in
such offering, such cutback shall be governed by Section 5(b). 
 (b) Expenses. The Company shall bear all Registration Expenses
in connection with any Incidental Registration pursuant to this Section 4. 
 5. Form F-3 Registration. 
 (a) Request for a Form F-3 Registration. As long as the Company is eligible to use Form F-3 (or any successor form thereto) under the Securities
Act in connection with a public offering of its securities, subject to Section 5(c) hereof, in the event that the Company shall receive from any of the General Atlantic Shareholders, the Fidelity Shareholders, the TianDi Shareholders or the UOB
Shareholders, (each, an “F-3 Initiating Holders”), a written request that the Company register, under the Securities Act on Form F-3 (or any successor form then in effect) (an “F-3 Registration”), all or a
portion of the Registrable Securities owned by such F-3 Initiating Holders, the Company shall give written notice of such request to all of the Designated Holders (other than F-3 Initiating Holders which have requested an F-3 Registration under this
Section 5(a)) at least ten (10) days before the anticipated filing date of such Form F-3, and such notice shall describe the proposed registration and offer such Designated Holders the opportunity to register the number of Registrable
Securities as each such Designated Holder may request in writing to the Company, given within ten (10) days after their receipt from the Company of the written notice of such registration. If requested by the F-3 Initiating Holders, such F-3
Registration shall be for an offering on a continuous basis pursuant to Rule 415 under the Securities Act and/or (ii) if the Company is a Well-Known Seasoned Issuer, such F-3 Registration shall be on an Automatic Shelf Registration Statement.
With 

 
respect to each F-3 Registration, the Company shall, subject to Section 5(b), (i) include in such offering the Registrable Securities of the F-3
Initiating Holders and (ii) use its reasonable best efforts to (x) cause such registration pursuant to this Section 5(a) to become and remain effective as soon as practicable, but in any event not later than forty five (45) days
(or, in the case of an Automatic Shelf Registration Statement, fifteen (15) Business Days) after it receives a request therefor and (y) include in such offering the Registrable Securities of the Designated Holders (other than F-3
Initiating Holders which have requested an F-3 Registration under this Section 5(a)) who have requested in writing to participate in such registration on the same terms and conditions as the Registrable Securities of the F-3 Initiating Holders
included therein. 
 (b) Form F-3 Underwriting Procedures. If the F-3 Initiating Holders holding a majority of the Registrable
Securities held by all of the F-3 Initiating Holders so elect, the Company shall use its commercially reasonable efforts to cause such F-3 Registration pursuant to this Section 5 to be in the form of a firm commitment underwritten offering and
the managing underwriter or underwriters selected for such offering shall be the Approved Underwriter selected in accordance with Section 3(d). In connection with any F-3 Registration under Section 5(a) involving an underwritten
offering, the Company shall not be required to include any Registrable Securities in such underwritten offering unless the Designated Holders thereof accept the terms of the underwritten offering as agreed upon between the Company, the Approved
Underwriter and the F-3 Initiating Holders, and then only in such quantity as such underwriter believes do not exceed the number that can be reasonably sold in such offering by the F-3 Initiating Holders. If the Approved Underwriter believes that
the registration of all or part of the Registrable Securities which the F-3 Initiating Holders and the other Designated Holders have requested to be included would exceed the number that can be reasonably sold in such public offering, then the
Company shall be required to include in the underwritten offering, to the extent of the amount that the Approved Underwriter believes may reasonably be sold, first, all of the Registrable Securities to be offered for the account of
the F-3 Initiating Holders, pro rata based on the number of Registrable Securities owned by such F-3 Initiating Holders; second, the Registrable Securities to be offered for the account of the other Designated Holders who requested
inclusion of their Registrable Securities pursuant to Section 5(a), pro rata based on the number of Registrable Securities owned by such Designated Holders; and third, any other securities requested to be included in such offering; and
any securities so excluded shall be withdrawn from and shall not be included in the F-3 Registration. 
 (c) Limitations on Form F-3
Registrations. If the Board of Directors has a Valid Business Reason, the Company may (i) postpone filing a Registration Statement relating to a F-3 Registration until such Valid Business Reason no longer exists, but in no event for more
than one hundred and twenty (120) days, and (ii) in case a Registration Statement has been filed relating to a F-3 Registration, if the Valid Business Reason has not resulted from actions taken by the Company, the Company, upon the
approval of a majority of the Board of Directors, may cause such Registration Statement to be withdrawn and its effectiveness terminated or may postpone amending or supplementing such Registration Statement. The Company shall give written notice to
the F-3 Initiating Holders of its determination to postpone or withdraw a Registration Statement and of the fact that the Valid Business Reason for such 

 
postponement or withdrawal no longer exists, in each case, promptly after the occurrence thereof. Notwithstanding anything to the contrary contained herein,
the Company may not postpone or withdraw a filing due to a Valid Business Reason more than once in any twelve (12) month period. In addition, the Company shall not be required to effect any registration pursuant to Section 5(a):

 (i) within one hundred thirty five (135) days after the effective date of any other Registration Statement of the Company (other than
with respect to a Registration Statement relating to a Rule 145 transaction (including S-4 or F-4 or any successor thereto) or an employee benefit plan (including Form S-8 or any successor thereto)); 
 (ii) if within the twelve (12) month period preceding the date of such request, the Company has effected two (2) registrations on Form F-3
pursuant to Section 5(a); 
 (iii) if Form F-3 is not available for such offering by the F-3 Initiating Holders; 
 (iv) more than three F-3 Registrations for each of the General Atlantic Shareholders as a group, the Fidelity Shareholders as a group, the TianDi
Shareholders as a group and the UOB Shareholders as a group; 
 (v) if the F-3 Initiating Holders, together with the Designated Holders
registering Registrable Securities in such registration, propose to sell their Registrable Securities at an aggregate price (calculated based upon the Market Price of the Registrable Securities on the date of the request by the F-3 Initiating
Holders for the F-3 Registration) to the public of less than US$20,000,000; 
 (vi) if the Company, within ten (10) days of the receipt
of the request of the F-3 Initiating Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the Commission within sixty (60) days of receipt of such request (other than with respect to a
Registration Statement relating to a Rule 145 transaction (including Form S-8 or any successor thereto), an employee benefit plan (including S-4 or F-4 or any successor thereto) or any other registration which is not appropriate for the
registration of Registrable Securities); or 
 (vii) in any particular jurisdiction in which the Company would be required to execute a
general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 
 (d) Expenses. The Company shall bear all Registration Expenses in connection with any F-3 Registration pursuant to this Section 5.

 (e) Automatic Shelf Registration. Upon the Company becoming a Well-Known Seasoned Issuer, the Company shall give written notice to
all of the Designated Holders as promptly as practicable but in no event later than 10 Business Days thereafter, 

 
and such notice shall describe, in reasonable detail, the basis on which the Company has become a Well-Known Seasoned Issuer. At any time after the filing of
an Automatic Shelf Registration Statement by the Company, if it is reasonably likely that it will no longer be a Well-Known Seasoned Issuer as of a future determination date (the “Determination Date”), at least 10 days prior to such
Determination Date, the Company shall give written notice thereof to all of the Designated Holders as promptly as practicable. 
 (f) No
Demand Registration. No registration requested by any F-3 Initiating Holder pursuant to this Section 5 shall be deemed a Demand Registration pursuant to Section 3. 
 6. Holdback Agreements. 
 (a)
Restrictions on Public Sale by Designated Holders. In the event of the Initial Public Offering, to the extent (i) requested by the Company’s managing underwriter of its Initial Public Offering and (ii) all of the Company’s
officers, directors and holders in excess of one percent (1%) of its outstanding voting share capital execute agreements identical to those referred to in this Section 6(a), each Designated Holder agrees (x) not to effect any sale or
distribution of any equity securities of the Company or of any securities convertible into or exchangeable or exercisable for equity securities of the Company, including a sale pursuant to Rule 144 under the Securities Act, or offer to sell,
contract to sell (including without limitation any short sale), grant any option to purchase, enter into any hedging or similar transaction with the same economic effect as a sale or otherwise dispose of any equity securities of the Company and
(y) not to make any request for a Demand Registration or F-3 Registration under this Agreement, during the 180 day period or such shorter period, if any, mutually agreed upon by such Designated Holder and the requesting party beginning on the
effective date of the Registration Statement (except as part of such registration) for such Initial Public Offering. No Designated Holder of Registrable Securities subject to this Section 6(a) shall be released from any obligation under any
agreement, arrangement or understanding entered into pursuant to this Section 6(a) unless all other Designated Holders of Registrable Securities subject to the same obligation are also released. Notwithstanding the foregoing, during such
restricted period, the Founder Trusts may transfer equity securities of the Company from such Founders Trusts back to their respective grantors in order to repay any annuity in connection therewith. 
 (b) Restrictions on Public Sale by the Company. The Company agrees not to effect any public sale or distribution of any of its securities, or any
securities convertible into or exchangeable or exercisable for such securities (except pursuant to registrations on Form F-4, S-4 or S-8 or any successor thereto), during the period beginning on the effective date of any Registration
Statement in which the Designated Holders of Registrable Securities are participating and ending on the earlier of (i) the date on which all Registrable Securities registered on such Registration Statement are sold and (ii) thirty
(30) days after the effective date of such Registration Statement (except as part of such registration). 

 7. Registration Procedures. 
 (a) Obligations of the Company. Whenever registration of Registrable Securities has been requested pursuant to Section 3, Section 4
or Section 5 of this Agreement, the Company shall use its commercially reasonable efforts to effect the registration and sale of such Registrable Securities in accordance with the intended method of distribution thereof as quickly as
practicable, and in connection with any such request, the Company shall, as expeditiously as possible: 
 (i) prepare and file with the
Commission a Registration Statement on any form for which the Company then qualifies or which counsel for the Company shall deem appropriate and which form shall be available for the sale of such Registrable Securities in accordance with the
intended method of distribution thereof, and use its best efforts to cause such Registration Statement to become effective; provided, however, that (x) before filing a Registration Statement or prospectus or any amendments or
supplements thereto, or before using any Free Writing Prospectus, the Company shall provide counsel selected by the Designated Holders holding a majority of the Registrable Securities being registered in such registration (“Holders’
Counsel”) with an adequate and appropriate opportunity to review and comment on such Registration Statement and each prospectus included therein (and each amendment or supplement thereto) and each Free Writing Prospectus to be filed with
the Commission, subject to such documents being under the Company’s control, and (y) the Company shall notify the Holders’ Counsel and each seller of Registrable Securities of any stop order issued or threatened by the Commission and
take all action required to prevent the entry of such stop order or to remove it if entered; 
 (ii) prepare and file with the Commission
such amendments and supplements to such Registration Statement and the prospectus and each Free Writing Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective for the lesser of (x) one hundred
twenty (120) days, (y) such shorter period which will terminate when all Registrable Securities covered by such Registration Statement have been sold and (z) such shorter period which will terminate when all of the Registrable
Securities registered under the Registration Statement are eligible for sale pursuant to Rule 144(k) in a single sale in the written opinion of counsel for the Company in a transaction exempt from the registration and prospectus delivery
requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale; provided, that if the F-3 Initiating Holders have requested that an F-3
Registration be for an offering on a continuous basis pursuant to Rule 415 under the Securities Act, then the Company shall keep such Registration Statement effective until the lesser of (x) one hundred eighty (180) days, (y) such
shorter period which will terminate when all Registrable Securities covered by such Registration Statement have been sold and (z) such shorter period which will terminate when all of the Registrable Securities registered under the F-3
Registration are eligible for sale pursuant to Rule 144(k) in a single sale in the written opinion of counsel for the Company in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act so that all
transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale; and shall 

 
comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement during such period
in accordance with the intended methods of disposition by the sellers thereof set forth in such Registration Statement; 
 (iii) furnish to
each seller of Registrable Securities, prior to filing a Registration Statement, at least one copy of such Registration Statement as is proposed to be filed, and thereafter such number of copies of such Registration Statement, each amendment and
supplement thereto (in each case including all exhibits thereto), and the prospectus included in such Registration Statement (including each preliminary prospectus), any prospectus filed under Rule 424 under the Securities Act and any Free Writing
Prospectus as each such seller may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such seller; 
 (iv) register or qualify such Registrable Securities under such other securities or “blue sky” laws of such jurisdictions as any seller of Registrable Securities may request, and to continue such qualification in effect in
such jurisdiction for as long as permissible pursuant to the laws of such jurisdiction, or for as long as any Registration Statement is required to remain effective in accordance with Section 7(a)(ii) above, whichever is shortest, and do any
and all other acts and things which may be reasonably necessary or advisable to enable any such seller to consummate the disposition in such jurisdictions of the Registrable Securities owned by such seller; provided, however, that the
Company shall not be required to (x) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 7(a)(iv), (y) subject itself to taxation in any such jurisdiction or
(z) consent to general service of process in any such jurisdiction; 
 (v) notify each seller of Registrable Securities at
any time when a prospectus or Free Writing Prospectus relating thereto is required to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result of which, the prospectus included in such
Registration Statement or such Free Writing Prospectus contains an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading, and in the event of such notice, the Company shall promptly prepare a supplement or amendment to such prospectus or Free Writing Prospectus, as the case may be, and furnish to each seller of Registrable
Securities a reasonable number of copies of such supplement to or an amendment of such prospectus or Free Writing Prospectus, as the case may be, as may be necessary so that, after delivery to the purchasers of such Registrable Securities, such
prospectus or Free Writing Prospectus, as the case may be, shall not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading; 
 (vi) enter into and perform customary agreements (including an underwriting
agreement in reasonable and customary form with the Approved Underwriter or Company Underwriter, if any, selected as provided in Section 3, Section 4 or 

 
Section 5, as the case may be, provided that each Designated Holder participating in such underwriting shall also enter into and perform its obligations
under such an agreement) and take such other actions as are prudent and reasonably required in order to expedite or facilitate the disposition of such Registrable Securities; 
 (vii) make available at times and places reasonably acceptable to the Company for inspection by any seller of Registrable Securities, any managing
underwriter participating in any disposition of such Registrable Securities pursuant to a Registration Statement, Holders’ Counsel and, in each case that is reasonably acceptable to the Company, any attorney, accountant or other advisor
retained by any such seller or any managing underwriter (each, an “Inspector” and collectively, the “Inspectors”), all financial and other records, pertinent corporate documents and properties of the Company and its
subsidiaries (collectively, the “Records”) as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company’s and its subsidiaries’ officers, directors and employees,
and the independent public accountants of the Company, to supply all information reasonably requested by any such Inspectors in connection with such Registration Statement. Records and other information that the Company determines, in good faith, to
be confidential shall not be disclosed by the Inspectors (and the Inspectors shall confirm their agreement in writing in advance to the Company if the Company shall so request) unless (x) the disclosure of such Records is necessary to avoid or
correct a misstatement or omission in the Registration Statement, (y) the release of such Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction or (z) the information in such Records was known to
the Inspectors on a non-confidential basis prior to its disclosure by the Company or has been made generally available to the public. Each seller of Registrable Securities agrees that it shall, upon learning that disclosure of such Records is
sought in a court of competent jurisdiction, give notice to the Company and allow the Company, at the Company’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential; 
 (viii) if such sale is pursuant to an underwritten offering, obtain “cold comfort” letters dated the effective date of the Registration
Statement and the date of the closing under the underwriting agreement from the Company’s independent public accountants in customary form and covering such matters of the type customarily covered by “cold comfort” letters as
Holders’ Counsel or the managing underwriter reasonably requests; 
 (ix) furnish, at the request of the Designated Holders
participating in the registration, on the date such securities are delivered to the underwriters for sale pursuant to such registration or, if such securities are not being sold through underwriters, on the date the Registration Statement with
respect to such securities becomes effective, an opinion, dated such date, of counsel representing the Company for the purposes of such registration, addressed to the underwriters, if any, and to the seller making such request, covering such legal
matters with respect to the registration in respect of which such opinion is being given as the underwriters, if any, and such seller may reasonably request and are customarily included in such opinions; 

 (x) with respect to each Free Writing Prospectus or other materials to be included in the Disclosure
Package, ensure that no Registrable Securities be sold “by means of” (as defined in Rule 159A(b) promulgated under the Securities Act) such Free Writing Prospectus or other materials without the prior written consent of the Designated
Holders of the Registrable Securities covered by such registration statement, which Free Writing Prospectuses or other materials shall be subject to the review of Holders’ Counsel; 
 (xi) as expeditiously as possible and within the deadlines specified by the Securities Act, make all required filings of all prospectuses and Free
Writing Prospectuses with the Commission; 
 (xii) as expeditiously as possible and within the deadlines specified by the Securities Act,
make all required filing fee payments in respect of any Registration Statement or prospectus used under this Agreement (and any offering covered thereby); 
 (xiii) comply with all applicable rules and regulations of the Commission; 
 (xiv) cause all such
Registrable Securities to be listed on each securities exchange on which similar securities issued by the Company are then listed; provided that the applicable listing requirements are satisfied; 
 (xv) keep Holders’ Counsel advised in writing as to the initiation and progress of any registration under Section 3, Section 4 or
Section 5 hereunder; 
 (xvi) cooperate with each seller of Registrable Securities and any underwriter participating in the disposition
of such Registrable Securities and their respective counsel in connection with any filings required to be made with the relevant securities exchange or the NASD; and 
 (xvii) take all other steps reasonably necessary to effect the registration of the Registrable Securities contemplated hereby. 
 (b) Seller Information. 
 (i) It shall be a condition precedent to the obligations of the Company to
register the Registrable Securities of any Designated Holder that such Designated Holder shall furnish to the Company such information regarding such Designated Holder or Designated Holders, the number of Registrable Securities held by them and the
manner of distribution of such securities as the Company may from time to time reasonably request in writing and as shall be required in connection with any registration, qualification or compliance referred to in this Agreement. 

 (ii) In connection with any offering under any Registration Statement under this Agreement, each
Designated Holder shall not use any Free Writing Prospectus without the prior written consent of the Company. 
 (c) Notice to
Discontinue. Each Designated Holder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 7(a)(v), such Designated Holder shall forthwith discontinue disposition of
Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Designated Holder’s receipt of the copies of the supplemented or amended prospectus or Free Writing Prospectus contemplated
by Section 7(a)(v) and, if so directed by the Company, such Designated Holder shall deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Designated Holder’s possession, of the
prospectus or Free Writing Prospectus covering such Registrable Securities which is current at the time of receipt of such notice. If the Company shall give any such notice, then the Company shall use it reasonable best efforts to extend the period
during which such Registration Statement shall be maintained effective pursuant to this Agreement (including, without limitation, the period referred to in Section 7(a)(ii)) by the number of days during the period from and including the date of
the giving of such notice pursuant to Section 7(a)(v) to and including the date when sellers of such Registrable Securities under such Registration Statement shall have received the copies of the supplemented or amended prospectus or Free
Writing Prospectus contemplated by and meeting the requirements of Section 7(a)(v). 
 (d) Registration Expenses. The Company
shall pay all reasonable expenses arising from or incident to its performance of, or compliance with, this Agreement, including, without limitation: (i) Commission, securities exchange and NASD registration and filing fees; (ii) all
fees and expenses incurred in complying with securities or “blue sky” laws (including reasonable fees, charges and disbursements of counsel to any underwriter incurred in connection with “blue sky” qualifications of the
Registrable Securities as may be set forth in any underwriting agreement); (iii) all printing, messenger and delivery expenses; (iv) the fees, charges and expenses of counsel to the Company and of its independent public accountants
and any other accounting fees, charges and expenses incurred by the Company (including, without limitation, any expenses arising from any “cold comfort” letters or any special audits incident to or required by any registration or
qualification) and the reasonable legal fees, charges and expenses of one counsel incurred, in the case of a Demand Registration or an F-3 Registration, by all Initiating Holders or all F-3 Initiating Holders, as the case may be, not to exceed
$25,000; (v) all fees of the depositary of the Company in connection with the deposit by any Designated Holder of their Ordinary Shares in exchange for ADSs; and (vi) any liability insurance or other premiums for insurance obtained in
connection with any Demand Registration or piggy-back registration thereon, Incidental Registration or F-3 Registration pursuant to the terms of this Agreement, regardless of whether such Registration Statement is declared effective. All of the
expenses described in the preceding sentence of this Section 7(d) are referred to herein as “Registration Expenses”; provided, however, that the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Section 3 or Section 5 if the registration request is subsequently withdrawn at the request of the Initiating Holder(s) or the F-3 Initiating 

 
Holder(s), as the case may be, in which case the Initiating Holder(s) or F-3 Initiating Holder(s) shall either bear such expenses pro rata on the basis of
the number of their Registrable Securities proposed to be so registered or forfeit one Demand Registration right or one F-3 Registration right); provided, further, however, that notwithstanding the foregoing, if the Demand
Registration or F-3 Registration as the case may be, is withdrawn at the request of the Initiating Holder(s) or the F-3 Initiating Holder(s), as the case may be, having learned of a material adverse change in the condition or business of the Company
from that known to the holders at the time of their request, then the holders shall not be required to pay any of such expenses if the Initiating Holder(s) or F-3 Initiating Holder(s) have withdrawn such request with reasonable promptness following
their learning of such material adverse change in the condition or business of the Company. The Designated Holders of Registrable Securities sold pursuant to a Registration Statement shall bear the expense of any broker’s and sales commission
or underwriter’s discount or commission relating to registration and sale of such Designated Holders’ Registrable Securities. 
 8.
Indemnification; Contribution. 
 (a) Indemnification by the Company. The Company agrees to indemnify and hold harmless
each Designated Holder, its partners, directors, officers, affiliates and each Person who controls (within the meaning of Section 15 of the Securities Act) such Designated Holder from and against any and all losses, claims, damages, liabilities
and expenses (including reasonable costs of investigation) (each, a “Liability” and collectively, “Liabilities”), arising out of or based upon any untrue, or allegedly untrue, statement of a material fact contained
in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto) or otherwise included in the Disclosure
Package or arising out of or based upon any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading except insofar as such Liability arises out of or is
based upon any untrue statement or alleged untrue statement or omission or alleged omission contained in such Registration Statement, Free Writing Prospectus, preliminary prospectus or final prospectus or otherwise included in the Disclosure
Package, in reliance and in conformity with information concerning such Designated Holder furnished in writing to the Company by such Designated Holder expressly for use therein, including, without limitation, the information furnished to the
Company pursuant to Section 8(b). The Company shall also provide customary indemnities to any underwriters of the Registrable Securities, their officers, directors and employees and each Person who controls such underwriters (within the meaning
of Section 15 of the Securities Act) to the same extent as provided above with respect to the indemnification of the Designated Holders of Registrable Securities. 
 (b) Indemnification by Designated Holders. In connection with any Registration Statement in which a Designated Holder is participating pursuant to Section 3, Section 4 or Section 5 hereof, each
such Designated Holder shall promptly furnish to the Company in writing such information with respect to such Designated Holder as the Company may reasonably request or as may be 

 
required by law for use in connection with any such Registration Statement prospectus or Free Writing Prospectus and all information required to be disclosed
in order to make the information previously furnished to the Company by such Designated Holder not materially misleading or necessary to cause such Registration Statement not to omit a material fact with respect to such Designated Holder necessary
in order to make the statements therein not misleading. Each Designated Holder agrees to indemnify and hold harmless the Company, any underwriter retained by the Company and each Person who controls the Company or such underwriter (within the
meaning of Section 15 of the Securities Act) to the same extent as the foregoing indemnity from the Company to the Designated Holders, but only if such statement or alleged statement or omission or alleged omission was made in reliance upon and
in conformity with information with respect to such Designated Holder furnished in writing to the Company by such Designated Holder expressly for use in such Registration Statement prospectus or Free Writing Prospectus, or otherwise included in the
Disclosure Package, including, without limitation, the information furnished to the Company pursuant to this Section 8(b); provided, however, that the total amount to be indemnified by such Designated Holder pursuant to this
Section 8(b) shall be limited to the net proceeds (after deducting the underwriters’ discounts and commissions) received by such Designated Holder in the offering to which the Registration Statement, prospectus or Free Writing Prospectus
(or Disclosure Package otherwise) relates, provided, however, that such limitation shall not apply in the case of willful fraud by such Designated Holder. 
 (c) Conduct of Indemnification Proceedings. Any Person entitled to indemnification hereunder (the “Indemnified Party”) agrees to give prompt written notice to the indemnifying party (the
“Indemnifying Party”) promptly after the Indemnified Party has actual knowledge of any action, suit, proceeding or investigation or threat thereof for which the Indemnified Party intends to claim indemnification or contribution
pursuant to this Agreement; provided, however, that the failure so to notify the Indemnifying Party shall not relieve the Indemnifying Party of any Liability that it may have to the Indemnified Party hereunder (except to the extent
that the Indemnifying Party is materially prejudiced or otherwise forfeits substantive rights or defenses by reason of such failure). If notice of commencement of any such action is given to the Indemnifying Party as above provided, the
Indemnifying Party shall have the option to assume the defense of such action or any litigation resulting therefrom at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party. The Indemnified Party shall
have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be paid by the Indemnified Party unless (i) the Indemnifying Party agrees to pay the same,
(ii) the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory to the Indemnified Party or (iii) the named parties to any such action (including any impleaded parties) include both the
Indemnifying Party and the Indemnified Party and such parties have been advised by such counsel that either (x) representation of such Indemnified Party and the Indemnifying Party by the same counsel would be inappropriate under applicable
standards of professional conduct or (y) there may be one or more legal defenses available to the Indemnified Party which are different from or additional to those available to the Indemnifying Party. In any of such cases, the Indemnifying
Party shall not 

 
have the right to assume the defense of such action on behalf of such Indemnified Party, it being understood, however, that the Indemnifying Party shall not
be liable for the fees and expenses of more than one separate firm of attorneys (in addition to any local counsel) for all Indemnified Parties. No Indemnifying Party shall be liable for any settlement entered into without its written consent, which
consent shall not be unreasonably withheld. No Indemnifying Party shall, without the consent of such Indemnified Party, effect any settlement of any pending or threatened proceeding in respect of which such Indemnified Party is a party and indemnity
has been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Party from all liability for claims that are the subject matter of such proceeding. 
 (d) Contribution. If the indemnification provided for in this Section 8 from the Indemnifying Party is unavailable to an Indemnified Party
hereunder in respect of any Liabilities referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Liabilities in such
proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions which resulted in such Liabilities, as well as any other relevant equitable considerations. The relative faults
of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact, has been made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action. The
amount paid or payable by a party as a result of the Liabilities referred to above shall be deemed to include, subject to the limitations set forth in Sections 8(a), 8(b) and 8(c), any legal or other fees, charges or expenses reasonably
incurred by such party in connection with any investigation or proceeding; provided that the total amount to be contributed by such Designated Holder shall be limited to the net proceeds (after deducting the underwriters’ discounts and
commissions) received by such Designated Holder in the offering. 
 The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 8(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph. No
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
 9. Additional Covenants. 
 (a)
Rule 144. The Company covenants that from and after the IPO Effectiveness Date or an Exchange Act Registration it shall use its best efforts to (i) file any reports required to be filed by it under the Exchange Act and (ii) take
such further action as each Designated Holder may reasonably request (including, without limitation, providing any information necessary to comply with Rule 144 under the Securities Act), all to the extent required from time to time to enable
such Designated Holder to 

 
sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by (x) Rule 144
under the Securities Act, as such rule may be amended from time to time, or Regulation S under the Securities Act, or (y) any successor rules or regulations hereafter adopted by the Commission to such rules or regulations. The Company
shall, upon the request of any Designated Holder, deliver to such Designated Holder a written statement as to whether it has complied with such requirements. 
 (b) ADSs. In the event that the Company pursues an offering or listing of ADSs in the United States, the Company will use its best efforts to file a Registration Statement on Form F-6 which registers a number
of ADSs that is sufficient to allow the Designated Holders to exercise their rights under, and sell their Registrable Securities in the United States in the manner contemplated by, Sections 3, 4 and 5 of this Agreement. 
 10. Non-U.S. Listings. 
 In the event
that the Ordinary Shares are listed on any securities exchange outside the United States, the Company shall (a) use all reasonable and diligent efforts to cause all Registrable Securities to be approved for listing and freely tradeable on such
stock exchange, subject to any lock-ups required pursuant to the rules and regulations of the relevant exchange or applicable securities law and (b) furnish to the Designated Holders such number of copies of prospectuses, Free Writing
Prospectuses and such other documents as they may reasonably request to facilitate the disposition of Registrable Securities by the Designated Holders on such exchange. 
 11. Miscellaneous. 
 (a) Recapitalizations, Exchanges, etc. The provisions of this Agreement
shall apply to the full extent set forth herein with respect to (i) the Ordinary Shares, (ii) any and all voting shares of the Company into which the Ordinary Shares are converted, exchanged or substituted in any recapitalization or other
capital reorganization by the Company and (iii) any and all equity securities of the Company or any successor or assign of the Company (whether by merger, consolidation, sale of assets or otherwise) which may be issued in respect of, in
conversion of, in exchange for or in substitution of, the Ordinary Shares and shall be appropriately adjusted for any stock dividends, splits, reverse splits, combinations, recapitalizations and the like occurring after the date hereof. The Company
shall cause any successor or assign (whether by merger, consolidation, sale of assets or otherwise) to enter into a new registration rights agreement with the Designated Holders on terms substantially the same as this Agreement as a condition of any
such transaction. 
 (b) No Inconsistent Agreements. The Company represents and warrants that it has not granted to any Person the
right to request or require the Company to register any securities issued by the Company, other than the rights granted to the Designated Holders herein. The Company shall not enter into any agreement with respect to its securities that is
inconsistent with the 

 
rights granted to the Designated Holders in this Agreement or grant any additional registration rights to any Person or with respect to any securities which
are not Registrable Securities which are prior in right to or inconsistent with the rights granted in this Agreement, except that the Company may grant the registration rights held by the Designated Holders to any Subsequent Purchaser. 

(c) Remedies. The Designated Holders, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
shall be entitled to specific performance of their rights under this Agreement. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Agreement and
hereby agrees to waive in any action for specific performance the defense that a remedy at law would be adequate. 
 (d) Amendments and
Waivers. Except as otherwise provided herein, the provisions of this Agreement may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given unless consented to in writing by
(i) the Company and (ii) a majority in interest of each of (a) the General Atlantic Shareholders, (b) the TianDi Shareholders, (c) the UOB Shareholders, (d) the Founder Group, (e) the Fidelity Shareholders and
(f) Rexbury. Any such written consent shall be binding upon the Company and all of the Designated Holders. Notwithstanding the first sentence of this Section 11(d), the Company, without the consent of any other party hereto, may amend this
Agreement to add any Subsequent Purchaser as a party to this Agreement as a Designated Holder. 
 (e) Notices. All notices, demands
and other communications provided for or permitted hereunder shall be made in writing and shall be made by registered or certified first-class mail, return receipt requested, facsimile, courier service or personal delivery: 
  

	 	(i)	if to the Company: 

 Wuxi PharmaTech (Cayman) Inc.

 No.1 Building, # 288 FuTe Zhong Lu 
 Waigaoqiao Free Trade Zone 
 Shanghai, 200131, PRC 
 Facsimile: (86-21) 5046-3718 
 Attention: Dr. Li Ge 
 with a copy to: 
 O’ Melveny &
Myers LLP 
 Plaza 66, 37th Floor, 1266 Nanjing 
 Road West 
 Shanghai, 200040, PRC 
 Facsimile: (86-21)
2307-7300 
 Attention: Kurt Berney 

	 	(ii)	if to any of the General Atlantic Shareholders, Fidelity Shareholders, the TianDi Shareholders, the UOB Shareholders, the Founder Group, Rexbury or JP Morgan, at its address as it
appears on the record books of the Company. 

 All such notices, demands and other communications shall be deemed to have been
duly given when delivered by hand, if personally delivered; when delivered by courier, if delivered by commercial courier service; five (5) Business Days after being deposited in the mail, postage prepaid, if mailed; and when receipt is
mechanically acknowledged, if sent by facsimile. Any party may by notice given in accordance with this Section 11(e) designate another address or Person for receipt of notices hereunder. 
 (f) Successors and Assigns; Third Party Beneficiaries. This Agreement shall inure, as hereinafter provided, to the benefit of and be binding upon
the successors and permitted assigns of the parties hereto who execute the joinder agreement in the form attached as Schedule 2 hereto. The Demand Registration rights and the F-3 Registration rights and related rights of the Designated
Holders contained in Sections 3 and 5 hereof, shall be (i) with respect to any Registrable Security that is proposed to be transferred to an Affiliate of such Designated Holder, transferred to such Affiliate with written notice to the
Company prior to or promptly after such transfer and (ii) with respect to any Registrable Security that is proposed to be transferred in all cases to a non-Affiliate, transferred only with the prior written consent of the Company, which consent
shall not be unreasonably withheld. The incidental or “piggy-back” registration rights of the Designated Holders contained in Section 4 hereof and the other rights of each of the Designated Holders with respect thereto shall be, with
respect to any Registrable Security, automatically transferred to any Person who is the transferee of such Registrable Security, but only if transferred in compliance with the Joint Venture Agreement. All of the obligations of the Company hereunder
shall survive any such transfer. Except as provided in Section 8, no Person other than the parties hereto and their successors and permitted assigns is intended to be a beneficiary of this Agreement. 
 (g) Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile shall be as effective as delivery
of a manually executed counterpart of a signature page of this Agreement. 
 (h) Headings. The headings in this Agreement are for
convenience of reference only and shall not limit or otherwise affect the meaning hereof. 
 (i) GOVERNING LAW. THIS AGREEMENT
SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, UNITED STATES OF AMERICA, WITHOUT 

 
REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. The parties hereto irrevocably submit to the exclusive jurisdiction of any state or
federal court sitting in the County of New York, in the State of New York over any suit, action or proceeding arising out of or relating to this Agreement or the affairs of the Company. To the fullest extent they may effectively do so under
applicable law, the parties hereto irrevocably waive and agree not to assert, by way of motion, as a defense or otherwise, any claim that they are not subject to the jurisdiction of any such court, any objection that they may now or hereafter have
to the laying of the venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 
 (j) WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A
TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE PARTIES HERETO HEREBY (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO
ENTER INTO THIS AGREEMENT AND THE TRANSACTONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 11(j). 
 (k) Severability. If any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal
or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired, unless the provisions held invalid,
illegal or unenforceable shall substantially impair the benefits of the remaining provisions hereof. 
 (l) Rules of Construction.
Unless the context otherwise requires, references to sections or subsections refer to sections or subsections of this Agreement. 
 (m)
Entire Agreement; Termination of Original Reg Rights Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the
parties hereto with respect to the subject matter contained herein. There are no restrictions, promises, representations, warranties or undertakings with respect to the subject matter contained herein, other than those set forth or referred to
herein. The Sub and the undersigned parties who are the holders in interest of a sufficient number of Registrable Securities to terminate the Original Reg Rights Agreement, hereby agree to terminate terminate the Original Reg Rights Agreement in its
entirety. Such termination shall be effective for all purposes as of the date hereof. This Agreement supersedes all prior agreements and understandings among the parties with respect to such subject matter. 

 (n) Further Assurances. Each of the parties shall execute such documents and perform such further
acts as may be reasonably required or desirable to carry out or to perform the provisions of this Agreement. 
 (o) Other Agreements.
Nothing contained in this Agreement shall be deemed to be a waiver of, or release from, any obligations any party hereto may have under, or any restrictions on the transfer of Registrable Securities or other securities of the Company imposed by, any
other agreement including, but not limited to, the Subscription Agreement or the Joint Venture Agreement. 
 (p) Termination. The
rights to cause the Company to register securities granted to a Designated Holder under Sections 3, 4 and 5 shall expire seven (7) years following the consummation of an Initial Public Offering. 
 [Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed, or have caused to be executed, this Registration
Rights Agreement on the date first written above. 
  

			
	 WUXI PHARMATECH (CAYMAN) INC.

		
		 	 /s/ Ge Li

	 Name:
	 	 Ge Li

	 Title:
	 	 Director

	
	 WUXI PHARMATECH (BVI) INC.

		
		 	 /s/ Ge Li

	 Name:
	 	 Ge Li

	 Title:
	 	 Chief Executive Office

  

					
		  		  	

			
	GENERAL ATLANTIC PARTNERS (BERMUDA), L.P.
		
	 By:
	 	GAP (BERMUDA) LIMITED, its General Partner
		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 Vice President

	
	 GAP-W INTERNATIONAL, LLC

		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 Vice President

	
	GAPSTAR, LLC
		
	 By:
	 	GENERAL ATLANTIC LLC, its Sole Member
		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 Managing Director

	
	 GAP COINVESTMENTS III, LLC

		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 A Managing Member

	
	 GAP COINVESTMENTS IV, LLC

		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 A Managing Member

  

					
		  		  	

			
	 GAP COINVESTMENTS CDA, L.P.

		
	 By:
	 	GENERAL ATLANTIC LLC, its General Partner
		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 Managing Director

	
	 GAPCO GMBH & CO. KG

		
	 By:
	 	GAPCO MANAGEMENT GMBH, its General Partner
		
		 	 /s/ Matthew Nimetz

	 Name:
	 	 Matthew Nimetz

	 Title:
	 	 Managing Director

			
	FIDELITY ASIA VENTURES FUND L.P.
		
	 By:
	 	Fidelity Asia Partners, L.P., its General Partner
		
	 By:
	 	FIL Asia Ventures Limited, its General Partner
		
		 	 /s/ Allan Pelvang

	 Name:
	 	 Allan Pelvang

	 Title:
	 	 Director

	
	FIDELITY ASIA PRINCIPALS FUND L.P.
		
	 By:
	 	Fidelity Asia Partners, L.P., its General Partner
		
	 By:
	 	FIL Asia Ventures Limited, its General Partner
		
		 	 /s/ Allan Pelvang

	 Name:
	 	 Allan Pelvang

	 Title:
	 	 Director

	
	FIDELITY GREATER CHINA VENTURES FUND L.P.
		
	 By:
	 	FIL Greater China Ltd., its General Partner
		
		 	 /s/ Ben Gufford

	 Name:
	 	 Ben Gufford

	 Title:
	 	 Director

  

					
		  		  	

			
	UOB HERMES ASIA TECHNOLOGY FUND
		
	By:	 	UOB Venture Management Pte Ltd, its investment manager
		
		 	 /s/ Kian-Wee Seah

	Name:	 	Kian-Wee Seah
	Title:	 	Managing Director
	
	UOB JAIC VENTURE BIO INVESTMENTS LTD
		
	By:	 	UOB Bioventures Management Pte Ltd, its investment manager
		
		 	 /s/ Kian-Wee Seah

	Name:	 	Kian-Wee Seah
	Title:	 	Executive Director
	
	UOB VENTURE TECHNOLOGY INVESTMENTS LTD
		
	By:	 	UOB Venture Management Pte Ltd, its investment manager
		
		 	 /s/ Kian-Wee Seah

	Name:	 	Kian-Wee Seah
	Title:	 	Managing Director

  

					
		  		  	

			
	 TIANDI GROWTH CAPITAL L.P.

		
		 	 /s/ Oliver D. Curme

	 Name:
	 	 Oliver D. Curme

	 Title:
	 	 Managing Partner

  

					
		  		  	

			
	DR. LI GE
		
		 	 /s/ Ge Li

	Name:	 	Ge Li
	
	LIU XIAOZHONG
		
		 	 /s/ Xiaozhong Liu

	Name:	 	Xiaozhong Liu
	
	LIN TAO
		
		 	 /s/ Tao Lin

	Name:	 	Tao Lin
	
	ZHANG ZHAOHUI
		
		 	 /s/ Zhaohui Zhang

	Name:	 	Zhaohui Zhang
	
	DR. NING ZHAO
		
		 	 /s/ Ning Zhao

	Name:	 	Ning Zhao

  

					
		  		  	

			
	I-INVEST WORLD LTD.
		
		 	 /s/ Xiaozhong Liu

	Name:	 	Xiaozhong Liu
	Title:	 	Director
	
	ASSETVALUE LTD.
		
		 	 /s/ Tao Lin

	Name:	 	Tao Lin
	Title:	 	Director
	
	I-GROWTH LTD.
		
		 	 /s/ Zhaohui Zhang

	Name:	 	Zhaohui Zhang
	Title:	 	Director

  

					
		  		  	

			
	J.P. MORGAN TRUST COMPANY OF DELAWARE, AS TRUSTEE OF THE GE LI 2006 GRANTOR RETAINED ANNUITY TRUST
		
		 	 /s/ Michael B. Yulsman

	 Name:
	 	Michael B. Yulsman
	 Title:
	 	Vice President
	
	J.P. MORGAN TRUST COMPANY OF DELAWARE, AS TRUSTEE OF THE NING ZHAO 2006 GRANTOR RETAINED ANNUITY TRUST
		
		 	 /s/ Michael B. Yulsman

	 Name:
	 	Michael B. Yulsman
	 Title:
	 	Vice President

  

					
		  		  	

			
	J. P. MORGAN SECURITIES LTD.
		
		 	 /s/ Simon D. Ulcickas

	 Name:
	 	 Simon D. Ulcickas

	 Title:
	 	 Executive Director

  

					
		  		  	

 Schedule 1 
  

			
	 UOB Hermes Asia Technology Fund
	  	 c/o UOB Venture Management Pte Ltd
 80 Raffles Place
#30-20
 UOB Plaza 2
 Singapore 048624
 Telephone: (65) 6539 3593/6539 3044
 Fax: (65) 6538-2569
 E-mail: Jean.ThohJH@UOBgroup.com

		
	 UOB JAIC Venture Bio Investments Limited
	  	 c/o UOB Bioventures Management Pte Ltd
 80 Raffles Place
#30-20
 UOB Plaza 2
 Singapore 048624
 Telephone: (65) 6539 3593/6539 3044
 Fax: (65) 6538-2569
 E-mail: Jean.ThohJH@UOBgroup.com

		
	 UOB Venture Technology Investments Ltd
	  	 c/o UOB Venture Management Pte Ltd
 80 Raffles Place
#30-20
 UOB Plaza 2
 Singapore 048624
 Telephone: (65) 6539 3593/6539 3044
 Fax: (65) 6538-2569
 E-mail: Jean.ThohJH@UOBgroup.com

		
	 The Fidelity Greater China Venture Fund L.P.
	  	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong
 Telephone: (852) 2629 2833

Fax: (852) 2509 0371
 E-mail: daniel.auerbach@fidelity.com/
norman.chen@fidelity.com

		
	 Fidelity Asia Ventures Fund LP
	  	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong
 Telephone: (852) 2629 2833

Fax: (852) 2509 0371
 E-mail: daniel.auerbach@fidelity.com/
norman.chen@fidelity.com

		
	 Fidelity Asia Principals Fund LP
	  	 17/F, One International Finance Center
 1 Harbour View
Street, Central
 Hong Kong
 Telephone: (852) 2629 2833

Fax: (852) 2509 0371
 E-mail: daniel.auerbach@fidelity.com/
norman.chen@fidelity.com

			
	 TianDi Growth Capital L.P.
	  	 930 Winter Street, Suite 2500
 Waltham, MA 02451,
USATelephone: (1- 617) 817 3610
 Fax: (1-781) 634 0202
 E-mail:
simin@tiandigrowth.com

		
	 General Atlantic Partners (Bermuda), L.P.
	  	 Clarendon House
 Church Street
 Hamilton HM 11, Bermuda
 Fax: (441) 299-4988
 Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein
     Carolyn Rego

		
	 GAP-W International, LLC
	  	 Clarendon House
 Church Street
 Hamilton HM 11, Bermuda
 Fax: (441) 299-4988
 Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein
     Carolyn Rego

		
	 GapStar, LLC
	  	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein

		
	 GAP Coinvestments III, LLC
	  	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein

		
	 GAP Coinvestments IV, LLC
	  	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
 Greenwich, CT 06830
 USA
 Fax: (203) 302-3044
 Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein

			
	 GAP Coinvestments CDA, L.P.
	  	 c/o General Atlantic Service Company, LLC
 3 Pickwick
Plaza
Greenwich, CT 06830
 USA
 Fax: (203) 302-3044

Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein

		
	 GAPCO GmbH & Co. KG
	  	 c/o General Atlantic GmbH
 Koenigsallee 62,
40212
 Dusseldorf, Germany
 Fax: +4921160288857
 Email: Drosenstein@generalatlantic.com
 Attention:  David A. Rosenstein

		
	 Dr. Li Ge
	  	 No. 1 Building, #288 FuTe ZhongLu,
 Waigaoqiao Free Trade
Zone, Shanghai
 200131, P.R.China
 Telephone:
86-21-50463309
 Fax: 86-21-50463718
 E-mail:
geli@pharmatechs.com

		
	 Liu Xiaozhong
	  	 No. 1 Building, #288 FuTe ZhongLu,
 Waigaoqiao Free Trade
Zone, Shanghai
 200131, P.R.China
 Telephone:
86-21-50463317
 Fax: 86-21-50463718
 E-mail:
liuxiaozhong@pharmatechs.com

		
	 Lin Tao
	  	 No. 1 Building, #288 FuTe ZhongLu,
 Waigaoqiao Free Trade
Zone, Shanghai
 200131, P.R.China
 Telephone:
86-21-50463320
 Fax: 86-21-50463718
 E-mail:
lintao@pharmatechs.com

		
	 Zhang Zhaohui
	  	 No. 1 Building, #288 FuTe ZhongLu,
 Waigaoqiao Free Trade
Zone, Shanghai
 200131, P.R.China
 Telephone:
86-21-50463320
 Fax: 86-21-50463718
 E-mail:
zhangzhaohui@pharmatechs.com

		
	 J.P. Morgan Trust Company of Delaware,
 as Trustee of the
Ge Li 2006 Grantor
 Retained Annuity Trust
	  	 c/o Dr. Li Ge
 No. 1 Building, #288 FuTe
ZhongLu,
 Waigaoqiao Free Trade Zone, Shanghai
 200131,
P.R.China
 Telephone: 86-21-50463309
 Fax:
86-21-50463718
 E-mail: geli@pharmatechs.com

			
	 EWEP Inc.
	  	 Building 15, Room 2404, 233 Nong,
 PuMing Lu, Shanghai
200120, P.R. China
 Telephone: 86-21-58793928
 Fax:
86-21-58798123
 Attention:  Mr. Shuo Li

		
	 NJZ Advance Limited
	  	 Room 305, Block 15, 233 Nong, PuMing
 Lu, Shanghai
200120, P.R. China
 Telephone: 86-21-58409398
 Fax:
86-21-58766536
 E-mail: junzhao323@126.com
 Attention:  Mr. Jun Zhao

		
	 J.P. Morgan Trust Company of Delaware,
 as Trustee of the
Ning Zhao 2006 Grantor
 Retained Annuity Trust
	  	 c/o Dr. Ning Zhao
 No. 1 Building, #288 FuTe
ZhongLu,
 Waigaoqiao Free Trade Zone, Shanghai
 200131,
P.R.China
 Telephone: 86-21-50463512
 Fax:
86-21-50463718
 E-mail: Zhao_ning@pharmatechs.com

		
	 I-Invest World Ltd
	  	 c/o Liu Xiaozhong
 No. 1 Building, #288 FuTe
ZhongLu,
 Waigaoqiao Free Trade Zone, Shanghai
 200131,
P.R.China
 Telephone: 86-21-50463317
 Fax:
86-21-50463718
 E-mail: liuxiaozhong@pharmatechs.com

		
	 AssetValue Ltd
	  	 c/o Lin Tao
 No. 1 Building, #288 FuTe
ZhongLu,
 Waigaoqiao Free Trade Zone, Shanghai
 200131,
P.R.China
 Telephone: 86-21-50463320
 Fax:
86-21-50463718
 E-mail: lintao@pharmatechs.com

		
	 i-growth Ltd
	  	 c/o Zhang Zhaohui
 No. 1 Building, #288 FuTe
ZhongLu,
 Waigaoqiao Free Trade Zone, Shanghai
 200131,
P.R.China
 Telephone: 86-21-50463320
 Fax:
86-21-50463718
 E-mail: zhangzhaohui@pharmatechs.com

		
	 J. P. Morgan Securities Ltd.
	  	 c/o J. P. Morgan Securities (Asia Pacific) Ltd.
 Chater
House 25th Floor
 8 Connaught Road
 Central Hong Kong

Facsimile: (852) 2525-8298
 Attention:  Convertible Bonds

			
	 Rexbury Limited
	  	 No. 5 Bridge, Mashan, Binhu District,
 Wuxi,
Municipality, Jiangsu Province,
 P.R. China
 Telephone:
86-510-8599-4817
 Fax: 86-510-8599-4817
 E-mail:
xyehen@pub.wx.jsinfo.net
 Attention:  Ms. Chen Xiuyu

 Schedule 2 
 FORM OF JOINDER 
 THIS JOINDER is made on the          day of
         
 BETWEEN 
  

	(1)	[    ] of [    ] (the “New Party”); 

 AND 
  

	(2)	THE PERSONS WHOSE NAMES ARE SET OUT IN SCHEDULE 1 (collectively the “Current Parties” and individually a “Current Party”);

 AND 
  

	(3)	WUXI PHARMATECH (CAYMAN) INC., a company incorporated in the Cayman Islands and having its registered address at P.O. Box 309GT, Ugland House, South Church Street, George Town,
Grand Cayman, Cayman Islands (the “Company”). 

 WHEREAS a Registration Rights Agreement was entered into on
                    , 2007 by and among, inter alia, the Current Parties and the Company (the “Registration Rights
Agreement”), a copy of which the New Party hereby confirms that it has been supplied with and acknowledges the terms therein. 
 NOW IT IS AGREED as
follows: 
  

	1.	In this Joinder, unless the context otherwise requires, words and expressions respectively defined or construed in the Registration Rights Agreement shall have the same meanings
when used or referred to herein. 

  

	2.	The New Party hereby accedes to and ratifies the Registration Rights Agreement and covenants and agrees with the Current Parties and the Company to be bound by the terms of the
Registration Rights Agreement as a              Shareholder and as if it had been a party thereto from the outset and to duly and punctually perform and discharge all liabilities and
obligations whatsoever from time to time to be performed or discharged by it under or by virtue of the Registration Rights Agreement in all respects as if named as a party therein. 

  

	3.	Each of the Current Parties and the Company covenants and agrees that the New Party shall be entitled to all the benefits of the terms and conditions of the Registration Rights
Agreement to the intent and effect that the New Party shall be deemed, with effect from the date on which the New Party is executes this Joinder, to be a party to the Registration Rights Agreement as a
             Shareholder. 

	4.	This Joinder shall hereafter be read and construed in conjunction and as one document with the Registration Rights Agreement and references in the Registration Rights Agreement to
“the Agreement” or “this Agreement”, and references in all other instruments and documents executed thereunder or pursuant thereto to the Registration Rights Agreement, shall for all purposes refer to the Registration Rights
Agreement incorporating and as supplemented by this Joinder. 

  

	5.	THIS JOINDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. The
parties hereto irrevocably submit to the exclusive jurisdiction of any state or federal court sitting in the County of New York, in the State of New York over any suit, action or proceeding arising out of or relating to this Agreement or the affairs
of the Company. To the fullest extent they may effectively do so under applicable law, the parties hereto irrevocably waive and agree not to assert, by way of motion, as a defense or otherwise, any claim that they are not subject to the jurisdiction
of any such court, any objection that they may now or hereafter have to the laying of the venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has
been brought in an inconvenient forum. 

  

	6.	Section 11(j) of the Registration Rights Agreement shall apply to this Joinder and shall be incorporated herein by reference. 

  

	7.	The address of the undersigned for purposes of all notices under the Registration Rights Agreement is: [        ]. 

 

			
	 [NEW PARTY]

		
	 By:
	 	  

	 Name:
	 	
	 Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]